var title_f15_8_15488="Nonunion lateral condyle fracture";
var content_f15_8_15488=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F76915&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F76915&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Lateral condyle fracture nonunion",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 340px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Avascular necrosis developed in this child because of extensive dissection and difficulty in obtaining a primary open reduction. Panel A) Injury film. Panel B) Two years later, there was extensive loss of bone in the metaphysis and a nonunion of the condyle.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Beaty JH, Kasser JR. The elbow: Physeal fractures, apophyseal injuries of the distal humerus, avascular necrosis of the trochlea, and T-condylar fractures. In: Rockwood and Wilkins' Fractures in Children, 5th ed, Beaty JH, Kasser JR (Eds), Lippincott Williams and Wilkins 2001.&nbsp;Copyright &copy; 2001 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_8_15488=[""].join("\n");
var outline_f15_8_15488=null;
var title_f15_8_15489="Bizzari Giuffrida blade";
var content_f15_8_15489=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F75199&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F75199&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Bizzari-Giuffrida laryngoscope blade",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 282px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAEaAYwDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDBBYD5sD1x0/CnRjPJ49qYpwVJHAxjNSDGCR0xjI619CjwxrKVwyn5gDnHShAxcAkHj8fpT9oyFDFu2e9AA8w9SQOR6U7CI1JYgjB9QR71OcmTCg4x3NRqURARwD/KnAjzlKgkEc4/nQhMcflIwAPqaQxspHQAClUBUG0Ftx6+gpQpLndx2UUxMMFgGBxjIxihSQR8u/HXtSoF+c5yelBCFPmGGPH0oEIqY7/L096ei4wUILfTpTVG1weMgEVIqhlIOfTn1poTEYAzYDdeMDrSS5BGFG48Y9qCMFcggDuDilXbtyRkZ65z+nagQ35ioBOCew9qQFiRgYyeQP8AGpAuAGfG09KRAWk6E55HuD70DuPC5CgEADqopypyzgr07+v0poYDEjDgEjI7D1o4LKQCFxz9KZIKNkbLj5+nPamkF5MMg5H3jzkU87GUscqDwRmnQqokYRhjjpntTsFxeGKkEHjkYpSASMqOuTzz9KUgKgxkAtTpFTzFI27scZpk3GRDBkAJI/hPt6UrrsiDNzzw1GFYydcDkk9PpTjhRtUEqB39KBsYU3rkqc46+tSBiVUgZxzwaZtUMTy2O2euKQbWA2nG7oP6UCY5s+a6DjPOT3oZR8oGCM9acpUbtxyR0FNyFjUsCCW6ZyOtAXBMbiHHbAb+lIrHADKCpIz3ApZCQ+AD07daG2mPao2kkD8aChoOHdeu4544OKUowJK4HOefelRh5rfeHHelZV8sqCSg556YoEKMlwRjOcYzSFG3kYXnqpHX3pJiDIuzlgB9DS43CQMxLdc+n0NACMHViAMjoRQu7kqoJx3pT8+0nIY9c9vwp4X5H3EN3GfUUDuNBwQD6ZI65oJZS424XqPUill2h1GDk8gCnop3SBzkEenQUA2MYbyAp5HQZppBaR9uCQPvE/zokCwKmTxnGPrTgFJIUDG3v70DQxizIvILN1J7cUMGBZQAAeRkZzUm3MQGCMcqPw61ECyMy4O5unp9aQ7jQr7Il4UgnPHb2oAy+1O+McfzpWwsSNywDd/T3pwbMpQLgkcjHt1oAahfysOMnOP8KQFmkLDbkdu1OicbCGGQTz65pYRiZQ4PIyB6Uihg3MmFJAyMAj3qQHB6ZHcd/wAabMuNzKMkdcntSnAYELznJOe1MCONMIyqR1wee39Kk2KQDuGcDPzYpvJjcnnPJyece1MwdqEFBlR1NINShzuGeOO3ak5ySRz6UpOdvykjAH40hGCwLHA9OBWZoxcb0A3dRk8dTS4ZydpwO/pQQFZSrckfKe1OjIErZXJ9e1MkagYRgZx7nrUqjYQc9sE4HNROq5LEEMT0AqYYD5bGQKEJiKXwAcD5sDPpUj5UoSOvUAVBgsigMSp74zUgyOgJyAOetMliENvLY2g56ClDHHzLg04oqKSc49hUYABXdkjoM+lMB6uWkG4cEE8j/P8AkUMC+CpIwc9etKmC5YEhjlh7AUpVShBcn5sigQ4ggY5JPPJpEIIduOvyk+lPBG4KQemBzz9abhQCPm2k5NMQ85JVSCOcE4pOQ/zgbgOuaUHKJu78cGhQo37QcnIz6UxDWdjGuANxbHFPznOQewpFAMYJx1zk0Jzu2jAIzxxQDFiB65yOc4FSYCJwDzlsE1GhwgBbgdW71I2FfBJJPOBTQhCSVwVzjj/GpJNrD5ccDmmsVVTg9COfSnbAJV67uaABFBRs/dPamsx8z5e4znNPZEwQB8oGOaCmWXJP1pkjCCR0JJ4pU5i/usDtIY5xTlVfOY7iSox14pzL+7XbgEHJ96B6Eak+aVxzng0hVgvAGQePSlJ+dgPmPU04svl55A+tACZPmFiCQRg8U7D+WSFXPpnpUZAkYY3HaM4J605VPlBSTk87utIYiA8khd+OeOlK25Sckc9O1MwDcbiT93kZp7FTjHLE/d60AKw3MrLzn5SR1HP/AOugLjpwDxgc044V1JIGfY9aiC/vmyTjGRzwDTBDpAE5QFj7igE4kyuO/B4NI7AqNpwDjPOaeV35bucc0g6DA21sEZHHGf5U7jcT1XBHXkUiDKjeG4wAaV1xIWwct2GOKBgwUjGC3v6Um4IxKlRuB6j86STG0fK3LA8nGTUjMCrbV5UZ/wDrUDGKW8vKBQc/UAU512yhnxuB/SmqCYi3JGc9eTTtuZ2znngj2oAT5tzJkEkZHtUMLkyfNndu9OpqUIp8xOoHfvn602NQCnDEtncfekNMMMxbDYOe4zShVB3AgkHOGpIskzDLAg569fb9KayFmV1Vlx2HGR70DSJQrJ5gXjcM5+vtSMhHl4IIIwQD1pIs7mBJJBw2OgodfLCbAwG77pNALciJwCDnpgEU5YwRny/rzipPKBUgDk9e1NhkfYMIB6g+tA0jMAOPQ9eP5frQgKg5AZ8ngcUY55J6c4pY/m3ZBx3zWZYucqmRzj0zigJk9Dj6803BRRgknGOacB+7ILcZ6DtQIUEFlVVwp9u9O58znpikA+QckYGadjILMeOTnPAFMkbGxKZMZBzwDTiRn5gABgZz/nimKgwCGIz365pWwHGW79AOaBMnJ4bn5c9TTACuOnqSOmKax6sWOemMUucoh3E5HYUxEhzuGMY5A9AKbztGRgjPy9/rSlcErwe9N4KE5w3cnrTETNv+X7uD1zSFcowRRjvnpTt25UGSfTAqM/KhO7kZ7YzQArbVj+6OvGQKkiZhliQRimFVfDZxn0705CEypfPp60xCnKNg4Ip+1nKgELxgg9qZhSoy/BP6U5GO/JOR39qYhAHWNsqPlx19KlyxABHJHNRRZcOQc4PBPWpFzkg8GhADMrxnywAcenFITtcbRw3P0pEXaCQdqcEY7fSnMC2wgkgHB44+tMQ7cf3hKjI6KBio4yUZAVGT1OeR6VMrAxPgk8889qRgWVTlgMdu9AaEfRic4XHPPWp8HauB8xH5VC20McsR7dhT1yB1/GhCYrcHJA6dT601lAA2dOuKcQucevbsaRzsTdjOPTmgBQvzYG0t2PrQuRExbGR2P+femhlBBbl8Y5+tPx+6HzE5PrQMaCTKF+Ugr2FABVyVOcDk+v40YO7IJx3GKCu55N2QSOCexoCwHez+vU+mPSnbiCykcHoc0xWbG5mG7pyOtODIwIJBP6igLDGGVU5BYj0xTs5LgcEjAHvS7fMTaDu2k5IFBRVlOc5PJ74460DRGgb7rN8xwCPSpQ2DtGcsO9NZQYyeMrggE46dqN25kAGAegHajYNxCRndnk4P+9UgPPHA64J/SoCQ6OS3K/d9c/41IoyVZMEkY5oHbuEoLIcMAcDlaarPv3HgdG571JIgZQBncOSc1HEwLhmztPqe9IaDc7biCOCOvQmlL4G48DPeo2G2SRv7w6dBTgBtTjKZ6ZzmgY8Phieh5xim/MDnI2k4+Xt9acd3Tkk9eaaMKpySeeDjpQAhcoQ2T0AoIc+Y5HPbnqaeykDhiR6UhKhSeT6YoGNYMjnPRh7GowqkAmPr6GpDkFcqC3XntTVkaMFQm7n1pDRnDG7d1pNoVCBweuM8CkAz7+o/rTsKAuSSM9azLEBLkBlxkZ6flS5O7a2AOCwA604KFbI5OOxpuWLMCc89hQIe4xgBSew+tLnDPtUkH+dIGI+YEng8inblRdxIUn36/wCcUyRAWPHcjII7e1L9AcevvSfMFBByxPHHagD97nov+f1piESQjf8AIx4zgjrUnDE7w3qBjpiiMlFYlgQf09qMArhSVI6k9KAuOD4YjAOecUEhVGVwD196asZyxZsj0oDjYRktj7oI5piJVyXO/IwB92mAkgDGcEkDpUeQ0gI2hR1AFCsVO4EYJ/Ki4WJiQpTIwMflTQ+GwPu44NQvKSRuOfp3NG/Zks6nPIz29qVw5S2r/uwwUYzwc9aUEs2TjB/I1W84bQoI3flTg4BUFuR8xFO4rFvB7KR9KUtk8jIx69KqpIdo2kL71J5o4Ib5s4JHpVXJsSL8u5XC4J44qRyeMgFeAR1qBZC7HcwO0dMVLuUsuAOO4NNCY9lIDAEgH1OaVcbVJU5J7Ugz875IzjBPan5zHjcWz0xTsS2IwJLdwO2KjYMuSORyeOv0qZAGcnOOe4oVQI2BbHP6Zp2EmNOQwHG337UwAsuOAQeg/wAKn8sbyx6E42nvSMh8o85OcDHSiw72I0OR1wD7UP8AIhA6g8elSFOcH5WUfL6Ypp+RTnHHJ/8ArUrAhhIDr8oJPJzTiWXeSMDPGacyKANuOec+tLgbyNxJPtRYdyIM2wkBSSc5J60FArf7WMk8UY2KoAx2yKmZQWJHHGMkUWHexHzgjHTjk9aWRlErALk47dhR8gjXae4696YdrT7Q3BFA7CygbWJx8wznvTlIGDkH0pjHep3YbpwfelVQOuCcDt1pAG3crfKCR69xSJwFZV9sCpDtAIySScc9BTB8pCFsDOAT3oGiQ5DEHjIxx61CVGCcEbTwvb6fSnDm45bgcdOM9f8AJpXAeNCdu3+XvQCDhX+8emQCOPpUYYrGSF+YHIHt6frUg2lx0B6qoqMZEeecDJwPSgYrn5RtHzDk0Bd0IDsPmxnjtTd27y+GxyPpSggpgDOOuTSGPwwWMhhj09KTcQpAwDyfrQwOUwcf7NDg9FJC9T3zmgY5gQFJwB1JzzUTMwPCj9KkkcFo9ik8ZI9frTJIEdyxVOfegZlHlmwMfjQoBRc9D0o+bJU5xyc+lKrEZ24YgcdxWRYHp67ucg8U7OANwHJ9PShARuzjPT8KUktgcA5pksbxsXGd3XrQowz5U+4z/ninMpAUjG3PJzzSD7gYMORxQA9QAqFsleh60gPzjPtgg96YXdfLBAxxn1qbABBBJ+tMkcMDICkjJ49ab8gZCcDPRf6UgEi4Y4OD0pJSAflXnd29KAtqLlshiOeaYSrDcvc547Ub2G4kqynlT7VWeV1XJK57begFJsaQTPtk4yc9CD0qKS4+QqvJHr61DLM3zAtz7dqpzTFY8lvmzxxWblY1jC5ae6REGQAT05PWoHvgMj+fU1k3N0TwrZJ6896pNO4bBIIBHf8ApWLqm0aRvi/GNxJH1POKcL8Z5IJPrXMS3ZDIqfcJwfYYppuuTh+MetT7ZlexR18WoIvQ9OxOfwqZL5GkUklf5detcat1wSpIYdT+FPS+Zctv468mqVYh0ex3Ed8ATyMGrTXGLQXW0JahwjTSOscak56uxCjoe/bHXiuSsftj4ZLWWfkbUJ8qNvZpTgL9Bk49OtZ/i7Tjr9+kmrav8sf7uG0s4i0cAx91AcAZPJx1PNYVcw5dIG1LAc2szp08Y6JFdXMNzrlvAkJIR7S1kvBP7KcxgfU1Na+OvCcq4kv/ABEHyQFhsIBn/vpzXnP/AAjuhWBRrs6qCegkhKfyFW1m8LCRP3lwpXptjbH45FcMsXWl9t/16HZHC0Y/ZX9ep3cnjrwZApZ9R8X56Y+x2gz2x1rHvPH+mRRJNZzag9i7Mqm6tEjbIAzwjnPBHPFcfrT+GvsrfYFluH6AlsgVh6u87aNYwC1UQ25chlVstuOcnnHbHGKj6zWurSf3lPD0mtYr7j1FfiRp6Dc8m5ev+oZT/wChEVoW3j3SZRiaaOLPPJbJ/wDHf614fb6hbqipLa/L3KPgn8KsG502WJ1zPGTgqXAYDH0rVY/ER6v8DN4LDy6fme/af4k0m7fEF3CW7gyL+nNaaXMZDMHBT/a4FfNypDcbWF1FIyjG2Q9ePetPSptVtLfdaXlzEC21RGWKYAyeFOOMjtXRHNZr4kYSyuD1iz6AGcIwBIxj6VKTywAJIXjI6fSvHtM8YanY2c817LBPDCobLxEtvPRSyFMZ9ecV0ulePIJJGXUbaa3yBta1nS4Qcf3TtOf+BGuunmdOXxKxzTy2a+F3O4H3e5Oefb1pSx3/ADY21DpN5p2tOU0fWLCeXaH8mdzazE+gSTAP1DGr97p17YswvrO5gVRuLPGdgH++Mr+tdcMRSqfDI5J4erT+KJSlIEZJ+6MHpyKbwZlCjPG7JPpTkBy2GBUng5zwe1OIUEYyQPlwK2sY3Gj5vMO3IJBpSoUoRnA455pwAUnDD/69IVG0fezzj3pWKAAtnP3T/nikbllBAyGyMc0D7w3NnPIpJMsoAkYNnqKAWgZDPtxwDkZobcQ2F3MDgDHH50sGWILfyqMBnG3cc560hkjRlnVhlT6j+tN+8shK/dyAtIQ6kAnAGM0qgHcMEc4JxQMaUbKkZzjpnilUsFfCcAZx60vABJ+6e/vmnFCcbWIbsaBkIbesbDAIOTg/d4qUAHIUcZ6/jSIhwvI443UAEsNrYJOMHvSGNLZfLcH09PrSlnJPy9/WlxuDKCcg9T71GUZ+cE9ugpFaGSke9ieduCSCaX7i7QRt7+9KeCcgAY7UqnJPGflz6HPpWRQ1sB1Pc9j2p3yMAe2cH1z9KYjBd2Onv2p4AJJ43Y4xTExQufXB6elOJXZIcZFIDgYOeKTzSMgBQ2MkA4/OmTuK5UIpI2nPHP8AOm5BfcBgAcn2qOSVlVAQjKxIP0qN58krtG1T1pXGkWQ6qgG7KkcDOPyqFpQWxgke/eqctztjL8nHTAqs93yCPyzxUuaLVNl150O4gEDB47VRlugEAV/lHqOtVJ7ssHx2qg9wWHb27YrKVQ1jTNB7nc3Gfl5xn196oT3G4E8EEdzVOS46D+LoTmqck+VPGT0AzWMpm0YElxOmVGTnvzxVWSUM33ugz9ajeQlAQnPf2qFid+Mcnn61i2apEnmcHB3Y6moywK8sBjoBSxRTTypDbwvLO3REGSfb610Nr4Puhapd6zd2+mWjLv8AMkYcjODj1Of4Rz7VjKtFaGqpSZg2sb3O/wAsfJ/G5OFHfqfp0711WkWotpFbTbX+0LxVL/aJomKRY7xxdWx/ebH0q3p0WmxpEmiafeaq6ZPn3ZNvAh6ZVT8xz34T61qXVnqs6SG5vI7eE8C0sgYo8HscfMw/3iaSpVqy0VkN1KVLd3Zm3h3XQPiPU2u5IyB9l3GQqPaOP5V+hZalHiB7VSml6eiEPxK7iE7e3yxjOf8AgVPi0KGPYquqrgfKuFA/Kop7CBTgMgZj8oLg5I/pWscAlrIzeLb0iVtW13XtQRVeWzhUH5SkTM4z/tM5rEn/ALdbJOuXijHRWVRj6ZrZkjRFYLsyAQeScnPWqs4OegO0evUVfsKa6C9pUfUzNV17VPsBs7rTba8kkTyBcvYojjnOS6HBbryefrUnjDx7rH2HRLayKWFtpkEUMQji/wBdtB5bPUHJyOh9O9TuzANkMBjjHf8A+tVC7W1ugq36eYsY2qrMcAeg54rmnho3vE2jVlazNzQ/iJ4K1VfK8beB9NMr9bvTh5Rx7rnr9CK6G40D4F6mnmQ6vqOllvRnIU/8CVh+tebSaXoksYYxbCcfdJ+nrVZ/D+kOf3d3LGOnJ4P6VPsH0ZXtV1R6PcfBnwVfQifRPiLbJExCqbmNWGT0BYMuD+FUr/8AZ58WWM+3StX0i6dl3IiXLRSuPYEY/WvP28Kwt89tqCjHrj/GrMWm65bPDLbak0nlNuTzGJwR6Zpexn2D2ke50eq+BfFvhnTbS68Z2aNazajb2iQvMkplDbiwLISQMLjPUduldjceBNKtoJ2ttM1PShOrGJUlS8jZcdVGNwPHds1njxNq3iR/CPh7UblJZYL1r6aSWcBVCACPLHoMkgfXFexwanrYvo49c0CQS+WxdY087zUyBwATknPPX8KymnHSxpFp6njQ8JPZaDie2kvbNmaQSXDeVOoGBgoxII5JxgHOPpWp4a13VvD+mbv7Z1HTLcYjgN1GzW8uTjaEkBA7fdxx616bb63p2pG6juLB0WyPziY+XsXvleOntVixuPDfiSGSG3EdzYRJuZJY1WMD15Bz25qLtFWRzdl4o0jU7WMarp+nyPISrS6Y32WVCOv7pztbHc7jx24p0Eeh6veyWvhrXLe5vomKvp9yfInB9BnAc+uMD3pfFvgHwvrel3NzoFy1hd2cEsm2Dc0JAXDLg9MjjK+teA6lYJcXT6xLKY5pblgwZAUd+pIBAHf1/CuyhiKsU2nojlrUKU9Gj3C5tpbWeS2uYXguAcmORCpPuAeo9xxUfzKgIU4zzjmvLdN8aeKNORbW6vLfW9LHAttTLPjoMxycOhA4G1sD0rr9N8SwXrRpb+dbzMwza3jjI56Rz4CuPZwp/wBo16VHHc38RW81scFXBW/hu/qdIVKtggM2M5xULyZIOOQ3GRzUltPHdIJIWPADEMpUgEZGQeR1z+NE244wQTXfdNXRw6p2YiBt2FQ47gngCiJiA2VYZOMZ5pc5YckcfmaZC7bMS8NnH/16Q+g0RsWJDfdyCTTiWKjjJ/u5o28KOeScg0seFkyCPm5+tAxGfLABBn8wKDuMvHG4jk05lVcAZJyMgdh6VHubzGHBHsKABx5ZxyFzx7UZYHDL0Gd1P3b41ZSpGOaGDOwXqpB60hjUPJZV4x0HWpUDFcgbfbANRABtyhsNzg56VJEzeWuMH3IpDvYwQRt+Yg7fypEZWZQH+XPfqaq/aF3dwAcmo2uAGHy4wO5xWHMbcpdk25UjjHXio9/K/MQ2ev4dqqNcpnI+9jmq8l4oxzwDmhyQKBqebjkkbu5qu84beA5I+nIrKN96kE9qrSXoHA5yQTjpUuoilTZsvcY2gucDg+5rOmvBv4Y4PG01mS3ecc4NU5brB7E1lKoaRpmrJeE5ALbTxn+tVZbnkdsDpWY94NoOMD0FQPcEs2eMcVk5mqhYvNdfMSWHOcZ61WkugRtDe/XpVQO0r7VQs7cAKpJJ9quWumPKCbiSO3VRkhiGYc4+6Dnt7VjOqo7s1jTctkQSTnIJIHFTWGn3eoFks7eSRwC5IGFUDqSTxXR6LYWbSM2n6TPqckYO6S8IjiQj1A6j6kfWota1S0WRrfVNSa7fZhdL0dNsXHTLDIPTk/NXNLE30ijeNC3xMxPsMZnS2gle/u/+eVnll6f3+/0UGtL+x7TTh52v3iwfKCtnanLtk4xu575zjJHdRT7eLWtSTyLKFNEsWyuy2B8119GI/wAT9K6jw/4ESLbNOhD4GZZW3y/men4VrTwteu9dEZVMTRorQybC+vEUR6Hp8WmxNnbLIgeds4wQvIz9cj/ZFatp4be4uUu9ZknvLlQNpmfzGUE9MnhB/sr+Vd3YaJbQBDBGBIOr9WNa6WkcaneoXAr1qGXwp6vc8uvmMp6I5KOwnVfLhiWCLuF7ipY9KlKOrSfN1AC4x3rcvL63gwqAOw/hPFZN3q7fvNgAxzlegPpXW4wjuc6nUnsik2hQFGEkpKEnJJxj/PFVZ9M0y3IYAlw2AAByKgm1CV4WwRnPC+vuarzGTaCDk9jnp71hKUOiOiMZ9WOuDaLvCW6L3GRnjtWfIwb59qqckfKBgGr2Su45wjHHA9vTvUUapxldozhgB29aylqbR0KMkZEmwqvzDOGHIqlJYK0bHYr/AFAwMVuLt8xuMMD1xnI9zT3TMRAwA2DtJ46c1LhctTscjNpETyKoijBbuBj+VZVxo4UllMoyCMZyK9EkgQyHjdGo3E55H+cio5LGJ8gqO5rOWHTLVex5dJp8sakxyg4/vCqJa9tgFIJHUlW616Xc6LlACFPHOBWReaKUJIAZMYJ7e1c8qDWxtGsmcOurlSTJkZGMsOo/Gtax8W6hbhRaanqVrtGF+z3TooH+7nFTXuk5Qr5YI+max7jREXmPKN7HFYOMluaqSPSdB+I+tSXEUd/4pvI4E+VXktY7g9uCrYyOPX0rvdF1+5vytxayeE75Zh5bp5DWlyzZ6Bd/fOcjH88fNL2l5bkmNlbFSRanPbyBZNwxggE9fpWbiuqsWmz6buNYj/sm+01NKTRmu18jzIrlnMinrt3oMgjIyGNeXfE1rO206w0uyjEYgfzSinkdue+TyefasQ+PtUvPDx0O8vpZdLcqfKcBtuOm1iCV/AgVVdLS7tGiiVYmY/ex8+MYxknkf49a3jL904RSu+phKH7xTk3ZHCTXtxIz/vZFRjnYHOB+FPg1O8gGIrmQLjG3dkflWpqPhq4tyfIxIByR0b8v8KzF06dmZQu1gcEMMVytOG+humpHZeBPH0+mXq2+tStLYSEATEZe398Dlk9U7dVwevuCPHcwZjkjdRg5RsrgqCGU9wQQQe4INfLj6bexuiNazbn+6FUkn6Yr1f4PeIpr1F8L3zAXkQY6azghpQCS9qT0/vMmcYbcufnGOvCYt0nyy+FnNicMqqut0elEDEedwGfunuc0jbH8zBwT8vfIP9KXzkmjSWMbkIDA+vcUjqFeQgcHnjpmvbPI23GrkiLAcex707H7wjA+UcCkO5UBYnIGSA2cD2pD8wJxyAOaQ2hUTKja2eoJJ5NPb76AAAYwcmmqCVwfvAYJxSZZZRgfKR1649qYgjIJYcEAkf8A6qcM5BxluvPpTQC0YK/ezxxUoyWBIAZT0NIZF97cQw685/lU0C/uxtAx79qiZSZWJ27SM+mPenlwgA29s9aBnmRvyOSR68VHJesDkN+vNc6bsnLZI/Cui+HFrZ61440iw1IFrWZ3DrnGdsbMM47ZUV5DrWVz1FSuyJr0hgN3zHgds1DJdMcldx9xzXY/2PoNuEJvp5BtBJggwGP1JFK7eH4OIrS+n7fvpgufwArleNb2Rv8AVUt2ccoupNuIXC46txQ1leFAxVAGOB+8Unj2zXRzahYxsDDpcA/33Z/61A+pySPiOKCJuMeVEFFS8TNlKhBGPB4e1S4IaMHaOpCtj+VXf+EURAjahrFvA2MlF/eN9MLnH4kVpvbXNwoN1cy84wMk8fSql3pjbsQkfLjLE5yTUOrN9SvZwXQprpegrNHAbi+mmc4zhY0/EnPFW9YtNHsvtjaLp/23+zxELia5uvLjV3z8oGMt91ufQe9ZF3pdyCQpZ2A44NX/AAvbPZ2usLqujXd3AEjuh+6O15I3+RWzgbG8wg85x0qW2+pSSXQj0Tw9rviaxe+D2Gh6IjANez5tLYdeFY/NI3Xp+dVjqmiadL9k8MW9z4hux8rXdxH5UGf9lOu3gcuRn0roNS8Mat4p1SPUvF97vO0Jb2UA2QwIBgIqjooA7Y9yea6bSPD1naQRpFEqoMlUAwB+FdtHLZz1noclTHwh8Opw9voOv+Iiq6zeyiAtuW0tPkjX2yOPy/Ouz0bwXY6fGAyRQoByI8ZP1NdPHCsaBYoxuA6jv9Kd5D4YsTgfnXr0cHTpLRHl1sZUqbsr28NpZZjtrdEJGdwHJPvVuFiOpyTzz6VE0USOo2DI6H0pWuFU/cBA9utdS0OV6mukyQW+/cu5eprF1bUv3eTJhSeAKinuw0BVvuk4ye1ZGoSHaVGeQRnr6ZqJz00Kp0kndlGa8dmLSyknoD6ehqMYeT5jvOcnHH5UgUPEUMQYDue9KQ4+UKQ2BgCuW7e53WS2GopSNiWXceRjng04xL5YjB2sVx8x69+/9KYkRYBo0zk845+tSqoLjKbFYAqB25oSBseQPMU4JbGGz600RDaVR+qjkcH/AD0qTyzv2rg98A8ZNOC+TETs+YdiPeqsRchjjXIUDt1A7igptkcgqF65JqYsoKrt+fbkEDoakjTMflqmSM8H17UJCciMg+Znjg4zjmngbSVGTt5GRT2xkOY2BHt3qYJiYMBu4P44qkiXIrhV2op6ZIJxz/npSXNos/VRnHIJ6danjBaP5s85HzCnKP3q5GXK4BI4PtT5QUjHk0qMgow4xg88k1j32iIZVAHLA9K7FE+XDKABnj09KJIUDKCu9ux64rOVFSNI1mjzK70ZkDZQYBxkisefSgFAkUEc8kZzj0r1lrFZY3DqBwCRwfasq80eN0UhTkdB7VzTw3Y6IYnueSXOjFXLW7FTwcHp+VVd11ZP+8jOB3HIr0u80R9/y/NkZ4GKxrrTSCS0ZxnHIrknQaOmNZMwbHWXTblt4HQPyPrWnHdWdzjzwqN2PUfn1rPv9Hjk3MFKN6r6+/rWbLaXNoTn94mOoHI/Cs7yjo9S7RkdWIzJEdrpPHjpIc4+hH+FVn0BpZUu9MlNre25E8eyXY6uGGCh7nOCADn2rn7XUmhcFXII/Aitu21eKbCyhs/3h/WpcKc9tGUnKPmey6Vqf/CRaUdTkTyb1JVi1O2YhTDckcuF6iOTBYE/xb1zwBVmdRs4BY5xjHQV5z4W1oaXrMN4c3NnJGbW8gU/NLbtjIBzkMpCspB4KivTbmOOGNLy1uBf6NOdsN+nQHg7JgP9XIMgcgA9sZ2j0cLX5UqdR+jODE0OZ+0h80UrgAA/KSAc8HpSuVDJt9M8n0qV1LdgQoAORyKhdnV41IIyMZ2/kK9BnChoZWR9oHJx1zz709xu2Etg+nTPFNJbDBMghsj0J9aDIZChH06daQEoIBPXB5xn2prMNiujDBP5U4cM3U5HXGc//XpqhvLU9MnpQAKo37xvBIwVPIp4YEtygwe7UYJwFPQZJ7ikQlxnC+nJA/nQPVo8CJbgcbjxg1r+D7qa08WaPNCpMgu4guMZJLBf5GslVULtQnPrjpU1hcNZ31vdRZ8y3kSYEf3lIb+leFa6PZvZnoMitCWjYkiNiP1x/Sqsh3s2xS2PvYHQe/pWrrMEkeq3wlQq3nOSpHTLE4rQ8P6p5OjWdvc3bQNaXEzpsYgkSYIPAycEd+MYHauI6Tl306+eVl+yTBlGdrKQQM45Bq7beHdZWaQDT3V40Z3DfwgLuII7Hbk7Tya2tS1LTLye5mvHjmnaZ5gzq84bOPlIb5TjkAgKec54oTxrd276k+wxtqUnmzHHP3doHOeME/nTuIzLTRdYuoVkhRVZghXdwSGjEi84x9w55PUEdcZ2IvDd/BLEl3JGipexWc6wqzmJnTfn0bHQ4/rWTL4n1KbayNtRHDKAx5ONvbqMdqhuvFeqG0MTXDqgDbVGQF3HJAHQZo1DQt6xaPZIjnzXBjE0UpVQeuMfKSCOnpXdaNr6eIPCM1h5sbSQRgzQMeSqsDuHqBjmvFtY1+5u2WNpR5cagDy1Cj9Px/Grnw11GQ+P9Jtov3j3UjW5Uk/MrqQfyzn8KXL7yl2dx3umu57dbyeZGRsDEHHzAfp6U4R2yEHy1ViOmKytJd3ik3MSzBW+mQP6irhwGDH05r7JO6PkJRs2iyZYoy20KMeneqMk4A2huvAqGaQbiM+pPtVV5VaJSjHAHDA8GpcrFxgPu53DAbuM/XP1quHB5BUjBxjiq7yAOzMSC+cVFA0ZdgX3KckjuDWTlqdCjZFiRyXUCT5sksM5HrVa6VpGAPCnnB6mhtgkUKTnOQzD7xx0/nS3CEBgAen4VL1KWjM5leFgwIzwAAe3epQgYhjJ8zAnB6ZxTvKQxBhuOcnvyKkMIGCeGXnaB0/CoSLciCDCBt5XAYYA4znPAp5iIjUliNnfPGKkIJVpCjBSBnIz7GpsOUQ4wvo3Pb/P500hSl1IIhuL5bC8duT6/rT3LyPt3HcDhc8gVaeJQ/yjCkcgjoarm3C7h82cnO7n9fWnYnmuCwkHJIwVx16nPSnpE2/IYEcZyKfJGoKMQXxj5SOtSbSwIPEZ65qkiWyJQQY2fIyMsPU06PKuMthe3GfWnYDEFsLk8+ppY0AfqTuzw3Tj0/SiwJkbqXGOB6kgEnrTiuJgQQRt4z2pxZETADYPIOOmO1Jg+YhZju6EDuPegOgqgoCpKls5z60fMFHXbznNRooXc20gDgkA9fpU5ILIFJ+YZ5poTImIVn6buAeufoP0pHT90u05AJHT3pVREdid2XGCexxSRBfLI2kqScfjSGmQyQ7pdzKPmXHHrWdfaYsyPghSDyR6VuSKCoUjJHPFIq/unDAbSASCcmk4J6MpVGtUcXeaCQvyfL6DrXO3WmvGxDrxnGT3r1aSNWIJHzE8c4rIn02GaZ0aLOBnJ/pXNUw6ex008Q+p5LqGlpIpym05znoRWHdWNzbbyp3oOB616xfaG6gmM4IyBmueu9L2y/OoPB7gmuGph2jsp1kzh7bUim0scHofWuw8LeMb3Q71rixnCl12Sq6ho5k5BWRDw4IJ6/hWPqejJMpIHzdiK56e1uLEsfvxA8sB/Sud80NHsbpqR9K6Bq+heIoIk0l49J1VuDp88p+zzsSeIZDnYfRG46AdCasXKSQ3DW9xG1tcp96GZSHXnGfce4yD2Jr5mtNUaJhhjt6Ee1eoeE/ieUtodO1+L+0tPi4j8yQrPbDAH7mXqo4X5TlSBjgGuihi5U9N1/WxhWwsamuzPQYs5bcCOc49x/kUKjZ+RsEHPzdxU9lJZ6jay3uiXf2+0VC0g2bbm2X1ljHb/bTKnBPy4qCMIUQ7tyEblJOeOterTqxqq8WebUpypu0gXIbcdv4CnEARlSeexFOfblR/CemMYoBCRMMEd/wrQzTE3kMBlVAGfrTXjYt8mNv+8aUFX2mTBJ4X0qRJQgwQM0hng+1SRj/gOKZKuQexI5NTZwPqfTvUTFg5GPl6c14p61z3KHT7jxHPDqcADwX1vFMxByN+xd4z/vBqNe8NWmnWJlndElJGEHJ/KuL0zxTKPD2n2enztDNbW3lSx9dzB2wQO+VI/Ksq4uPEOqTAQieQqM7vJfPTocgV5zpy5vI7lKPLsa9xMltLsRCZGGPbNZ11dRyN+929h1/Hiq8eg+J7uQb94yu35lQYJHuwqyvgHU5givcIOdzF5TjPpgL/ACNa2M7BDqVnCoBbJI45759ax9b1i2mZUibhAcIOdx/rXTp8ON5jjm1CNVPXEbMQcY45H+TXTQfC7SoLSC4nupYGO5jMAkZKjgtkjhe3X1paBY8n07T9R1aY+XF5KSNgM4yz5B+6g5Nek+DPAt5pVwLu2eS0umztuHXdcgHghR0j479etWbrxp4P8LKttouL6/5VRbkPznvIRj04XIrD1Pxf4g1k/Z7Jre2065j3SC1OAPmP7tmPzZGOeg9quMJTdoilNR3O8s5IYHmjidm8tQhZ2yWI6knj1qR75TI20LjHB9K4XRIHs7UxPIHDkHYoIAroIp5APkxsHB4/rX0NGbUFF9Dwq1KLm5Ivm4+YAdMnk+3aq0rs0fmZDDcG5PTn8qgty7Slcgrg5XryTUzRybPlZenORgD/AD1qrtkpKOhCxlWaPKnG7Ix2H1pFkLNJ8hDLn+HrzxTtkm7O5GweM9u/T/PWpDGGRioUZx+HNTZlXRGrEBM5LL+OP/r09huLZXp3/p9aUBlRQSqnoSefy/GgqCQSQMEgfN+tVYlsMjbGUXAI2kHgn+gpO4O37xwxJ/WlfcsYzhivQn/PSlZSAQcHIBzj+VAhuC5BIO0HoRyRUpJADNs2r2AwPyoQP1IJIGFz2p00nykKAMjj1z6UxMeQXYZIAxnPrUU44dtrBiOv408k79xfbtHI7/4U0qQhG/5scntjtxTEOLNujyoK57dvXNBdSuSp4BPFNUFZAY2BPcf4/wCFKwBzsYh89R29MUC0HDosmzox/KlIOSu0+m/3pgyoKklQM89jnoKeBtJyAcg9RQMG3tH2JDYzRyEXaBtJ5PtTDtZQGkbcONw5zUoCbvkBULnv1oAajH96u0gLwGJ4/wA9KHA3KQu4k+nSljCsXJO4dMEd6Q47Fjs56fpQAzYd5DfdxksO5p7FlQEdeDgY5o+YsTkFTyMCm4KxkZ2noD14oAfIQXAUgjrkColYsjq6BW5/GnFQpVsgR8jHqacg2BlZtwbtjmgdxjK2E2sQvA4Ip8g2nKDk4XHtQSrgAnbg5K59qSJcyhvmwARggcmgLjGi81fmQs2MEA9KztQ0pZYg5UZC4IHWtRSqxjLEYbGTjk+/6U98HYG4ABIC96lxUtylJx2OA1PQ2iUMoyAew4xXNX2nsMlguT0yOfxr1uW2SSGVQSeOc/X/ADxXN6to4KBoc7VOee/+ea46uH6o7KVfozyLVNHG5miASTPPYGsKZJbdysgZTnrXp2o6cFfBUkjtmuY1C0D7vNXj1NedUpW2O6FS5S8O+KL/AEO/t7uzuJYpYWzG8bYdOxwfccEdCODXtnhnxjpHibHnT22lao5G+RgVs5zg/fH/ACwc8HcMoTk4BIr5+u7F4cleV9O9MsL2aynWWFiCOo7EehrOFSUHdFyipKzPqeSKW3uGtL6Jre8RRvhYYI5wGGOCDg8gkHsaQnMjDIx2+prg/BHjcPpVvbavFPqGlQ/dWN8XNl6mFj1Tgfu2yvAxjHPoEsDQ6bFqsMi6no0wJXUrJd0Y5/5aJ96Nh3ByB3PYetRxiaSqaP8ABnm1cI07w1X4kDqxRS5GehHT8RUE29pMovy4GMEinlxJEjJJmP72Qcg+mPamXMgSYgtsHYEjpXWctjxSXBJB6knApjZ3ZzwBT5xgDKkZqtI+GOOT7ivFuetY774T3qo2q2qsSzrFKwz6ZXp/wIV1fjTUY/C2j217dJLK91kxIOjAdST0A6Dueeh5rzv4VyAeKJUYlPMtpFUepBVv6Gu+8X6pqdtLp99pQgkjt7OWzniuIWmRc72EgQAnJLY3AYBAzxXLUfvG8NiLwZ40h1y9FpNYvZXMkZmgRnDrIo5OGwMnvjHQE5rp9WmKQbUCRt0Xrz9RXH+EtWTW7jQL2TQorC40y2lilkijKLcuVMa8nljhgT2GG55AHXOqyn94WbB4qLlWM+x84HfctubqoB6VB8Uru4bwAzQP+6QBLhOSxjJPyjHABJGc8VtLAvGwYX2FLc2iXNpNbXA3QSoY3TOAVIwRQnZgfNOjz6OJ1kukcyBgQXYgL+WOPrXpmgxjUSkenR+co+6sK8KP8/yrbh+FfhhdS+1tBdPFnP2Vpv3XT2Abrz96uzJsPD2lqY7dIICSIba3QKZmA6KAOeOrdq6KeIcdEjKdJS3Zxgjms7iS3ureeKZRkCSP5XT1Un7w68j0NX7eMfLjzMH1PUjt71j2+o6jrepTalqB/cBdsEWOAuTwM8BfQfUnk1sRdO6qvGCOh7/U169CTlFOR5tZJSaRaVY0lfAw4X5gPpUvljymKg4IyTuOf0qKJ9qYKFmJBJzwaFkMY5YA8ZGM59/0roRzu447ScyIc4HQkdf85poCo7+ZhgACfp/n+tI5ZVIVslQM9yc9xSIxLsJCwU4IyAC3/wBagVhxZTGT84XPBJ5xnrQYzI5lHLY+7nFOkxGEA4JHUDtnpSxcsSynIxj39s/lQTe2oJIpUYydvJz2HvTyULKCSSAACOhpCpWMDABxyMdaRd29MKoU8ZPGPemLfUVPkJEecDqB/npQVIThsgHI5xipFMisQR06MOhOP/1Uj7nQCPaMnndycU7BcWNx2G1gMk/5/Co9saoVHzb+56n8akA8uViNxVl6+9MC5Ls4IzgDB7igVxQ2R+7wGYZzg4pkQLqw6EA9PWnxjcCBjPU4FERJyGUrs5/3gaAuOdUcqSenT2NNZQZkJVuVJDEe9S7cIGK888AcUKWJXCnkc98fSgBiKfmZVwC270xSyyEKSEGSPvd6SMsysJBjJwTnoM05t8brjBUkA8dPpQAlq+1j5iFSTuzjg5oYFDwuUB6Dg/Umn7soSgYOeOT0qNAcswOSOCM0DFIweE68YPalLfeO0AZwO9OJy2F7dzTUL4GGRiBjIHegSDhiqspA7EjjOetIScsAhbnIH/1/wpzZYHaNxzkZHSm7t0rbTuGO3agZHJsAJAy+R0pyKd2eRu7EcdaayyFflbDEjPGeKkkyHOGPHByKBilvlYsvGemKaclVToOq+tNJPzMVUtng7sUp3EIXyD0Pp+VAXHRgqrqCRkCmyQpJEPkDZIwH9aaWLSP8wA6Y9uOf8+tPYOVAVgDnjPP/AOukO7Mi+0sTZCoq8celcnqfh6YiTCEkfeAz+lejAYbsR0J68U9ER0beoZufT8PxrKdCMzWOIlA8N1DQ51BPkMQOcHPFcxqGlzLI22Jl54yOtfSf2SNo0SRVJb727+f51FceHNMuvlmto/mB6YGPeuSeX82zOmOPS3R86aBp19qPmQQyPFa5/eYOM+2O9eu/CPxPd+CvEEtibRp/D97tW5i6hTgjeB64xn1rctPBOlWZdrYTR7n3FQ/GfUVpW+mQ2wVYFCkfxgAk/jURy9tWky3j0neJLJHaIsq6fBPFaMxdIpWyVyckAgDj0HaojlsHYx4+lSOriJiWK8/KO3/6qjiikCYRN4Hc16EYckVFdDjlLnbk+p4/eWkittwfWsq5jdRlhjuB6V6vJpMEoOVGM9utZdx4ahljLAkH9K8+WHl0OyOIj1OP+HjiLxxpXmEgSM8eQRglkZQPzIr2/wApJGy4BxnqORXllt4Tkt7uC5gm2PC6yoCOcg5/pXTXV94gmUrHNboN3WNAG+nINcs8JUb0R0RxFO251gRFwI4wgHGSO1SKjKMgcdzg15xdS66FPm6lcKOmPMIrmdS8O6pdBwuq3kkjtwrSkp+Q9qh4WaLVeDPa3v7OFmSW8t1ZeSpmUEAe2aoP4u0Fd+NWtjt6qm5vbsK4nwdNd+F70XukaZpC3H2YW0r3KvcbiB8zgEjBOD04571WvdOs5rua8aztUlmfc6wxbV3ewJOOT0FEMLN/ErBKvFbHYXHjyxRiljbz3Eh4VnARD7kZyR+VVLDXb6Zb4zBPtN3iKSYj544Rz5cY/gU9/Ue/NY0dtFEq4RcqOg/n71bgVQqgA+YCef8AGuynhoxOedZs0oYsxYZV2ZGOwH4VKysxwCM7+nvinQxr5KAqx5+YE8e1IcDopJBIB9/f+Vd9tDib1HxlssU25IIAB5znv6U7c0ihl4HADE+3PSow0YJwBnP0IPXrUZPlJjcxXnaev5UXJLUHDgllKdNqjt+FPkyXUseR0z1P+f6U0IpZSq4dRgHHHWkhEW4FZAxzwewP9KsgmhHmCPLlcMc88mpwGX7oyPT+X+NQyx5aJ1kZNvTB4NCZc43MNoztHH/66aIZM+WjC5J55IPAGKZwRkMMkDg89u1OUBXZTkMTnGcYoQAyKSmCT1P+eaYh7KN/mckkYHHQ9zTZWQRY3DKnPSkOXBYKNp5Z14P0pfke3AKtjPPB5piD+Lbk5Kk7V6HmnI/3QuCRxnrj/PShMGRdgOQDj86QKN2UBGeWx/WgW45hlQQSoz06HNJGdr4J5xjHp9TTiVTbuUnsec475oiOdxB4IwRTDoKm4Rgs2HzjIpS4E3IJUg4GO/8Ak1GMOBuQkNwc1LIqu6kop2HOce1AFcxnEh3hgcg9h1Hp/nmpWyfKwwXnJzzx6U2PbI0hCbgeuaXcpX5weucHqKQ76joiuXVDkAY5/OmLsVMBhsIxu/wqQY3SHblsDHuKNuY9oA9efWmFxpO6TJOQccex6GlbEYdiyjj0PNOJKxn5V35xwMnFRRgtnhcdWDc96QbiowAj2kFR1BNNCK0rM2eeg/rQ+FVdvy4PGB1yetSgYOCo54zjpmgbI1dApwx2KeWz972NDKCCzEq7HjFOQIoZQoGOfx7mglgAoUcZA74oHcaNgjbJ4798e1BjQhFI+XJOPWpAoIIKgevuKASuXA55IB70CIyQJim0kspJBGaSICTBDHA5BH+NKvNxuAzxwTTsAFxtJBHToKB7IRgJGQqzKF+Y89fY0qBcS4wB0z0psbKSmEMf90Y/nTlILPhOnI4oQMeSnlYHyqT196mjcbwoOCBVc7sMAo3AggYpyg+YTgbz6mgTLCHch2tnHGBSuqqc56jjniombavy4zx070O5XYTjHI3EjincSVxpIHXk4zzSW7RLEFbjBPajG5hjIGMjioghP8Cn64JqWWjMB/g2DpxR1IOAMHnjGai3srDAHGRnP40/a2AAx39SfpWSZo0LLhwAAoBOM4zScBwV5yOp4JxSKWcLu+XI5xSsTHjf9RzxTuIqyxvKV3AKCecjoOvem/ZTGwwMrnPTrVpwwOQAWJwN3p/+qhlLsAsgwvHB60rD5rFRYHQsQvyjoSQD9KglikcqxCrznAXkf4dq0wrgNk5Unjgev/1qiMBcgNkOBuYkHnHpScSlMp/ZWjIeNUGCC/yj9fWrcShSSdoO3O4LnH0/Sn7cDCc/L6gfj+ZqRVKqu44VhhsjnH19aFGwOdx24quwIX2j7uBz3pBGXCbhtGOh5K4/nUqL8oUsCFP3iPqef0pACzxlX4HXI5/z1q7EX6II1IkIIJ2ryT0IoeMDJjJzkkDGcZ//AF0uAzfNJ0B6fxVIOLZVdsMQMk9TTsTcIwsgRZl3sPm4/lT3RvLwo2N0Cgf5/wAimBcFAG+Xq2ePwqUMyg8DcG6ZxkZpku4xdwIyCQAB05PHJpQSGOQD82BjHNKyFiuzCg8Ljg+vWgKplcnDEjHA6UwYikuWBQKQeQRnDVK5PVFBOcEkkf8A66iEeYyS+WbgNt6c1IcBlORxkEAZJ/z/AFoRLHRlmaTfj5Tx0oBZgCwKv3UHvnrTtqmUkDgDrnNRtgllJPXqOuPQUxDgzGX5QAHxz6e1Ep6bcEYI4Pf0oC/OASBxjHY0OUcn5jzz9Men+NAdRHVgigAtzgsT1605AQoUHHckDOCKjOM4JOQMA9KcyhXH97rgUDH4cMQhIXB24HH5U8E7QFXAx2qM7Fyy87PQ809dgxhugz+FMQ1R8xXvjAzTpF+VeQT1PFOwoaTDFs84P8PqaapBTYxyc4PqeBx/KgQgLhxtIKgYJ6f57U4BnQ4ODjCgdKQjzHyOg/h4waFPQodwJ5INA+g9lZV4xkEDkfh/jTVGSwbbz09aVwcKRjHX375zRxkqvzAjJGP84oAhIl8gBsFwccnAqQk5UsDt5JA+lNONgRt2RjnOKfIuWQKoA284pDZFKrsu5WUyE9uwqVhvwu/5mGT/AJ+lClQSFBGeuOMcU1NoBHAAwQxPWmA8AZCjPHpTUDvFjO1s8DikYAzADhiMcGnKflJ+Yjkjt+FAIYMfaODxjPHTvSqCN27lTzzSsVZVb2+X3pF2sD8zcDPHakMYUzIreYd2QCB6U75vPIDADIwp6+9I4YFMsy4bt/EPSnMylwRuz0PH+fSgBueW5wQc568ZpcgsOn1/z0pE5zt5ODx6Y4/pSlhiIn5Se2etADwwO4k4D4wAOlNH+rG58nhRnvzQWX5uRg8tuHSmxjbGvy4Ge5HrSGT4AbqcFe9QxMUXDuEOc4xmnu6duMdMjpVeWUo5CWrS+rK4H86GykZQXK5zjHfHSlQjaBvOCOrHv6UiOC7rtPGMH1PemGRdmAuVHIGCOaxNbEvAJ5/WmqACWwcP1JOaQkK24ANjnFPL5T5jyDg/SmIaQHG0MwTOc5wTUjAZXHbvn86jhIJAwcdBwef880vmAuSEIAHBOQKBWJESPy2xjGcnHelbDH5FAUk4INRxuRHJuQjn0wSf85pYmkIHmqi7jxxwOlO5I5tsbEjJZjwM/n/SpEAMnUA4Od2M4+tRg5fCrtXGeecU751DFVBbB4PGaYDmVSgVmIVz93Ofxp6kSOQ5QqDwfbFMhJZMgBSo6deaVGKtjB3AgYwDnmmiWO2LvcuvX5eT09acFhZMDBBH5f40ISqE4XGeCBUjEQw4AJxg8DNMQ0KpkAOQQOtJvAkfAD/KAxx9aczl2w64IPBB7U5NoRmcD2B9KAFVY2VSpIYnII9e+PelXaULMArMDwO/vmmEsWAIwOuKeFCkIq5A5Jzk0yWNDpLCVAI529ccdj/P8qWIxoEGPlGBv7E/WmwZfcOhA4H1/wAmny+YCqoMkDLAHvkc+9HmHkKVUMylSOd3XinuvyKG3YJye5pM5LFlBQDIbpk03LFTuByOAc9vr+NMRKONhAO8DGe9RxmNd2F+XndgdKVtyKETCkMQadjKu3O7GSOxFMCNXjYAbQVwM7uOPX9KlBToNoAHryDUUf3M53kDBB/zzUm5mdBGeGPOelJA/IASqsRhRyCTz9Dj1pyoiMrqgJ6Yx0phaSTzNi52kYIxz705RmMArnAGSrc569aYDiwLDaCDjHKn9KgiyVIMTDnGc5IOe9TltuAuSOSQexqNmcI5KA8ggbhz26UMEP8ANUMAAfb1pm0AlimFx8wHelA+c8DIGRz/AJ9Kc3meWyk8AAqBQCFOD5YOMjoOp+lNYuCzABixHFKjEYUEng8YpMkOquV6dc9f/rcUAI2S4JUbc8D+v1pWbDrkYJPPGaGXH8Xfn/PrTdv70mM8BuGzwaQyQFxkbFwD0BprMCMKNwBPB/mKApyxALAjAz9aUxA5yxDfdB7gfWmIkQOSvAQdcetN3EIVBG8ZB5602MrleWIA604KVLFuRyTk5/WgBq4aMKyEx4C+uaRhyyHGODntz2pIu2WOehI5FOfiQsp+9yR0xSH1EGRGwXJI4wfWkBKvwQDzng9fekdmIUJyM9fSnhuF6HuQfrQMjgRykjfmc9T2pXZisZZeCxAz1WpYzhiG/DHrUY8wDe2AQQCMfpQAEkuwOcdPrQrMY1AU7t3AP+FBIByc7QAfXNIo+QluCScZ5xSGLKztKp2huMNx0/CmNIyMR5GR2Ocf0qXYTgDk9Tz2NI4kz8kyIPRlzSZSszCcMwODtI6CkRiChZl3jqB603aOdzktnPpg/wCQKUnGCXGTx05rE2Hxsd3U4b3/AEoYNtb7pHUAjPbpSlV4bO0jqAaVskAqPvHnaKZI2LlQ5Jywz9KcoJwSRz97nn8PSo4WcRjzCrDP8PQU8MquyliSAD06CmgAl9ibpB1G1amc/u1BYAdSex+lQKpyACvXPJyfpipcRgqGOVAzlhnpQSEW/q2zkZG0/wA6f8zKCjBAoOM9TTVTax4chiOM5GKVICehdVYcZ6j/AOtVITFG4Mo5EmTnn/PFOTcZBliBjHPt2prRKVTBJX+EevB5oRhuCjqT1IwPwoEyUfIhfcCTyBj/AD2oRWcKzPlj1OewFIQrPIqk7jnHP8v0pU2lQScDpg8E/wCcUxMcRufO/cDzlF5I4/GpRnyypADHqR2piEnowwF4xwTSKwA5wI+cFTjHNMkfIhBAVwitjBHbjpTWOeQcdAST270pCjnI5OeF/wA+lKuMtkDJHAH86YDcPGSFIxt6nsamY7AqjOS3f0xSE70O7BPp6Y4zml3KVVG5II6DvQJ6gzbFbPA4HPTIpBg4XcoBG3359qUIvnk9wMFc9PwpqKpABORn7p6/5zmmFiRQGYLnBIIJ6ZoICvgMcE5DLxgU3KsVJUBh3xT0bG5iucZztHOP84oFsN4aMlG5HTIHTNIC3nFOMEfKKXYqhWYAr27kUBlWQK3BUEnHr6UB6EhXIJJ+XPY+lNkUEHb8hY5yBkH2pImR07ZBxkj2pGIZU3YOCQVPr0H9aAtqOjZssDgqTgY4IFJ5alSASSSSSTwBSRhfMK/xH7xA6j/GkhbKNwdikDnPGaB2JCPnB5K469R9aczruZUbBAwT14/z/OmI3YjnHABoYhXbacddxHO3PrTEl3HJhFRscA44P5DFRxKfNUSEbMjYoHoO59akXHlhMFV6fKePenZDOqkYCrweoHrn8KQXGkKRkliDkAjtSuqhg2SNxxyKTu2wLsIyDjrmmbwyHIZR1GOv1x+lAyYBROSSfz4+lICDH8wwBSRGNyQ23DDJI9KGON5wSu3IBGR9KYhNquwPoBjGOacv3v7wK4J96jY4QPzufHbHoKl53KP4ehHU8CkNjCit2II5BHt/+ulZSxVlzt2jHr70kb5duASPT/ClwAykLz1/CgepHldrEc857elB4CkMQoHBzjNOcbVUMPU7jjmhjgZcEpkkHjp60hiqeSyYLAc03aSCCTtJyADiguv2jhTyuQfUf480IxJKjdgbiPegLDFxvTGQM9u/+TT+qlccHqM5xSuSHRcLg57Zx7UuXjGQgLn+7wKAEBC7SOY0OPrUc1qJ33+Rv9wTUqkbQOQ2eg9ailEny4dQAMDJ60Dv2MRWAUlTkAnOaVQNq5HB7Hr9DTF+6cqc56kcH8KlU/NkLuBGDmsEbi/KJFYL8xBOcUBlCAKhIA2kDn8KF8wSZdcKqgqRz7YpZCzYKth8dMd+1MQ0Iu1dgxtHGe3PepWIXO5MgDoBk/lVfAUZ4Ylck596sK+Ffrv6c9/b86EJoQMGIwAVI+bJ/OnNlUUFQV425xniomeQ8LsBByfpxT5AxkHX5jtYZ6d6YicM2FLjJ744GakDyBEKrx1z/eqHLKAO54x2+maeQxVVB5OSwJ7VSIYjbzCEKKcZ4HQ8/wD6qVXG44UnjhvcdqP3meMEnj06daaqkov+1zjHQ0APU7ozgMNuQcfn/Wl4QKCpIByeSeeTTR821iQd3OelOCNvIWQfewSTgA+1MQ9Wx8wHoeemMUMSDhEXcCQewz2o37Sy5LHqCSOtAxzyA7cg/wB3mmLYjMoVEYqVxwcjoe9ORgn+sIXAypHHtxTnUx7QCQQ3IPzEnHPSpGjMjFSBhRjp39DQGg7DFcgbsYIweSeaRAyqhK85y271pVTOFyFVcgY7dx/SkiBUqyncByGJ+9/nNMQ+Uu7KqoOcZzjt/n9aiQsd5I2YI/8Ar0/kszkgKwxnuT9KbGhKszkNzgHA9OtArEjHnYAFUjPIxj/P9acgbfgAbfUdWpUGdy7/ALoxuP8Ae/yaYM5IQMR6KfamIG3s2Mr1yeaRg7lG+QKfvZH8jR5QQMCx2gZXHX6Z/KkKMrgsc8Z3ZznigY9lOCeBk857/WkLOyg7RyDlD1H+fSnBMqQcYGCKB8pjyRkZJAzjv+tAkJHuHPygnBHcE8U6JmBcqhAJGB6+/wClMZRgAHJBGV6ADPp6U4oFjbLgAHAJ6/jQMX5zyCoLDJPTHFIrOuA2CoGCc8k0FMbQjcA/X/PQ08kPKRl+D64AoExHZjv2LjZjv2pr7klBVuMfdzxinRhecM2Cec8Y9RTZMM6kEgjtxkj0oGC7xOyniPGQx5+tKd7YbADYXI6UqREKc53H5QMjimsBuCBuCSP8/hQBImWUlSpxwM9x71E+9WYM6nccA56D6flUvBYNkhccpSTeXlsdTjqO/wBP60AhnlsjB1IA4XGe3r7c/wAqVw5aMkjGOgPApD+8ALuw5BJP+FKiqcYXKgEk57elAwDNjL4DA9ufp/OlBO8ZK5zkewoG0KRxyMYPI5pkixnnJIzsyOvAoBK7HnDlgpbnPXsKadwiHy4Y9TnI+tOIAUEnlh6/ypgwsBRjjk9B+lADl3iWIg/uzw2ev1oRDgh8kZwuDggf/qNMIHyyBjgKcL2Jxnn6U7PLOrZJADH+7SGMAILEsCB047GpVJckhsjrj1pGKtghcZAxnv7U4bSVEvyg8gAUARNl0xuG4jhvT61Kg3jJDnnsKrOqoWCjKngnuKtRFVQBjL6/IOKLjauc/GeTtPAJxxwKQu25SH3BuCMZx0pkfzKNpwCe46/jT3UbkJHb7w55rnOiw9lZioYKEGcc459fypqnDKnBBx07jrTSQZM5LNtBPbPtihcMu3J2454polomcKJAMHjknGM+gpAMOcsQCenWkcgFS5JOPu9z/wDX5FKgXAYEDHOD2zTAdGqlQ2QeeMjtQshYbSx2g8nufWlK/ICud2Pl5yMetDOAFA+70GDn/P1pk+g5fLRwMou4/l6/0of5m2KxLDjcO1NVVjlZwmcjH+R/npSw7ViUhSRjGOOPY0xCkfIiCXaeoB5yQe9SR4WRlRfl5Oc1EwwMOFBUnbxkgetOJXediruAwvOMg9aEDQ9AEh5AIzwQOn1HpSlQQVyh6Md3SmsqspRADhvug9TQJAs21kKnJHJwc9vwpisSABCOQDngHnpUhO4kqQzdQxGcHvzUbD5izjBOMYwcfjREwVNpTjkYHf8AzimTYklG0p8pKgjoefUmlHyowycAk/NwT9cU132hcg5UgdM9f8/pSysN+7AJJxvxxTCw+EpsbaWAwM+3emKFTHznj5lOOTT3fEeCFAAyT1z07UzO2P5l3EYOCOP/AK+KZJKUXzWUFsMcDnGcDr/OhGKYUZKg7S3p69KQOBIG2BmwCCPQ9BTQQY2OzhuRjjP50BbQcGVGVA2QPb/PFO+RiFxkkE4A6D1x9aZ82BhSQTkk/hwakAImbjgqDkDk0CEhIK4yS2OW7n6mgqAw5CsPlX0NGAEY7BjGOmSfpT85fKqWJ4G4cCmAmVJcMCB1bPIHpQCr85IDcLn+tNZiHUIuVJweafECWBbOMc8daA8wLDzQcEbl5HXj3prrEck5Ck8gdv8AOac7P5qqMbcZGM4/z1oYSbiqKAAOWNABG6EKAcqy5X9KkGGc/fBAx14xTFYOAWVdjHODng/WhSU5YMWxnOO/1oAEVRGwVdnXpzjFMZlklj3BtpG4E8ZPpUqgsh4VRnnsabuZWRcNg84B+7igBVYxqSSCAcMV9T/Ojl1cxgIp9RyfpS4YM4GMY7f59qTLbT0JA4CnvQOwkbjykLKSec+x/wD1UjnDYK44yW/SpFQ5BKjPcj+fvTGEuVG4Eevc8UBuK7iNA7j5fujI4J/pSRtvlwRtGO4+9+NNcON6qxznKjPFPAIlyo4HG4nAoC1gfLh8Y5GMc9BTcq8I3ock5GOfypMlJWG1tmPvHinIr7GLcYxjHekO1gJIkXAYjPAPAAqORkCMXQ7SwyAOtLIX8wd9uCcdBTossz85A5H0NArASFVRtyB1IpQVDHrwBkAYyDTQjrGWkZCwPOB27UgDb0KknGP/ANdAx0jAg5/g9+M0ly5YoIScZwD/ADoYkZJ6r0zQ+7aoVlXHQjnFAxgb7xAyx4PrQ27IKvKoPPyDj/8AXUm0bwVwQw25FNAbHCAj3yKQ0rmBDMGBRo2wM9VyPw/OnoHJYMcKDxjnNPUnAPeo4f8AVn2x/OsDo3FYYGMKVXqCeScUbxkDG08496JCfJJyc8/yNSZPlnn/ADkUyR3G3DLtK9NvOKRZmYZZSuFyScUkfWX2A/8AQqefuvTFcJ32xjAOFyT2zj0prRpvXIJOM88H6UqAFVJHJ/xp5J+bk9QP5U9yXpsAc5Hy4Yjj8PagMQUVQQHPz49aYxJVMk9G/lUjk7nGTjA/kKYEi5x8oO7ueOlLscKdmB/hVcE7TyeCRU5++vuRTEwjDlsFlDHnjnoO9Du3lttBkZjk8/5H4Uqf6sf7x/nSfxD8P50EknzgjYSAckjAOaVyyjAwxGMgnpzinMSJcAnAPA/EUvQDH9+qEOIPC4UlgT93tTRvLvyNnBJ68/0qRuhPfPX8aYOJkxxkc0CBFlZCXChyPy9/aiLe3EgO4jJO7gHtx+FIoHkIcc9M/jQwALkDnI5/A0DH7JA/OAoGfl5P0p+1wnykbveoVY+WnJ6nvUuN0xDcjjr9aZLBlKlR93jPPt/9ekUkSMWYjJ4+br68VNcfdT/e/wDZqhIBnGR6H9KYIcvmFFYlXYfN6Yp5bPllcAdxnJ+lVmP7lf8Adz/49T5CREpHByf50rhYmbiTk7VxkkHOPaiYFYn+dWcjrnA68inMBs6D7wNRXJIhTBPJA/nQOw4cH52KlRkkjj35pymQOVJBOMrz2qKX/XR+68/rUzcMfduf0piSGDcCuTnAyRmnliX2gMV2lgSKa4G2Q4GeeadgMiEjJw3JoHYauVOJG4HRu59j70p5UpnLqcc9/pSQnMoB5GAcUkxxI4HAx/7NQJK46QHbksSox3/Smp0Y7m9dv+fxqFCfNj5P3h/Wng/6QB23EfyoAsuSFYqQVHOR1xSFh5jZbgdv1qBSftDjJxuP8qmThhj0oG1Yjm3HLpIOo7dqRlJ2lSSBxxxmlJPlz89F49qLX5rWAtyfMxzSAdyCXXJUcAY5FKy7I23N85PHOaJRiRscfKP5VCQPJY455Gfzpi6ggDNuQkAnlgf0pyrscnJUc4x29c0MAskYUADBGB9KRuoHbFIp6AQ+zbkA55ZuQV+nrSlAWJQE5xgE9B70jD/Qj9D/AFoIBnhBAIx3oBDwq7iCyhcnA7n6frSRgbQNwYH/AD1psYBDZANRZxAwHTzcf+PUhk0e5pRkBcDOfakEQYZeQA/zqTAN0mQDk8+9NEUe5/kX7x7UAf/Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Bizzari-Giuffrida laryngoscope blade: no vertical flange is present, to allow insertion into small oral cavity or those patients who cannot open the mouth well.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Orebaugh SL. Retraction blades for direct laryngoscopy. In: Atlas of Airway Management: Techniques and Tools, Lippincott Williams &amp; Wilkins, Philadelphia 2007. Copyright &copy; 2007 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_8_15489=[""].join("\n");
var outline_f15_8_15489=null;
var title_f15_8_15490="Yeasts incubate agar";
var content_f15_8_15490=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F52809&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F52809&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Colonies of",
"    <em>",
"     Penicillium marneffei",
"    </em>",
"    yeasts after incubating at 37&deg;C on brain heart infusion agar",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 286px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Drs. Khuanchai Supparatpinyo and Thira Sirisanthana.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_8_15490=[""].join("\n");
var outline_f15_8_15490=null;
var title_f15_8_15491="Patient information: Pap tests (The Basics)";
var content_f15_8_15491=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/16110\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/52/15171\">",
"         Female reproductive anatomy",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?9/63/10227\">",
"         Patient information: Cancer screening (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?27/32/28163\">",
"         Patient information: Cervical cancer (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?5/22/5475\">",
"         Patient information: Human papillomavirus (HPV) vaccine (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?32/40/33411\">",
"         Patient information: Vaginal cancer (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?7/53/8019\">",
"         Patient information: Cervical cancer screening (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?15/4/15429\">",
"         Patient information: Cervical cancer treatment; early stage cancer (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?6/48/6914\">",
"         Patient information: Colposcopy (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?29/46/30436\">",
"         Patient information: Fertility preservation in women with early stage cervical cancer (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?16/44/17092\">",
"         Patient information: Management of high grade cervical squamous intraepithelial lesions (HSIL) and glandular abnormalities (AGC) (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?13/57/14227\">",
"         Patient information: Treatment of precancerous cells of the cervix (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Pap tests (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/pap-tests-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H31191745\">",
"      <span class=\"h1\">",
"       What is a Pap test?",
"      </span>",
"      &nbsp;&mdash;&nbsp;A Pap test (sometimes called a &ldquo;Pap smear&rdquo;) is a test that doctors use to check the cervix for early signs of cancer. The cervix is the part of a woman&rsquo;s body where the uterus and the vagina meet. It is the bottom part of the uterus (",
"      <a class=\"graphic graphic_figure graphicRef80271 \" href=\"UTD.htm?14/52/15171\">",
"       figure 1",
"      </a>",
"      ).",
"     </p>",
"     <p>",
"      To do a Pap test, your doctor or nurse will push apart the walls of your vagina using a device that looks like a duck beak (called a speculum). Then, he or she will use a small tool to collect cells from your cervix. The staff at a lab will look at those cells under a microscope to see if they are abnormal.",
"     </p>",
"     <p>",
"      Do not assume that you are having a Pap test every time the doctor or nurse uses a speculum. That device&mdash;the one that looks like a duck beak&mdash;is used for other reasons, too. If the doctor or nurses uses a speculum, ask whether you are being checked for cervical cancer. &nbsp; &nbsp;",
"     </p>",
"     <p>",
"      Pap tests can find cancer cells or cells that could turn into cancer, called &ldquo;precancer.&rdquo; The test can usually find cancer in the early stages, when it can be treated or even cured.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H31191752\">",
"      <span class=\"h1\">",
"       When should a woman start having Pap tests?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Women should start having Pap tests when they turn 21. They do not need to be sexually active before they start getting Pap tests. When they turn 30, their doctors might also suggest doing another test to check for cervical cancer, called an HPV test. &nbsp;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H31191759\">",
"      <span class=\"h1\">",
"       What should I do to prepare for a Pap test?",
"      </span>",
"      &nbsp;&mdash;&nbsp;You do not need to do anything special to prepare for a pap test. Women sometimes hear that they should not have sex or put anything in their vagina for 2 days before a pap test, but it turns out that recommendation is not necessary. Pap tests work fine even in women who have had sex recently or who have used vaginal lubricants or creams.",
"     </p>",
"     <p>",
"      Do not worry if you have your period on the day of the test. It can still be done even if you are bleeding. If your bleeding is very heavy, you may want to call your doctor or nurse to see if you need to reschedule.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H31191766\">",
"      <span class=\"h1\">",
"       How often should a woman have a Pap test?",
"      </span>",
"      &nbsp;&mdash;&nbsp;That depends on how old she is and what the results of her past Pap tests have been.",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Women age 21 to 29 should have a Pap test every 3 years.",
"       </li>",
"       <li>",
"        Women age 30 and older can have a Pap test every 3 years or a Pap test and HPV test every 5 years.",
"       </li>",
"       <li>",
"        Women age 65 and older should stop having Pap tests if they meet all 3 of these requirements:",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"hyphen-block\">",
"       <li>",
"        They had Pap tests done regularly until they turned 65.",
"       </li>",
"       <li>",
"        They had 3 normal Pap tests in a row.",
"       </li>",
"       <li>",
"        They had no abnormal Pap tests in the past 10 years.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H31191773\">",
"      <span class=\"h1\">",
"       Do I need to get Pap tests if I had a hysterectomy?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you had surgery called a &ldquo;hysterectomy&rdquo; to remove your uterus, ask your doctor if you need to keep having Pap tests. If you no longer have a cervix, and if you did not have cervical cancer before your hysterectomy, you most likely do not need to have Pap testing after surgery.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H31191780\">",
"      <span class=\"h1\">",
"       Do I need to get Pap tests if I had the HPV vaccine?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. You still need to get Pap tests if you got the HPV vaccine. HPV stands for &ldquo;human papillomavirus.&rdquo; It is the virus that causes cervical cancer. Getting the HPV vaccine reduces your chances of getting cervical cancer. But it does not completely protect you. You still need to be checked for cancer.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H31191787\">",
"      <span class=\"h1\">",
"       What if I have an abnormal Pap test?",
"      </span>",
"      &nbsp;&mdash;&nbsp;First, you should know that abnormal Pap tests are common. They are just an initial test, and most women with an abnormal Pap test do not have cancer. If your Pap test has cells that look &ldquo;abnormal,&rdquo; your doctor or nurse can follow up with another test to find out for sure what is going on.",
"     </p>",
"     <p>",
"      Depending on the result of your Pap test, your doctor or nurse might order an HPV test done on the sample that he or she collected for the Pap test. The HPV test checks for infection with a type of HPV virus that can cause cancer. If you do not have this type of HPV virus, you probably do not have cancer. &nbsp;",
"     </p>",
"     <p>",
"      Your doctor might also suggest that you have another Pap test or a test called a colposcopy. These are explained below:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Another Pap test at 12 months &mdash; Sometimes a Pap test shows cells that could be either normal or abnormal. If you wait a few months and have another Pap test, you could find that the cells are back to normal. &nbsp;",
"       </li>",
"       <li>",
"        A colposcopy &mdash; For this test, the doctor or nurse looks at your cervix using a device that looks like a microscope. It allows the doctor or nurse to see the cervix in fine detail. During this test, the doctor or nurse might also take tiny samples of tissue from the cervix. This is called a &ldquo;biopsy.&rdquo; Tissue from the biopsy can go to the lab and be checked for anything abnormal.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      If it turns out that you have cervical cancer or precancer, there are effective treatments available. If your condition was found early, there is a good chance you can be cured.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H31191920\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?27/32/28163?source=see_link\">",
"       Patient information: Cervical cancer (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?32/40/33411?source=see_link\">",
"       Patient information: Vaginal cancer (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?5/22/5475?source=see_link\">",
"       Patient information: Human papillomavirus (HPV) vaccine (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?9/63/10227?source=see_link\">",
"       Patient information: Cancer screening (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?7/53/8019?source=see_link\">",
"       Patient information: Cervical cancer screening (Beyond the Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?6/48/6914?source=see_link\">",
"       Patient information: Colposcopy (Beyond the Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?13/57/14227?source=see_link\">",
"       Patient information: Treatment of precancerous cells of the cervix (Beyond the Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?15/4/15429?source=see_link\">",
"       Patient information: Cervical cancer treatment; early stage cancer (Beyond the Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?29/46/30436?source=see_link\">",
"       Patient information: Fertility preservation in women with early stage cervical cancer (Beyond the Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?16/44/17092?source=see_link\">",
"       Patient information: Management of high grade cervical squamous intraepithelial lesions (HSIL) and glandular abnormalities (AGC) (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?15/8/15491?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 16110 Version 5.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-115.25.216.6-2972EEEA2C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_8_15491=[""].join("\n");
var outline_f15_8_15491=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31191745\">",
"      What is a Pap test?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31191752\">",
"      When should a woman start having Pap tests?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31191759\">",
"      What should I do to prepare for a Pap test?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31191766\">",
"      How often should a woman have a Pap test?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31191773\">",
"      Do I need to get Pap tests if I had a hysterectomy?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31191780\">",
"      Do I need to get Pap tests if I had the HPV vaccine?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31191787\">",
"      What if I have an abnormal Pap test?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31191920\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/16110\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/52/15171\">",
"      Female reproductive anatomy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?9/63/10227?source=related_link\">",
"      Patient information: Cancer screening (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?27/32/28163?source=related_link\">",
"      Patient information: Cervical cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?7/53/8019?source=related_link\">",
"      Patient information: Cervical cancer screening (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?15/4/15429?source=related_link\">",
"      Patient information: Cervical cancer treatment; early stage cancer (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?6/48/6914?source=related_link\">",
"      Patient information: Colposcopy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?29/46/30436?source=related_link\">",
"      Patient information: Fertility preservation in women with early stage cervical cancer (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?5/22/5475?source=related_link\">",
"      Patient information: Human papillomavirus (HPV) vaccine (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?16/44/17092?source=related_link\">",
"      Patient information: Management of high grade cervical squamous intraepithelial lesions (HSIL) and glandular abnormalities (AGC) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?13/57/14227?source=related_link\">",
"      Patient information: Treatment of precancerous cells of the cervix (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?32/40/33411?source=related_link\">",
"      Patient information: Vaginal cancer (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_8_15492="Benzoyl peroxide and hydrocortisone: Patient drug information";
var content_f15_8_15492=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Benzoyl peroxide and hydrocortisone: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/3/59?source=see_link\">",
"     see \"Benzoyl peroxide and hydrocortisone: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F140114\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Vanoxide-HC&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F140115\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Vanoxide-HC&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10013892\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691693",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat pimples (acne).",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10013891\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701607",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to benzoyl peroxide, hydrocortisone, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10013896\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697762",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use of other skin products may cause more irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697788",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may get sunburned more easily. Avoid sun, sunlamps, and tanning beds. Use sunscreen and wear clothing and eyewear that protects you from the sun.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697705",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may stain clothing or fabric.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697667",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may stain hair.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10013897\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698029",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry skin.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698344",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698191",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Itching.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697946",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in color of skin.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10013899\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10013894\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694772",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take this drug by mouth. Use on your skin only. Keep out of your mouth, nose, and eyes (may burn).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694623",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Clean affected part before use. Make sure to dry well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Shake well before use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694440",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put a thin layer on the affected skin and rub in gently.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695334",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Makeup may be used after the skin has dried.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10013895\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696441",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put on a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696452",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not put on 2 doses or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10013900\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Throw away any part not used after 3 months.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10013901\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11904 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-200.131.240.2-CEC8CE9A1B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_8_15492=[""].join("\n");
var outline_f15_8_15492=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140114\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140115\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013892\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013891\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013896\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013897\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013899\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013894\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013895\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013900\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013901\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?0/3/59?source=related_link\">",
"      Benzoyl peroxide and hydrocortisone: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_8_15493="Dihydrocodeine, chlorpheniramine, and phenylephrine: Patient drug information";
var content_f15_8_15493=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Dihydrocodeine, chlorpheniramine, and phenylephrine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/20/8516?source=see_link\">",
"     see \"Dihydrocodeine, chlorpheniramine, and phenylephrine: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F160362\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Coldcough PD;",
"     </li>",
"     <li>",
"      Novahistine DH;",
"     </li>",
"     <li>",
"      Tusscough DHC&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10018981\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700543",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before giving this drug to a child. Check all of your child's drugs, including OTC, with doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10018983\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691646",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop coughing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691589",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to ease allergy signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691980",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat nose stuffiness.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10018982\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702731",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to phenylephrine, dihydrocodeine, chlorpheniramine, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705190",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Asthma, glaucoma, very bad heart disease, very high blood pressure, bowel block, ulcer disease, or trouble passing urine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703859",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have taken certain drugs used for low mood (depression) like isocarboxazid, phenelzine, or tranylcypromine or drugs used for Parkinson's disease like selegiline or rasagiline in the last 14 days. Taking this drug within 14 days of those drugs can cause very bad high blood pressure. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10018987\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697780",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wear disease medical alert ID (identification).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697693",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may be habit-forming with long-term use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697679",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug is not for coughs due to smoking or lung disease.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697197",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes), talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697161",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an enlarged prostate, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697265",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood pressure, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697340",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have seizures, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697343",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have thyroid disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, mixed drinks, or other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697564",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Limit your use of caffeine (for example, tea, coffee, cola) and chocolate. Use with this drug may cause nervousness, shakiness, and a fast heartbeat.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10018988\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry mouth. Good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help. See a dentist often.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698279",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Nervous and excitable.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698162",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to sleep.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10018990\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698625",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure, a fast heartbeat, or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Cough that does not go away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699014",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very hard stools (constipation).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10018985\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10018986\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696540",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Many times this drug is taken on an as needed basis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10018991\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10018992\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11630 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-58.240.98.179-9F9DC17642-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_8_15493=[""].join("\n");
var outline_f15_8_15493=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160362\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018981\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018983\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018982\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018987\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018988\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018990\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018985\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018986\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018991\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018992\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?8/20/8516?source=related_link\">",
"      Dihydrocodeine, chlorpheniramine, and phenylephrine: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_8_15494="Periodic fever syndromes and other autoinflammatory diseases: An overview";
var content_f15_8_15494=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Periodic fever syndromes and other autoinflammatory diseases: An overview",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/8/15494/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/8/15494/contributors\">",
"     Peter A Nigrovic, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/8/15494/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/8/15494/contributors\">",
"     E Richard Stiehm, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/8/15494/contributors\">",
"     Sheldon L Kaplan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/8/15494/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/8/15494/contributors\">",
"     Elizabeth TePas, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?15/8/15494/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 5, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Host defenses involve both antigen-specific and antigen-independent mechanisms. The antigen-specific arm of the immune response, referred to as acquired or adaptive immunity, involves antigen recognition by T and B lymphocytes. Many well-known disorders of immune excess result from a failure of",
"    <span class=\"nowrap\">",
"     self/non-self",
"    </span>",
"    discrimination by these cells. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/57/3992?source=see_link\">",
"     \"Overview of autoimmunity\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Another, phylogenetically older arm of the immune response is termed the innate immune system. Innate immune mechanisms become activated upon recognition of molecular markers of infection or injury. Examples include complement, which &ldquo;fixes&rdquo; on certain microbial surfaces, and the Toll-like receptors on the surface of many cell types that recognize pathogen-associated molecular patterns (PAMPs), such as bacterial lipopolysaccharides (LPS). Macrophages, neutrophils, mast cells, and natural killer cells are among the principal cellular effectors of innate immunity. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/59/11190?source=see_link\">",
"     \"Complement pathways\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/54/23401?source=see_link\">",
"     \"Toll-like receptors: Roles in disease and therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    While the paradigm of autoimmunity is well established, a second category of immune-mediated diseases not based on aberrant targeting of self by lymphocytes and antibodies is still being defined. Autoinflammatory diseases arise through inappropriate activation of antigen-independent inflammatory mechanisms. Since autoinflammatory diseases prominently involve mediators and cells of the innate immune system, they may broadly be considered to represent primary diseases of innate immunity, though cells more typically associated with adaptive immunity (such as lymphocytes) could potentially also contribute to autoinflammation [",
"    <a class=\"abstract\" href=\"UTD.htm?15/8/15494/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The best characterized autoinflammatory diseases are relatively rare but florid conditions arising from mutations in single genes. The prototypical autoinflammatory disorders are the periodic fever syndromes. However, other autoinflammatory disorders have been identified in which fever is generally not the most compelling clinical feature.",
"   </p>",
"   <p>",
"    An overview of autoinflammatory diseases is presented here with a focus on shared pathogenetic and pathophysiologic mechanisms. While the most salient features of the individual disorders are discussed in this topic, more detailed descriptions of the clinical manifestations, diagnosis, and treatment of the major autoinflammatory diseases are presented elsewhere. (See appropriate topics.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     THE PERIODIC FEVER SYNDROMES",
"    </span>",
"    &nbsp;&mdash;&nbsp;On occasion, the clinician encounters a patient with a history of fevers that recur over months or years in the absence of associated viral or bacterial infection. In such cases, after exclusion of unusual infections and malignancy, consideration turns to a set of uncommon disorders whose hallmark is episodic fever (",
"    <a class=\"graphic graphic_table graphicRef67805 \" href=\"UTD.htm?5/54/5997\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/8/15494/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Diagnosis in these cases is important because of potential implications for therapy, monitoring for the development of secondary (AA) amyloidosis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/8/15494/abstract/4\">",
"     4",
"    </a>",
"    ], and the need for genetic counseling [",
"    <a class=\"abstract\" href=\"UTD.htm?15/8/15494/abstract/5\">",
"     5",
"    </a>",
"    ]. However, many patients still defy diagnostic classification despite advances in diagnostic testing [",
"    <a class=\"abstract\" href=\"UTD.htm?15/8/15494/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Careful attention to the clinical history can help guide the clinician when deciding whom to refer for genetic testing. In a study of 228 Italian patients with periodic fever, the following findings were noted [",
"    <a class=\"abstract\" href=\"UTD.htm?15/8/15494/abstract/7\">",
"     7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Detection of a relevant mutation was more likely in the presence of a family history of periodic fever, early age at disease onset, and the presence of abdominal pain (which was the strongest positive predictor), chest pain, or diarrhea. In contrast, aphthous ulcers (also known as canker sores) were a negative predictor (odds ratio 0.2).",
"     </li>",
"     <li>",
"      Two features were helpful in distinguishing among the disorders: the duration of fever, which is shortest in familial Mediterranean fever (mean two to three days) and longest in the tumor necrosis factor alpha receptor 1 associated syndrome (TRAPS, mean 15 days in severe disease and five to nine days in mild disease), and the presence of vomiting or splenomegaly, which may be seen in the hyperimmunoglobulin D syndrome.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Fever in most of these disorders is usually episodic and recurrent rather than truly periodic, with the exception of PFAPA (periodic fevers with aphthous stomatitis, pharyngitis, and adenitis). (See",
"    <a class=\"local\" href=\"#H6\">",
"     'PFAPA syndrome'",
"    </a>",
"    below.) The presence of a predictable recurrent fever pattern should also trigger consideration of cyclic neutropenia, which may be of childhood or adult onset. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/61/42966?source=see_link\">",
"     \"Cyclic neutropenia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Familial Mediterranean fever",
"    </span>",
"    &nbsp;&mdash;&nbsp;Familial Mediterranean fever (FMF) is the most common of the periodic fever syndromes. FMF is an autosomal recessive disorder in which there is a mutation in the MEFV gene encoding the protein pyrin, one function of which is regulation of the production of interleukin-1 beta, a mediator also implicated in several other autoinflammatory disorders.",
"   </p>",
"   <p>",
"    FMF is characterized by episodic attacks of fever lasting one to three days and is accompanied, in most cases, by abdominal pain, pleurisy, and arthralgias or arthritis, the result of accompanying serositis and synovitis. Attacks are accompanied by an elevation in peripheral white blood cell count and acute phase markers, while fluid from inflamed joints exhibits a neutrophil-predominant leukocytosis. Persistent inflammation can lead to secondary (AA) amyloidosis.",
"   </p>",
"   <p>",
"    The diagnosis may be strongly suggested by patient ethnicity. Sephardic Jews, Armenians, North Africans, Turks, and, to a lesser extent, Ashkenazi Jews, Greeks, and Italians are potential carriers. However, individuals outside these groups have also been affected.",
"   </p>",
"   <p>",
"    The pathophysiology, clinical manifestations, diagnosis, and management of FMF are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/32/32261?source=see_link\">",
"     \"Pathophysiology of familial Mediterranean fever\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/31/25078?source=see_link\">",
"     \"Clinical manifestations and diagnosis of familial Mediterranean fever\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/3/8247?source=see_link\">",
"     \"Management of familial Mediterranean fever\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     TNF receptor-1 associated periodic syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The second periodic fever for which the genetic defect was described is tumor necrosis factor (TNF) receptor-1 associated periodic syndrome (TRAPS), formerly known as familial Hibernian fever or familial periodic fever. TRAPS is inherited in an autosomal dominant fashion with incomplete penetrance. The genetic defect in TRAPS resides in the gene that encodes the 55 kDa receptor for tumor necrosis factor (the TNFR1 gene).",
"   </p>",
"   <p>",
"    Patients may present from infancy to the 40s and even beyond, though more than half develop symptoms in the first decade of life. Though many patients are of Irish (Hibernian) and Scottish descent, other ethnicities are also represented. Flares commonly last for at least five days and often continue for more than two weeks. They are typically accompanied by conjunctivitis and periorbital edema in addition to focal migratory myalgias, rash, abdominal pain, and, occasionally, monoarthritis. The rash may take a relatively characteristic form, with single or multiple erythematous patches that may spread distally down an extremity.",
"   </p>",
"   <p>",
"    The genetics, clinical manifestations, pathogenesis, prognosis, and treatment of TRAPS are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/56/28551?source=see_link\">",
"     \"Tumor necrosis factor receptor-1 associated periodic syndrome (TRAPS)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Hyper-IgD syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The hyperimmunoglobulin D syndrome (HIDS) is an autosomal recessive periodic fever syndrome usually associated with mutations in the MVK gene that encodes mevalonate kinase.",
"   </p>",
"   <p>",
"    More than two-thirds of patients present within the first year of life with episodic attacks of fever lasting three to seven days, accompanied, in most cases, by chills, cervical lymphadenopathy, abdominal pain, and vomiting or diarrhea. Some patients experience headache, arthralgias or arthritis, aphthous ulceration, a pleomorphic rash, and, occasionally, splenomegaly. Attacks may be precipitated by vaccination, viral infection, trauma, and stress.",
"   </p>",
"   <p>",
"    Most patients have characteristic abnormalities in immunoglobulins, including elevated levels of IgD (&gt;100 international",
"    <span class=\"nowrap\">",
"     units/mL),",
"    </span>",
"    and 80 percent also have elevated IgA. Acute phase reactants rise strikingly with fevers and sometimes remain elevated between episodes.",
"   </p>",
"   <p>",
"    The clinical manifestations, diagnosis, pathophysiology, and management of this condition are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/43/3768?source=see_link\">",
"     \"Hyperimmunoglobulin-D syndrome: Clinical manifestations and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/31/9720?source=see_link\">",
"     \"Hyperimmunoglobulin-D syndrome: Pathophysiology\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/7/23670?source=see_link\">",
"     \"Hyperimmunoglobulin-D syndrome: Management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     PFAPA syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Periodic fever with aphthous stomatitis, pharyngitis, and adenitis (PFAPA) is a relatively common entity compared with the other periodic fever syndromes. The PFAPA syndrome is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/11/8377?source=see_link\">",
"     \"Periodic fever with aphthous stomatitis, pharyngitis and adenitis (PFAPA syndrome)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Briefly, the disorder is characterized by febrile episodes beginning in early childhood that recur approximately every three to four weeks and that are associated with typical clinical features in the absence of other cause.",
"   </p>",
"   <p>",
"    Episodes are abrupt in onset, last three to six days, and may be accompanied by one or more of the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Pharyngitis (exudative or nonexudative)",
"     </li>",
"     <li>",
"      Mild aphthous ulcerations",
"     </li>",
"     <li>",
"      Lymphadenopathy",
"     </li>",
"     <li>",
"      Chills (rigors)",
"     </li>",
"     <li>",
"      Fatigue",
"     </li>",
"     <li>",
"      Headache",
"     </li>",
"     <li>",
"      Mild abdominal pain",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, in many patients, regularly recurrent fevers are the only prominent clinical finding. Leukocytosis and elevation of inflammatory markers occur acutely during episodes and return to normal between episodes, when patients are vigorous and grow normally. Most patients with PFAPA outgrow the febrile episodes with time, and no long-term consequences have been identified.",
"   </p>",
"   <p>",
"    The etiology of PFAPA has not been defined. It is discussed here because of its presentation as recurrent, unexplained fever, but whether the disease truly represents an autoinflammatory condition remains uncertain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES",
"    </span>",
"    &nbsp;&mdash;&nbsp;A group of three clinically overlapping autoinflammatory disorders, known collectively as the cryopyrin-associated periodic syndromes (CAPS) or cryopyrinopathies, include fever usually as an ancillary feature rather than the presenting complaint. These conditions include familial cold autoinflammatory syndrome, Muckle-Wells syndrome, and neonatal onset multisystem inflammatory disorder. These disorders are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/58/24487?source=see_link\">",
"     \"Cryopyrin-associated periodic syndromes and related disorders\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     PAPA SYNDROME",
"    </span>",
"    &nbsp;&mdash;&nbsp;The syndrome of pyogenic sterile arthritis, pyoderma gangrenosum, and acne (PAPA) is a rare autosomal dominant condition that presents in the first decade of life with pauciarticular, destructive arthritis typically involving the elbow, knee,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    ankle [",
"    <a class=\"abstract\" href=\"UTD.htm?15/8/15494/abstract/8\">",
"     8",
"    </a>",
"    ]. Severe cystic acne develops in most patients in early adolescence, while pyoderma gangrenosum and pathergy-like sterile abscesses at injection sites occur in a subset of patients. Bone marrow suppression in the event of exposure to sulfonamide medications may also be observed.",
"   </p>",
"   <p>",
"    Linkage analysis identified mutations in the gene PSTPIP1, encoding a protein that interacts with pyrin (the protein mutated in familial Mediterranean fever) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/8/15494/abstract/9\">",
"     9",
"    </a>",
"    ]. These mutations strikingly increase the binding of the PSTPIP1 protein to pyrin, presumably interfering with the inhibitory effect of pyrin on the production of active IL-1 [",
"    <a class=\"abstract\" href=\"UTD.htm?15/8/15494/abstract/10\">",
"     10",
"    </a>",
"    ]. Treatment has been with glucocorticoids, although anti-TNF therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"     etanercept",
"    </a>",
"    , as well as IL-1 antagonism with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/18/294?source=see_link\">",
"     anakinra",
"    </a>",
"    , appears promising [",
"    <a class=\"abstract\" href=\"UTD.htm?15/8/15494/abstract/11-13\">",
"     11-13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     BLAU SYNDROME",
"    </span>",
"    &nbsp;&mdash;&nbsp;Blau syndrome is an autosomal dominant condition characterized by granulomatous inflammation of the skin, eye, and joints (MIM 186580) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/8/15494/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. Patients exhibit a papular erythematous rash, sometimes only transiently. Arthritis develops in the first decade of life, often as minimally symptomatic swelling in wrists, ankles, knees,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    elbows with progressive flexion contractures of the fingers (camptodactyly). Biopsy usually reveals synovial granulomas. Granulomatous uveitis may also occur and can lead to glaucoma and blindness.",
"   </p>",
"   <p>",
"    Blau syndrome appears to be due to mutations in NOD2 that are located in a different region from mutations of the same gene seen in some cases of Crohn&rsquo;s disease, another disease of granulomatous inflammation [",
"    <a class=\"abstract\" href=\"UTD.htm?15/8/15494/abstract/16\">",
"     16",
"    </a>",
"    ]. Mutations in NOD2 (also called CARD15 and IBD1) are also found in children with early-onset sarcoidosis (MIM 609464), a sporadically occurring condition usually appearing before age four that shares an identical phenotype with Blau syndrome. Blau syndrome and early sarcoid are believed to belong to the same disease spectrum [",
"    <a class=\"abstract\" href=\"UTD.htm?15/8/15494/abstract/17,18\">",
"     17,18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An international registry of patients with pediatric granulomatous arthritis, including Blau syndrome and early-onset sarcoidosis, has been established to advance the study of this syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?15/8/15494/abstract/19\">",
"     19",
"    </a>",
"    ]. Atypical manifestations other than the classic triad include fever, cranial neuropathies, arteritis, and granulomatous involvement of visceral organs [",
"    <a class=\"abstract\" href=\"UTD.htm?15/8/15494/abstract/20\">",
"     20",
"    </a>",
"    ]. The term &ldquo;juvenile systemic granulomatosis&rdquo; has also been used for this condition. At least four asymptomatic carriers of the disease-related mutation have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?15/8/15494/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    NOD2 has several potential functions. These include mediating responsiveness to the bacterial cell wall component muramyl dipeptide, activating NF kappa B, and regulating apoptosis. The role of interleukin-1 beta overproduction is controversial [",
"    <a class=\"abstract\" href=\"UTD.htm?15/8/15494/abstract/22,23\">",
"     22,23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The autoinflammatory diseases constitute a family of disorders characterized by aberrant activation of inflammatory pathways in the absence of antigen-directed autoimmunity. These include the periodic fever syndromes (familial Mediterranean fever [FMF], TNF receptor-1 associated periodic syndrome [TRAPS]), the hyper-IgD syndrome; periodic fevers with aphthous stomatitis pharyngitis and adenitis (PFAPA) syndrome; and the three overlapping syndromes related to mutations in the gene for the protein cryopyrin (familial cold autoinflammatory syndrome, Muckle-Wells syndrome, and neonatal onset multisystem inflammatory disease).",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15494/abstract/1\">",
"      McDermott MF, Aksentijevich I, Galon J, et al. Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes. Cell 1999; 97:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15494/abstract/2\">",
"      Stojanov S, Kastner DL. Familial autoinflammatory diseases: genetics, pathogenesis and treatment. Curr Opin Rheumatol 2005; 17:586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15494/abstract/3\">",
"      Tunca M, Ozdogan H. Molecular and genetic characteristics of hereditary autoinflammatory diseases. Curr Drug Targets Inflamm Allergy 2005; 4:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15494/abstract/4\">",
"      van der Hilst JC, Simon A, Drenth JP. Hereditary periodic fever and reactive amyloidosis. Clin Exp Med 2005; 5:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15494/abstract/5\">",
"      Shinar Y, Obici L, Aksentijevich I, et al. Guidelines for the genetic diagnosis of hereditary recurrent fevers. Ann Rheum Dis 2012; 71:1599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15494/abstract/6\">",
"      Simon A, van der Meer JW, Vesely R, et al. Approach to genetic analysis in the diagnosis of hereditary autoinflammatory syndromes. Rheumatology (Oxford) 2006; 45:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15494/abstract/7\">",
"      Gattorno M, Sormani MP, D'Osualdo A, et al. A diagnostic score for molecular analysis of hereditary autoinflammatory syndromes with periodic fever in children. Arthritis Rheum 2008; 58:1823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15494/abstract/8\">",
"      Lindor NM, Arsenault TM, Solomon H, et al. A new autosomal dominant disorder of pyogenic sterile arthritis, pyoderma gangrenosum, and acne: PAPA syndrome. Mayo Clin Proc 1997; 72:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15494/abstract/9\">",
"      Wise CA, Gillum JD, Seidman CE, et al. Mutations in CD2BP1 disrupt binding to PTP PEST and are responsible for PAPA syndrome, an autoinflammatory disorder. Hum Mol Genet 2002; 11:961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15494/abstract/10\">",
"      Shoham NG, Centola M, Mansfield E, et al. Pyrin binds the PSTPIP1/CD2BP1 protein, defining familial Mediterranean fever and PAPA syndrome as disorders in the same pathway. Proc Natl Acad Sci U S A 2003; 100:13501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15494/abstract/11\">",
"      Cortis E, De Benedetti F, Insalaco A, et al. Abnormal production of tumor necrosis factor (TNF) -- alpha and clinical efficacy of the TNF inhibitor etanercept in a patient with PAPA syndrome [corrected]. J Pediatr 2004; 145:851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15494/abstract/12\">",
"      Stichweh DS, Punaro M, Pascual V. Dramatic improvement of pyoderma gangrenosum with infliximab in a patient with PAPA syndrome. Pediatr Dermatol 2005; 22:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15494/abstract/13\">",
"      Dierselhuis MP, Frenkel J, Wulffraat NM, Boelens JJ. Anakinra for flares of pyogenic arthritis in PAPA syndrome. Rheumatology (Oxford) 2005; 44:406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15494/abstract/14\">",
"      Blau EB. Familial granulomatous arthritis, iritis, and rash. J Pediatr 1985; 107:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15494/abstract/15\">",
"      Manouvrier-Hanu S, Puech B, Piette F, et al. Blau syndrome of granulomatous arthritis, iritis, and skin rash: a new family and review of the literature. Am J Med Genet 1998; 76:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15494/abstract/16\">",
"      Miceli-Richard C, Lesage S, Rybojad M, et al. CARD15 mutations in Blau syndrome. Nat Genet 2001; 29:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15494/abstract/17\">",
"      Kanazawa N, Okafuji I, Kambe N, et al. Early-onset sarcoidosis and CARD15 mutations with constitutive nuclear factor-kappaB activation: common genetic etiology with Blau syndrome. Blood 2005; 105:1195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15494/abstract/18\">",
"      Ros&eacute; CD, Doyle TM, McIlvain-Simpson G, et al. Blau syndrome mutation of CARD15/NOD2 in sporadic early onset granulomatous arthritis. J Rheumatol 2005; 32:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15494/abstract/19\">",
"      Ros&eacute; CD, Wouters CH, Meiorin S, et al. Pediatric granulomatous arthritis: an international registry. Arthritis Rheum 2006; 54:3337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15494/abstract/20\">",
"      Ros&eacute; CD, Ar&oacute;stegui JI, Martin TM, et al. NOD2-associated pediatric granulomatous arthritis, an expanding phenotype: study of an international registry and a national cohort in Spain. Arthritis Rheum 2009; 60:1797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15494/abstract/21\">",
"      Saulsbury FT, Wouters CH, Martin TM, et al. Incomplete penetrance of the NOD2 E383K substitution among members of a pediatric granulomatous arthritis pedigree. Arthritis Rheum 2009; 60:1804.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15494/abstract/22\">",
"      Ar&oacute;stegui JI, Arnal C, Merino R, et al. NOD2 gene-associated pediatric granulomatous arthritis: clinical diversity, novel and recurrent mutations, and evidence of clinical improvement with interleukin-1 blockade in a Spanish cohort. Arthritis Rheum 2007; 56:3805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15494/abstract/23\">",
"      Martin TM, Zhang Z, Kurz P, et al. The NOD2 defect in Blau syndrome does not result in excess interleukin-1 activity. Arthritis Rheum 2009; 60:611.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5597 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-201.65.114.212-C0B5FDA9AB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_8_15494=[""].join("\n");
var outline_f15_8_15494=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H10\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      THE PERIODIC FEVER SYNDROMES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Familial Mediterranean fever",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      TNF receptor-1 associated periodic syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Hyper-IgD syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      PFAPA syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      PAPA SYNDROME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      BLAU SYNDROME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/5597\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/5597|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?5/54/5997\" title=\"table 1\">",
"      Hereditary periodic fevers",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/31/25078?source=related_link\">",
"      Clinical manifestations and diagnosis of familial Mediterranean fever",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/59/11190?source=related_link\">",
"      Complement pathways",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/58/24487?source=related_link\">",
"      Cryopyrin-associated periodic syndromes and related disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/61/42966?source=related_link\">",
"      Cyclic neutropenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/43/3768?source=related_link\">",
"      Hyperimmunoglobulin-D syndrome: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/7/23670?source=related_link\">",
"      Hyperimmunoglobulin-D syndrome: Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/31/9720?source=related_link\">",
"      Hyperimmunoglobulin-D syndrome: Pathophysiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/3/8247?source=related_link\">",
"      Management of familial Mediterranean fever",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/57/3992?source=related_link\">",
"      Overview of autoimmunity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/32/32261?source=related_link\">",
"      Pathophysiology of familial Mediterranean fever",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/11/8377?source=related_link\">",
"      Periodic fever with aphthous stomatitis, pharyngitis and adenitis (PFAPA syndrome)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/54/23401?source=related_link\">",
"      Toll-like receptors: Roles in disease and therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/56/28551?source=related_link\">",
"      Tumor necrosis factor receptor-1 associated periodic syndrome (TRAPS)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_8_15495="Etoposide phosphate: Drug information";
var content_f15_8_15495=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Etoposide phosphate: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?39/43/40628?source=see_link\">",
"    see \"Etoposide phosphate: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708770\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F169380\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Etopophos&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F169405\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antineoplastic Agent, Podophyllotoxin Derivative;",
"     </li>",
"     <li>",
"      Antineoplastic Agent, Topoisomerase II Inhibitor",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F169383\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual protocols.",
"     <b>",
"      Note:",
"     </b>",
"     Etoposide phosphate is a prodrug of etoposide, doses should be expressed as the desired",
"     <b>",
"      ETOPOSIDE",
"     </b>",
"     dose;",
"     <b>",
"      not",
"     </b>",
"     as the etoposide phosphate dose. (eg, etoposide phosphate equivalent to ____ mg etoposide). Etoposide phosphate 113.5 mg is equivalent to etoposide 100 mg.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Small cell lung cancer:",
"     </b>",
"     I.V. (in combination with other approved chemotherapeutic drugs): Etoposide 35 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day for 4 days up to 50 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day for 5 days. Courses are repeated at 3- to 4-week intervals after adequate recovery from toxicity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Testicular cancer:",
"     </b>",
"     I.V. (in combination with other approved chemotherapeutic agents): Etoposide 50-100 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day on days 1-5 to 100 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day on days 1, 3, and 5. Courses are repeated at 3- to 4-week intervals after adequate recovery from toxicity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Indication-specific unlabeled dosing:",
"     </b>",
"     Refer to Etoposide monograph.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F169384\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F169385\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Manufacturer recommended guidelines:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &gt;50 mL/minute: No adjustment required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     15-50 mL/minute: Administer 75% of dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;15 mL minute: Data are not available; consider further dose reductions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Etoposide phosphate is rapidly and completely converted to etoposide in plasma, please refer to Etoposide monograph for additional renal dosing adjustments (for etoposide).",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F169386\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">",
"     The FDA-approved labeling does not contain dosing adjustment guidelines. Etoposide phosphate is rapidly and completely converted to etoposide in plasma; please refer to Etoposide monograph for etoposide hepatic dosing adjustments.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F169361\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution [strength expressed as base]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Etopophos&reg;: 100 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F169346\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F169365\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Infuse by slow I.V. infusion over 5-210 minutes; risk of hypotension may increase with rate of infusion. Do not administer as a bolus injection.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F169411\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     W, NS, sterile water for injection.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Acyclovir, amikacin, aminophylline, ampicillin, ampicillin/sulbactam, anidulafungin, aztreonam, bleomycin, bumetanide, buprenorphine, butorphanol, calcium gluconate, carboplatin, carmustine, caspofungin, cefazolin, cefotaxime, cefotetan, cefoxitin, ceftazidime, cefuroxime, cimetidine, ciprofloxacin, cisplatin, clindamycin, cyclophosphamide, cytarabine, dacarbazine, dactinomycin, daunorubicin, dexamethasone sodium phosphate, diphenhydramine, dobutamine, dopamine, doripenem, doxorubicin, doxycycline, droperidol, enalaprilat, famotidine, floxuridine, fluconazole, fludarabine, fluorouracil, furosemide, gallium nitrate, ganciclovir, gemcitabine, gentamicin, granisetron, haloperidol, heparin, hydrocortisone sodium phosphate, hydrocortisone sodium succinate, hydromorphone, hydroxyzine, idarubicin, ifosfamide, leucovorin calcium, linezolid, lorazepam, magnesium sulfate, mannitol, meperidine, mesna, methotrexate, metoclopramide, metronidazole, minocycline, mitoxantrone, morphine, nalbuphine, ondansetron, oxaliplatin, paclitaxel, piperacillin, piperacillin/tazobactam, potassium chloride, promethazine, ranitidine, sodium bicarbonate, streptozocin, sulfamethoxazole/trimethoprim, teniposide, thiotepa, ticarcillin/clavulanate, tobramycin, vancomycin, vinblastine, vincristine, zidovudine.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Amphotericin B, cefepime, chlorpromazine, imipenem/cilastatin, methylprednisolone sodium succinate, mitomycin, prochlorperazine edisylate.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Ceftriaxone.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Incompatible:",
"     </b>",
"     Ceftriaxone.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F169364\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of refractory testicular tumors; treatment of small cell lung cancer",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F2138084\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Etoposide phosphate may be confused with etoposide,  teniposide",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Etoposide phosphate is a prodrug of etoposide and is rapidly converted in the plasma to etoposide. To avoid confusion or dosing errors,",
"       <b>",
"        dosage should be expressed as the desired etoposide dose,",
"       </b>",
"       not as the etoposide phosphate dose (eg, etoposide phosphate equivalent to ____ mg etoposide).",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F169403\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Also see adverse reactions for",
"     <b>",
"      etoposide;",
"     </b>",
"     etoposide phosphate is converted to etoposide, adverse reactions experienced with etoposide would also be expected with etoposide phosphate.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Chills/fever (24%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Alopecia (33% to 44%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea/vomiting (37%), anorexia (16%), mucositis (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Leukopenia (91%; grade 4: 17%; nadir: day 15-22; recovery: usually by day 21), neutropenia (88%; grade 4: 37%; nadir: day 12-19; recovery: usually by day 21), anemia (72%; grades 3/4: 19%), thrombocytopenia (23%; grade 4: 9%; nadir: day 10-15; recovery: usually by day 21)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Weakness/malaise (39%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Hypotension (1% to 5%), hypertension (3%), facial flushing (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Dizziness (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Skin rash (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Constipation (8%), abdominal pain (7%), diarrhea (6%), taste perversion (6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Extravasation/phlebitis (5%; including swelling, pain, cellulitis, necrosis, and/or skin necrosis at site of infiltration)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Anaphylactic-type reactions (3%; including chills, diaphoresis, fever, rigor, tachycardia, bronchospasm, dyspnea, pruritus)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Acute leukemia (with/without preleukemia phase), anaphylactic-like reactions, blindness (transient, cortical), cyanosis, dysphagia, erythema, facial swelling, hepatic toxicity, hyperpigmentation, hypersensitivity-associated apnea, infection, interstitial pneumonitis, laryngospasm, maculopapular rash, neutropenic fever, optic neuritis, perivasculitis, pruritus, pulmonary fibrosis, radiation recall dermatitis, seizure, Stevens-Johnson syndrome, tongue swelling, toxic epidermal necrolysis, urticaria",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F169368\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to etoposide, etoposide phosphate, or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F169350\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bone marrow suppression:",
"     <b>",
"      [U.S. Boxed Warning]: Severe dose-limiting and dose-related myelosuppression with resulting infection or bleeding may occur.",
"     </b>",
"     Treatment should be withheld for platelets &lt;50,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     or absolute neutrophil count (ANC) &lt;500/mm",
"     <sup>",
"      3",
"     </sup>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity reaction: May cause anaphylactic-like reactions manifested by chills, fever, tachycardia, bronchospasm, dyspnea, and hypotension. In addition, facial/tongue swelling, coughing, throat tightness, cyanosis, laryngospasm, diaphoresis, back pain, hypertension, flushing, apnea and loss of consciousness have also been reported less commonly. Anaphylactic-type reactions have occurred with the first infusion. Infusion should be interrupted and medications for the treatment of anaphylaxis should be available for immediate use. Underlying mechanisms behind the development of hypersensitivity reactions is unknown, but have been attributed to high drug concentration and rate of infusion. Another possible mechanism may be due to the differences between available etoposide intravenous formulations. Etoposide intravenous formulation contains polysorbate 80 and benzyl alcohol, while etoposide phosphate (the water soluble prodrug of etoposide) intravenous formulation does not contain either vehicle. Case reports have suggested that etoposide phosphate has been used successfully in patients with previous hypersensitivity reactions to etoposide (Collier, 2008; Siderov, 2002).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Secondary malignancies: Secondary acute leukemias have been reported with etoposide, either as monotherapy or in combination with other chemotherapy agents.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment; dosage should be adjusted.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypoalbuminemia: Use with caution in patients with low serum albumin; may increase risk for toxicities.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment; dosage should be adjusted.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use with caution in elderly patients; may be more likely to develop severe myelosuppression and/or GI effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Administration: Administer by slow I.V. infusion; hypotension has been reported with etoposide phosphate administration, generally associated with rapid I.V. infusion. Injection site reactions may occur; monitor infusion site closely.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Dosage: Doses of etoposide phosphate &gt;175 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     have not been evaluated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Experienced physician:",
"     <b>",
"      [U.S. Boxed Warning]: Should be administered under the supervision of an experienced cancer chemotherapy physician.",
"     </b>",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F169400\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP1A2 (minor), CYP2E1 (minor), CYP3A4 (major), P-glycoprotein;",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2C9 (weak), CYP3A4 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F169355\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May decrease the serum concentration of Etoposide Phosphate. Barbiturates may increase the metabolism, via CYP isoenzymes, of etoposide phosphate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Immunosuppressants may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for agranulocytosis may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Coccidioidin Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioidin Skin Test.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): May increase the serum concentration of Etoposide Phosphate. CycloSPORINE may decrease the metabolism, via CYP isoenzymes, and decrease the p-glycoprotein-mediated elimination of Etoposide Phosphate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Echinacea: May diminish the therapeutic effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: May decrease the serum concentration of Etoposide Phosphate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (CYP3A4 Inducers): May increase the metabolism of CYP3A4 Substrates. Management: Consider avoiding CYP3A4 inducing herbs in order to avoid therapeutic failure of the substrate. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP3A4 Substrates. Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inducers: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inducers may also further limit the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: May decrease the serum concentration of Etoposide Phosphate. Phenytoin may increase the metabolism, via CYP isoenzymes, of etoposide phosphate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or other non-disease modifying antirheumatic drugs (non-DMARDs) is permitted, and this warning seems to particularly focused on more potent immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Vaccinial infections may develop. Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F169377\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: Avoid ethanol (may increase GI irritation).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: Avoid St John's wort (may decrease etoposide levels).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F169357\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F2650055\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal studies have demonstrated teratogenicity and fetal loss. There are no adequate and well-controlled studies in pregnant women. Women of childbearing potential should be advised to avoid pregnancy.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F169395\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F12855681\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Due to the potential for serious adverse reactions in the nursing infant, breast feeding is not recommended.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323141\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Etopophos Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (1): $159.55",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F169359\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CBC with differential and platelets (prior to initial treatment and each cycle), vital signs (blood pressure), bilirubin, AST/ALT, renal function",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F5539856\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Etopofos (AT, DK, FI, NO, SE);",
"     </li>",
"     <li>",
"      Etopophos (AU, CH, FR, GB, IE, NL, NZ, ZA);",
"     </li>",
"     <li>",
"      Etopos (BR, MX);",
"     </li>",
"     <li>",
"      Fytosid (IN, PH, SG, TH, TW);",
"     </li>",
"     <li>",
"      Posyd (ID)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F169349\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Etoposide phosphate is converted",
"     <i>",
"      in vivo",
"     </i>",
"     to the active moiety, etoposide, by dephosphorylation. Etoposide inhibits mitotic activity; inhibits cells from entering prophase; inhibits DNA synthesis. Initially thought to be mitotic inhibitors similar to podophyllotoxin, but actually have no effect on microtubule assembly. However, later shown to induce DNA strand breakage and inhibition of topoisomerase II (an enzyme which breaks and repairs DNA); etoposide acts in late S or early G2 phases.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F169367\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Average V",
"     <sub>",
"      d",
"     </sub>",
"     : 7-17 L/m",
"     <sup>",
"      2",
"     </sup>",
"     ; poor penetration across blood-brain barrier; concentrations in CSF being &lt;10% that of plasma",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 97%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Etoposide phosphate: Rapidly and completely converted to etoposide in plasma",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Etoposide: Hepatic, via CYP3A4 and 3A5 to various metabolites; in addition, conversion of etoposide to the O-demethylated metabolites (catechol and quinine) via prostaglandin synthases or myeloperoxidase occurs, as well as glutathione and glucuronide conjugation via GSTT1/GSTP1 and UGT1A1 (Yang, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Terminal: 4-11 hours; Children: Normal renal/hepatic function: 6-8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (56%; 45% as etoposide) within 120 hours; feces (44%) within 120 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children: Urine (~55% as etoposide) in 24 hours",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Aronoff GR, Bennett WM, Berns JS, et al,",
"      <i>",
"       Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children",
"      </i>",
"      , 5th ed. Philadelphia, PA: American College of Physicians; 2007, p 97.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Collier K, Schink C, Young AM, et al, &ldquo;Case Report: Successful Treatment with Etoposide Phosphate in Patients With Previous Etoposide Hypersensitivity,&rdquo;",
"      <i>",
"       J Oncol Pharm Pract",
"      </i>",
"      , 2008, 14(1):51-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/8/15495/abstract-text/18337441/pubmed\" id=\"18337441\" target=\"_blank\">",
"        18337441",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Donelli MG, Zucchetti M, Munzone E, et al,  &ldquo;Pharmacokinetics of Anticancer Agents in Patients With Impaired Liver Function,&rdquo;",
"      <i>",
"       Eur J Cancer",
"      </i>",
"      , 1998, 34(1):33-46.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/8/15495/abstract-text/9624235/pubmed\" id=\"9624235\" target=\"_blank\">",
"        9624235",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dorr RT, Briggs A, Kintzel P, et al, &ldquo;Comparative Pharmacokinetic Study of High-Dose Etoposide and Etoposide Phosphate in Patients With Lymphoid Malignancy Receiving Autologous Stem Cell Transplantation,&rdquo;",
"      <i>",
"       Bone Marrow Transplant",
"      </i>",
"      , 2003, 31(8):643-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/8/15495/abstract-text/12692603/pubmed\" id=\"12692603\" target=\"_blank\">",
"        12692603",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Floyd J, Mirza I, Sachs B, et al, \"Hepatotoxicity of Chemotherapy,\"",
"      <i>",
"       Semin Oncol",
"      </i>",
"      , 2006, 33(1):50-67.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/8/15495/abstract-text/16473644/pubmed\" id=\"16473644\" target=\"_blank\">",
"        16473644",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Greco FA and Hainsworth JD, &ldquo;Clinical Studies With Etoposide Phosphate,&rdquo;",
"      <i>",
"       Semin Oncol",
"      </i>",
"      , 1996, 23(6 Suppl 13):45-50.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/8/15495/abstract-text/8996575/pubmed\" id=\"8996575\" target=\"_blank\">",
"        8996575",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      King PD and Perry MC, &ldquo;Hepatotoxicity of Chemotherapy,&rdquo;",
"      <i>",
"       Oncologist",
"      </i>",
"      , 2001, 6(2):162-76.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/8/15495/abstract-text/11306728/pubmed\" id=\"11306728\" target=\"_blank\">",
"        11306728",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kintzel PE and Dorr RT, \"Anticancer Drug Renal Toxicity and Elimination: Dosing Guidelines for Altered Renal Function,\"",
"      <i>",
"       Cancer Treat Rev",
"      </i>",
"      , 1995, 21(1):33-64.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/8/15495/abstract-text/7859226/pubmed\" id=\"7859226\" target=\"_blank\">",
"        7859226",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Koren G, Beatty K, Seto A, et al, &ldquo;The Effects of Impaired Liver Function on the Elimination of Antineoplastic Agents,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 1992,  26(3):363-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/8/15495/abstract-text/1554959/pubmed\" id=\"1554959\" target=\"_blank\">",
"        1554959",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mummaneni V, Kaul S, Igwemezie LN, et al, &ldquo;Bioequivalence Assessment of Etoposide Phosphate and Etoposide Using Pharmacodynamic and Traditional Pharmacokinetic Parameters,&rdquo;",
"      <i>",
"       J Pharmacokinet Biopharm",
"      </i>",
"      , 1996, 24(4):313-25.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/8/15495/abstract-text/9044163/pubmed\" id=\"9044163\" target=\"_blank\">",
"        9044163",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Perry MC, &ldquo;Hepatotoxicity of Chemotherapeutic Agents,&rdquo;",
"      <i>",
"       Semin Oncol",
"      </i>",
"      , 1982, 9(1):65-73.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/8/15495/abstract-text/7071610/pubmed\" id=\"7071610\" target=\"_blank\">",
"        7071610",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Schacter LP, Igwemezie LN, Seyedsadr M, et al, &ldquo;Clinical and Pharmacokinetic Overview of Parenteral Etoposide Phosphate,&rdquo;",
"      <i>",
"       Cancer Chemother Pharmacol",
"      </i>",
"      , 1994, 34(Suppl):58-63.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Siderov J, Prasad P, De Boer R, et al, &ldquo;Safe Administration of Etoposide Phosphate After Hypersensitivity Reaction to Intravenous Etoposide,&rdquo;",
"      <i>",
"       Br J Cancer",
"      </i>",
"      , 2002, 86(1):12-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/8/15495/abstract-text/11857004/pubmed\" id=\"11857004\" target=\"_blank\">",
"        11857004",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Witterland AH, Koks CH, and Beijnen JH, &ldquo;Etoposide Phosphate, the Water Soluble Prodrug of Etoposide,&rdquo;",
"      <i>",
"       Pharm World Sci",
"      </i>",
"      , 1996, 18(5):163-70.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/8/15495/abstract-text/8933576/pubmed\" id=\"8933576\" target=\"_blank\">",
"        8933576",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Yang J, Bogni A, Schuetz EG, &ldquo;Etoposide Pathway,&rdquo;",
"      <i>",
"       Pharmacogenet Genomics",
"      </i>",
"      , 2009, 19(7):552-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/8/15495/abstract-text/19512958/pubmed\" id=\"19512958\" target=\"_blank\">",
"        19512958",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8431 Version 42.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-197.136.42.3-C3CD4DCF74-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_8_15495=[""].join("\n");
var outline_f15_8_15495=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708770\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169380\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169405\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169383\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169384\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169385\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169386\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169361\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169346\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169365\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169411\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169364\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2138084\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169403\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169368\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169350\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169400\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169355\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169377\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169357\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2650055\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169395\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12855681\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323141\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169359\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5539856\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169349\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169367\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8431\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8431|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?39/43/40628?source=related_link\">",
"      Etoposide phosphate: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_8_15496="Migrainous vertigo";
var content_f15_8_15496=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Migrainous vertigo",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/8/15496/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/8/15496/contributors\">",
"     David F Black, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/8/15496/contributors\">",
"     Carrie Elizabeth Robertson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/8/15496/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/8/15496/contributors\">",
"     Jerry W Swanson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/8/15496/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/8/15496/contributors\">",
"     Janet L Wilterdink, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?15/8/15496/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 8, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Migrainous vertigo is a term used to describe episodic vertigo in patients with a history of migraines or with other clinical features of migraine. While an association between episodic vertigo and migraine was noted as long ago as 1873, attempts at a more scientific analysis of this relationship have only begun over the last 20 years [",
"    <a class=\"abstract\" href=\"UTD.htm?15/8/15496/abstract/1\">",
"     1",
"    </a>",
"    ]. Many reports have documented a relationship between vestibular and migraine disorders, but problems with terminology and spurious correlations have limited progress [",
"    <a class=\"abstract\" href=\"UTD.htm?15/8/15496/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. Alternative terms that have been used include migraine-associated vertigo, migraine-related vestibulopathy, vestibular migraine, benign recurrent vertigo, and benign paroxysmal vertigo of childhood, highlight some of the uncertainties surrounding our understanding of this disorder.",
"   </p>",
"   <p>",
"    Whether migrainous vertigo is even a clinical entity is debated. Migrainous vertigo is not included in the 2004 International Headache Society (IHS) classification scheme.",
"   </p>",
"   <p>",
"    Migrainous vertigo is considered to be distinct from basilar type migraine (BTM). While vertigo is a common feature of BTM, the diagnostic criteria for BTM require that more than one neurologic symptom of putative brainstem or bilateral cortical origin occur as part of a headache aura. Patients with migrainous vertigo typically do not have other neurologic symptoms and may not even have headache with their attacks of vertigo.",
"   </p>",
"   <p>",
"    This topic will discuss migrainous vertigo. Basilar-type migraine and other manifestations of migraine are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/44/44743?source=see_link\">",
"     \"Basilar-type migraine\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/4/26698?source=see_link\">",
"     \"Pathophysiology, clinical manifestations, and diagnosis of migraine in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PROPOSED CRITERIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Criteria proposed for a diagnosis of definite migrainous vertigo are (",
"    <a class=\"graphic graphic_table graphicRef75023 \" href=\"UTD.htm?38/60/39883\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?15/8/15496/abstract/5\">",
"     5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Recurrent episodic vestibular symptoms of at least moderate severity and",
"     </li>",
"     <li>",
"      Current or previous history of migraine according to the criteria of the International Headache Society (IHS) and",
"     </li>",
"     <li>",
"      One of the following migrainous symptoms during at least two vertiginous attacks:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Migrainous headache",
"     </li>",
"     <li>",
"      Photophobia",
"     </li>",
"     <li>",
"      Phonophobia",
"     </li>",
"     <li>",
"      Visual or other aura symptoms",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Other causes ruled out by appropriate investigations",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Vestibular symptoms include rotational vertigo or another illusion of motion of self or environment. Symptoms may be spontaneous, positional, or provoked or aggravated by head motion. Vestibular symptoms are \"moderate\" if they interfere with but do not prohibit daily activities, and \"severe\" if patients cannot continue daily activities.",
"   </p>",
"   <p>",
"    Criteria for probable migrainous vertigo are also proposed (",
"    <a class=\"graphic graphic_table graphicRef75023 \" href=\"UTD.htm?38/60/39883\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?15/8/15496/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Evidence of vestibular dysfunction in migraine",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of clinical series report a high prevalence of vestibular signs and symptoms in patients with migraine, suggesting that vestibular involvement may be an integral feature of migraine.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among series of patients with migraine who present for treatment of headache, a history of episodic vertigo is reported by 20 to 33 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?15/8/15496/abstract/4,6-9\">",
"       4,6-9",
"      </a>",
"      ]. The lifetime prevalence of vertigo was estimated in one general population survey to be less than 8 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?15/8/15496/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      One-half to two-thirds of migraineurs suffer motion sickness [",
"      <a class=\"abstract\" href=\"UTD.htm?15/8/15496/abstract/4,6,11-13\">",
"       4,6,11-13",
"      </a>",
"      ]. This prevalence is probably two to five times greater than in the general population. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/24/18824?source=see_link\">",
"       \"Motion sickness\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A number of studies have performed vestibular laboratory tests in patients with migraine [",
"      <a class=\"abstract\" href=\"UTD.htm?15/8/15496/abstract/4,6,8,9,14-21\">",
"       4,6,8,9,14-21",
"      </a>",
"      ]. A literature review that summarized many of these studies reported a 25 percent prevalence of peripheral vestibular abnormalities in migraine patients [",
"      <a class=\"abstract\" href=\"UTD.htm?15/8/15496/abstract/14\">",
"       14",
"      </a>",
"      ]. Many of these patients did not suffer from clinical vertigo. Nonlocalizing vestibular signs and signs suggestive of central vestibular dysfunction were also common but also quite variable between studies.",
"     </li>",
"     <li>",
"      The previous studies refer to findings in migraine patients in a symptom-free period. Twenty patients examined during acute migrainous vertigo revealed findings consistent with central vestibular dysfunction in 10 and peripheral dysfunction in 3; in 7 the site of involvement was unclear [",
"      <a class=\"abstract\" href=\"UTD.htm?15/8/15496/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Migrainous vertigo may represent the adult equivalent of benign paroxysmal (recurrent) vertigo of childhood [",
"      <a class=\"abstract\" href=\"UTD.htm?15/8/15496/abstract/23-25\">",
"       23-25",
"      </a>",
"      ]. Long-term follow-up of children with this entity suggests that most will go on to develop migraine later in life [",
"      <a class=\"abstract\" href=\"UTD.htm?15/8/15496/abstract/25\">",
"       25",
"      </a>",
"      ]. This disorder is accepted by the International Headache Society (IHS) as a migraine equivalent. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/21/42327?source=see_link&amp;anchor=H13#H13\">",
"       \"Classification of migraine in children\", section on 'Benign paroxysmal vertigo of childhood'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The association of vertigo and migraine is specific, not extending to other headache syndromes. In one series comparing unselected groups of migraine and tension-type headache patients, migraineurs were more likely than tension-type headache sufferers to report episodic vertigo (27 versus 8 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?15/8/15496/abstract/4\">",
"       4",
"      </a>",
"      ]. In another study, stabilometric evaluation revealed evidence of interictal vestibular dysfunction in a group of 21 patients with migraine; patients with tension-type headaches had findings that were similar to controls [",
"      <a class=\"abstract\" href=\"UTD.htm?15/8/15496/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Auditory symptoms also occur during migraine attacks. The most common is sensitivity to sound, or phonophobia, which occurs in two-thirds of patients [",
"      <a class=\"abstract\" href=\"UTD.htm?15/8/15496/abstract/11\">",
"       11",
"      </a>",
"      ]. A smaller number of patients report aural fullness, decreased hearing, or tinnitus during their migraine attacks [",
"      <a class=\"abstract\" href=\"UTD.htm?15/8/15496/abstract/4,6,9,11\">",
"       4,6,9,11",
"      </a>",
"      ]. Both sudden, permanent as well as episodic, fluctuant, low-frequency hearing loss (similar to that seen in Meniere disease) has been attributed to migraine, but in general the prevalence of baseline hearing loss is low in patients with migraine [",
"      <a class=\"abstract\" href=\"UTD.htm?15/8/15496/abstract/6,11,16,26,27\">",
"       6,11,16,26,27",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Migraine in patients with vertigo",
"    </span>",
"    &nbsp;&mdash;&nbsp;Migraine also appears to be more prevalent than otherwise expected in patients with episodic vertigo. In a series of 200 consecutive patients presenting to a dizziness clinic, the lifetime prevalence of migraine was higher compared with an age- and sex-matched control group from an orthopedic clinic (38 versus 24 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/8/15496/abstract/28\">",
"     28",
"    </a>",
"    ]. However, the dizziness was attributed to migraine in only 14 patients.",
"   </p>",
"   <p>",
"    One study surveyed family members of 24 patients with chronic recurrent attacks of vertigo with no identified auditory or neurologic pathology who had also reported a family history of vertigo. Half of relatives reported symptoms meeting criteria for migraine compared with 2 percent of unrelated spouses [",
"    <a class=\"abstract\" href=\"UTD.htm?15/8/15496/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Proposed mechanisms",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathophysiology of migraine is incompletely understood. This is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/4/26698?source=see_link\">",
"     \"Pathophysiology, clinical manifestations, and diagnosis of migraine in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The mechanisms underlying migrainous vertigo are also incompletely understood. The wide spectrum of clinical and laboratory features of vestibular dysfunction in migraine discussed above suggests a heterogeneous pathophysiology. Many potential mechanisms are proposed; these are not mutually exclusive.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Migraine aura &mdash; In some patients, migrainous vertigo may represent a typical migraine aura. The mechanism of migraine aura is understood to be a wave of neuronal and glial depolarization, so-called cortical spreading depression. Migrainous vertigo may be a \"brainstem aura\" due to noncortical spreading depression. Alternatively, true cortical spreading depression may, via direct projections from the posterior parietal cortex, influence vestibular nuclei [",
"      <a class=\"abstract\" href=\"UTD.htm?15/8/15496/abstract/14,18\">",
"       14,18",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/4/26698?source=see_link&amp;anchor=H130649634#H130649634\">",
"       \"Pathophysiology, clinical manifestations, and diagnosis of migraine in adults\", section on 'Cortical spreading depression'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Migraine aura is likely to be the mechanism when the vestibular symptoms share features similar to other migrainous auras: a typical time duration of 5 to 60 minutes, accompanying positive visual phenomena and subsequent migraine headache. However, this mechanism is probably unlikely in most cases. In different case series, less than one-third of patients with migrainous vertigo had vestibular symptoms meeting this description [",
"      <a class=\"abstract\" href=\"UTD.htm?15/8/15496/abstract/18,19,28,30\">",
"       18,19,28,30",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Trigeminovascular system &mdash; Longer-lasting vestibular symptoms may stem from a process that parallels the headache phase of migraine, but does not necessarily include headache [",
"      <a class=\"abstract\" href=\"UTD.htm?15/8/15496/abstract/19\">",
"       19",
"      </a>",
"      ]. One mechanism proposed for migraine headache includes a primary brainstem event involving the trigeminal nucleus. Stimulation of the trigeminal neuron produces vasodilation and antidromic release of inflammatory neuropeptides into the dural circulation, potentially causing headache. Vestibular receptors exist to at least one of these peptides (calcitonin gene-related peptide).",
"      <br/>",
"      <br/>",
"      Reciprocal connections between the vestibular nuclei and the trigeminal nucleus caudalis and other brainstem nuclei linked to migraine may link vestibular and trigeminal processes in other ways as well [",
"      <a class=\"abstract\" href=\"UTD.htm?15/8/15496/abstract/14\">",
"       14",
"      </a>",
"      ]. Activation of central vestibular nuclei can alter monoaminergic activation that in turn modulate migrainous symptoms and pain pathways. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/4/26698?source=see_link&amp;anchor=H130649641#H130649641\">",
"       \"Pathophysiology, clinical manifestations, and diagnosis of migraine in adults\", section on 'Trigeminovascular system'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Labyrinthine sensitivity &mdash; Patients with migraine have a reduced threshold to numerous sensory stimuli, including motion sickness, as well as lights, sound, tactile stimuli, and smells. They are more likely to exhibit subclinical vestibulocerebellar abnormalities [",
"      <a class=\"abstract\" href=\"UTD.htm?15/8/15496/abstract/14,16\">",
"       14,16",
"      </a>",
"      ]. In one study, patients with migraine were more sensitive than control subjects to optokinetic stimulation inducing motion sickness [",
"      <a class=\"abstract\" href=\"UTD.htm?15/8/15496/abstract/31\">",
"       31",
"      </a>",
"      ]. This stimulation also induced allodynia and photophobia in migraineurs.",
"      <br/>",
"      <br/>",
"      Labyrinthine sensitivity may be an integral feature of individuals predisposed to migraine, or this may result from injury to the labyrinth, perhaps because of migraine-induced ischemia [",
"      <a class=\"abstract\" href=\"UTD.htm?15/8/15496/abstract/32\">",
"       32",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Channelopathy &mdash; The vestibular symptoms suffered by some patients with migraine may arise from a channelopathy [",
"      <a class=\"abstract\" href=\"UTD.htm?15/8/15496/abstract/11\">",
"       11",
"      </a>",
"      ]. One channelopathy, episodic ataxia type 2 (EA-2), manifests clinically with episodic vertigo. Half of patients with this disorder have migraine [",
"      <a class=\"abstract\" href=\"UTD.htm?15/8/15496/abstract/33,34\">",
"       33,34",
"      </a>",
"      ]. Another disorder, familial hemiplegic migraine (FHM), is associated with a genetic abnormality of the same calcium channel [",
"      <a class=\"abstract\" href=\"UTD.htm?15/8/15496/abstract/35\">",
"       35",
"      </a>",
"      ]. Both of these disorders have been linked to a mutation on chromosome 19p. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/35/37433?source=see_link&amp;anchor=H19#H19\">",
"       \"Overview of the hereditary ataxias\", section on 'Episodic ataxias'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/4/26698?source=see_link&amp;anchor=H130650654#H130650654\">",
"       \"Pathophysiology, clinical manifestations, and diagnosis of migraine in adults\", section on 'Familial hemiplegic migraine'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Other kindreds with apparently dominantly inherited syndromes which include both migraine and episodic vertigo have been described [",
"      <a class=\"abstract\" href=\"UTD.htm?15/8/15496/abstract/36,37\">",
"       36,37",
"      </a>",
"      ]. While a similar ion channel genetic defect is suspected, a gene locus in these families is not yet identified; linkage analysis ruled out a linkage to the 19p locus associated with EA-2 and FHM.",
"      <br/>",
"      <br/>",
"      A channelopathy may cause a local rise in extracellular potassium. This may lead to either the spreading depression of migraine",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      a paroxysmal osmotic disequilibrium that in turn may yield endolymphatic hydrops",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      hyperkalemic toxicity to the inner hair cells.",
"     </li>",
"     <li>",
"      Migraine-related ischemia &mdash; Migraine appears to be a risk factor for ischemic stroke, perhaps related to vasospasm. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/11/32953?source=see_link\">",
"       \"Headache, migraine, and stroke\"",
"      </a>",
"      .) Migraine-induced ischemia of the inner ear may lead to cochlear and labyrinth injury [",
"      <a class=\"abstract\" href=\"UTD.htm?15/8/15496/abstract/38,39\">",
"       38,39",
"      </a>",
"      ]. Vascular injury may cause a frank infarction of the labyrinth; less severe ischemic injury can cause endolymphatic hydrops and benign positional vertigo.",
"     </li>",
"     <li>",
"      Endolymphatic hydrops &mdash; Endolymphatic hydrops, a distention of the membranous, endolymph-containing portions of the labyrinthine system, is the pathologic lesion underlying Meniere disease. Some suggest that migrainous vertigo and Meniere disease are associated, while others suggest that the overlap in presentation may lead to misdiagnosis (see",
"      <a class=\"local\" href=\"#H8\">",
"       'Differential diagnosis'",
"      </a>",
"      below and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/61/32729?source=see_link\">",
"       \"Meniere disease\"",
"      </a>",
"      ).",
"      <br/>",
"      <br/>",
"      The attacks of vertigo that characterize Meniere disease and migraine are similar in their characteristic duration. One study observed that attacks of vertigo in patients with Meniere disease have a migrainous feature (headache, photophobia, or visual aura) in 45 percent of patients [",
"      <a class=\"abstract\" href=\"UTD.htm?15/8/15496/abstract/38\">",
"       38",
"      </a>",
"      ]. This study also reported that patients with Meniere disease had an increased lifetime prevalence of migraine compared with controls (56 versus 25 percent).",
"      <br/>",
"      <br/>",
"      It has been suggested that a channelopathy causing migraine could also cause an osmotic disequilibrium in the inner ear, resulting in endolymphatic hydrops [",
"      <a class=\"abstract\" href=\"UTD.htm?15/8/15496/abstract/38\">",
"       38",
"      </a>",
"      ]. Alternatively, migraine-associated ischemia could damage the labyrinth and produce endolymphatic hydrops on that basis [",
"      <a class=\"abstract\" href=\"UTD.htm?15/8/15496/abstract/39\">",
"       39",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Benign paroxysmal positional vertigo &mdash; Migraine has also been linked to benign paroxysmal positional vertigo (BPPV) [",
"      <a class=\"abstract\" href=\"UTD.htm?15/8/15496/abstract/28,40-42\">",
"       28,40-42",
"      </a>",
"      ]. Among a series of 247 patients, migraine was three times more common in patients with idiopathic BPPV compared with those with secondary BPPV [",
"      <a class=\"abstract\" href=\"UTD.htm?15/8/15496/abstract/41\">",
"       41",
"      </a>",
"      ]. Migraine was present in more than half of patients who developed BPPV under the age 50 years. Significant minorities of patients with migrainous vertigo have clinical episodes that are similar to those of BPPV, ie, brief, positionally-induced attacks of vertigo. It is hypothesized that migraine-induced ischemia to the utricle may cause release of otoconia into the semicircular canal [",
"      <a class=\"abstract\" href=\"UTD.htm?15/8/15496/abstract/28\">",
"       28",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/13/19673?source=see_link\">",
"       \"Benign paroxysmal positional vertigo\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Migraine trigger &mdash; Another hypothesis is that vertigo may act as a migraine trigger. Evidence for this is somewhat limited but includes a report of three individuals who had migraine attacks shortly after caloric testing [",
"      <a class=\"abstract\" href=\"UTD.htm?15/8/15496/abstract/43\">",
"       43",
"      </a>",
"      ]. In another observational study based in a neuro-otology clinic, nearly half of migraine patients who underwent vestibular testing experienced a migraine within 24 hours of testing, compared with 12 percent of patients without a migraine history [",
"      <a class=\"abstract\" href=\"UTD.htm?15/8/15496/abstract/44\">",
"       44",
"      </a>",
"      ]. The 24-hour incidence of migraine in a control group of individuals with a migraine history who did not receive vestibular testing was 5 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     CLINICAL AND EPIDEMIOLOGIC FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with migrainous vertigo have vestibular symptoms without other neurologic symptoms. This distinguishes migrainous vertigo from basilar-type migraine, in which at least two symptoms from the posterior circulation are required. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/44/44743?source=see_link\">",
"     \"Basilar-type migraine\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A population-based study in Germany, screening a representative sample of the population using the criteria described above, estimated a lifetime prevalence of migrainous vertigo of approximately 1 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?15/8/15496/abstract/30\">",
"     30",
"    </a>",
"    ]. While two-thirds of patients identified as having migrainous vertigo had consulted a clinician regarding this problem, only 20 percent were given that diagnosis.",
"   </p>",
"   <p>",
"    Clinical case series have described features of migrainous vertigo. In the absence of a diagnostic test, most investigators, but not all, have used the clinical criteria shown in the Table, either implicitly or explicitly (",
"    <a class=\"graphic graphic_table graphicRef75023 \" href=\"UTD.htm?38/60/39883\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?15/8/15496/abstract/6,18,19,28,45\">",
"     6,18,19,28,45",
"    </a>",
"    ]. Referral bias likely influences some of the findings, as these series are based in neurotology clinics.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The duration of an episode of migrainous vertigo js variable and can last seconds to a few minutes (&lt;15 percent), hours (30 percent), or days (25 percent), with most lasting at least several hours. [",
"      <a class=\"abstract\" href=\"UTD.htm?15/8/15496/abstract/6,14,18,19,28,30,45,46\">",
"       6,14,18,19,28,30,45,46",
"      </a>",
"      ]. &nbsp;",
"     </li>",
"     <li>",
"      The vertigo may occur with or without the patient&rsquo;s typical migraine headache [",
"      <a class=\"abstract\" href=\"UTD.htm?15/8/15496/abstract/6,28,30,45\">",
"       6,28,30,45",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Episodes may occur several times a day or only a few times each year [",
"      <a class=\"abstract\" href=\"UTD.htm?15/8/15496/abstract/6,18,19\">",
"       6,18,19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      One or more nonheadache migraine symptoms (photophobia, phonophobia, visual aura) often occur during the episodes of vertigo [",
"      <a class=\"abstract\" href=\"UTD.htm?15/8/15496/abstract/6,28,30\">",
"       6,28,30",
"      </a>",
"      ]. Nausea and vomiting are also frequent, but nonspecific, complaints. Other commonly associated symptoms include: head motion intolerance (a sense of motion and nausea provoked or aggravated by head movement), visual vertigo (dizziness provoked by opticokinetic stimuli such as moving visual scenes, ie, traffic or moving trains), and non-vertiginous &ldquo;dizzy&rdquo; symptoms such as lightheadedness, imbalance, or &ldquo;boat-like&rdquo; rocking [",
"      <a class=\"abstract\" href=\"UTD.htm?15/8/15496/abstract/46,47\">",
"       46,47",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      On laboratory testing, interictal vestibular signs (spontaneous, positional, or gaze-evoked nystagmus, abnormal vestibuloocular reflex) are common, in 53 to 66 percent of patients [",
"      <a class=\"abstract\" href=\"UTD.htm?15/8/15496/abstract/6,18\">",
"       6,18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Auditory symptoms, other than phonophobia, are not common in patients with migrainous vertigo, but hearing loss, aural fullness, and tinnitus are reported in a few patients [",
"      <a class=\"abstract\" href=\"UTD.htm?15/8/15496/abstract/4-6,30,45\">",
"       4-6,30,45",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Women tend to predominate in case series (60 to 83 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?15/8/15496/abstract/6,18,19,28,30,45\">",
"       6,18,19,28,30,45",
"      </a>",
"      ]. This gender ratio is similar to that seen in migraine.",
"     </li>",
"     <li>",
"      Migrainous vertigo is diagnosed more frequently in children than adults (35 versus 6 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?15/8/15496/abstract/14\">",
"       14",
"      </a>",
"      ]. In adult case series, the mean age of onset of vertigo in migraine is approximately 40 years old [",
"      <a class=\"abstract\" href=\"UTD.htm?15/8/15496/abstract/6,18,30\">",
"       6,18,30",
"      </a>",
"      ]. However, in one series, a first attack occurred as late as 72 years [",
"      <a class=\"abstract\" href=\"UTD.htm?15/8/15496/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      While some note that migraine headache precedes the development of migrainous vertigo, often by several years, it seems plausible that diagnostic criteria influence this finding [",
"      <a class=\"abstract\" href=\"UTD.htm?15/8/15496/abstract/20,28,30\">",
"       20,28,30",
"      </a>",
"      ]. The opposite order of symptom appearance occurs in those who have benign paroxysmal vertigo of childhood and later develop migraine headaches.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of patients with vertigo is extensive (",
"    <a class=\"graphic graphic_table graphicRef66539 \" href=\"UTD.htm?24/29/25051\">",
"     table 2",
"    </a>",
"    ). These disorders are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/38/17001?source=see_link\">",
"     \"Pathophysiology, etiology, and differential diagnosis of vertigo\"",
"    </a>",
"    .) In general, clinical features of the vertigo, especially the duration of attacks, help distinguish between diagnostic entities (",
"    <a class=\"graphic graphic_table graphicRef81596 \" href=\"UTD.htm?9/14/9453\">",
"     table 3",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/19/32057?source=see_link\">",
"     \"Approach to the patient with vertigo\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Major considerations in the differential diagnosis of migrainous vertigo are those disorders that produce vertigo with a similar tempo of symptoms. These most often include Meniere disease and vertebrobasilar transient ischemic attack.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In general, Meniere disease is distinguished from migrainous vertigo by symptoms of ear fullness or pain preceding the attack or at attack onset, and accompanying tinnitus",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      hearing loss during the episode. These symptoms are not typical or prominent in migrainous vertigo. However, in rare patients with Meniere disease, audiologic symptoms may be absent. Audiometry in these patients may be helpful, by showing the typical low-frequency hearing loss. In some patients, treatment trials for either Meniere disease or migraine may be useful for differentiating the two syndromes [",
"      <a class=\"abstract\" href=\"UTD.htm?15/8/15496/abstract/20,48\">",
"       20,48",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/61/32729?source=see_link\">",
"       \"Meniere disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Brainstem ischemia generally produces other symptoms (numbness, weakness, diplopia, dysarthria, dysphagia) in addition to vertigo. It is debated whether vertigo without brainstem symptoms can occur with transient vertebrobasilar ischemia. Certainly, brainstem infarctions producing restricted injury to the vestibular pathways and vertigo alone as a symptom are reported [",
"      <a class=\"abstract\" href=\"UTD.htm?15/8/15496/abstract/49\">",
"       49",
"      </a>",
"      ]. Given the prognostic implications, it seems reasonable to consider the diagnosis, especially in older patients or those with vascular risk factors who do not have a history of vertigo attacks [",
"      <a class=\"abstract\" href=\"UTD.htm?15/8/15496/abstract/50\">",
"       50",
"      </a>",
"      ]. Magnetic resonance imaging (MRI) with diffusion-weighted imaging may be helpful if performed in close temporal proximity to the event, but its sensitivity for transient ischemia is less than 50 percent; magnetic resonance angiography (MRA) may demonstrate arterial occlusive disease in the posterior circulation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC CONSIDERATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no conclusive diagnostic tests for migraine or migrainous vertigo. Given the uncertainties surrounding this clinical entity, it should be considered a diagnosis of exclusion.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If a first episode lasts longer than a few minutes, patients should undergo magnetic resonance imaging (MRI) with diffusion-weighted imaging and magnetic resonance angiography (MRA) of the posterior circulation to exclude the possibility of vascular or structural brainstem disease.",
"     </li>",
"     <li>",
"      Audiometry is advised to evaluate subclinical hearing loss and possible Meniere disease. In some cases, treatment trials for either migraine or Meniere disease can help to differentiate between these disorders [",
"      <a class=\"abstract\" href=\"UTD.htm?15/8/15496/abstract/20,48\">",
"       20,48",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/61/32729?source=see_link\">",
"       \"Meniere disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with very brief attacks of vertigo that are positionally induced should be evaluated for benign paroxysmal positional vertigo. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/13/19673?source=see_link\">",
"       \"Benign paroxysmal positional vertigo\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of therapy for migrainous vertigo is not well studied [",
"    <a class=\"abstract\" href=\"UTD.htm?15/8/15496/abstract/5\">",
"     5",
"    </a>",
"    ]. There are no randomized, controlled studies. Most of the data come from case reports and retrospective reviews [",
"    <a class=\"abstract\" href=\"UTD.htm?15/8/15496/abstract/6,11,18,36,45,51,52\">",
"     6,11,18,36,45,51,52",
"    </a>",
"    ]. From these reports, the following observations emerge:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acute migraine treatments such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/20/23877?source=see_link\">",
"       ergotamine",
"      </a>",
"      and triptans may offer benefit [",
"      <a class=\"abstract\" href=\"UTD.htm?15/8/15496/abstract/11\">",
"       11",
"      </a>",
"      ]. In one observational study,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/38/5736?source=see_link\">",
"       sumatriptan",
"      </a>",
"      was reported to be particularly efficacious in improving vertigo [",
"      <a class=\"abstract\" href=\"UTD.htm?15/8/15496/abstract/53\">",
"       53",
"      </a>",
"      ]. A pilot trial of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/40/2694?source=see_link\">",
"       zolmitriptan",
"      </a>",
"      for migrainous vertigo found a nonsignificantly improved response rate with treatment versus placebo (38 versus 22 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?15/8/15496/abstract/52\">",
"       52",
"      </a>",
"      ]. Low enrollment because of infrequent or brief attacks limited the power of this study.",
"     </li>",
"     <li>",
"      Others use vestibular suppressants to treat acute attacks of migrainous vertigo. These agents include benzodiazepines, antiemetics, antihistamines, and anticholinergic agents [",
"      <a class=\"abstract\" href=\"UTD.htm?15/8/15496/abstract/6,11\">",
"       6,11",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/15/13559?source=see_link&amp;anchor=H3#H3\">",
"       \"Treatment of vertigo\", section on 'Symptomatic treatment'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with frequent episodes of migrainous vertigo may find relief with approaches used in migraine prevention [",
"      <a class=\"abstract\" href=\"UTD.htm?15/8/15496/abstract/45,53\">",
"       45,53",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/56/42889?source=see_link\">",
"       \"Preventive treatment of migraine in adults\"",
"      </a>",
"      .) In a retrospective chart review of 81 patients with migraine-related vertigo, a treatment approach that included avoidance of migraine dietary triggers, with or without migraine prophylactic therapy using tricyclic antidepressants, beta blockers, or calcium channel blockers, produced substantial symptom relief in greater than 50 percent of patients [",
"      <a class=\"abstract\" href=\"UTD.htm?15/8/15496/abstract/45\">",
"       45",
"      </a>",
"      ]. These patients experienced an equal reduction in headache and vertigo.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/19/19768?source=see_link\">",
"       Gabapentin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/28/6602?source=see_link\">",
"       lamotrigine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/11/25785?source=see_link\">",
"       valproate",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/27/5561?source=see_link\">",
"       topiramate",
"      </a>",
"      have also been used anecdotally to treat migrainous vertigo [",
"      <a class=\"abstract\" href=\"UTD.htm?15/8/15496/abstract/6,45,54,55\">",
"       6,45,54,55",
"      </a>",
"      ], and in a small randomized pilot study,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/14/29925?source=see_link\">",
"       rizatriptan",
"      </a>",
"      prevented the development of motion sickness symptoms in patients with migrainous vertigo [",
"      <a class=\"abstract\" href=\"UTD.htm?15/8/15496/abstract/56\">",
"       56",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In one case series of patients with migrainous vertigo who were treated with abortive",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      prophylactic medication for migraine, there was a correlation between the efficacy of treatment for vertigo with the efficacy of treatment for headache [",
"      <a class=\"abstract\" href=\"UTD.htm?15/8/15496/abstract/53\">",
"       53",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Vestibular physical therapy was associated with improved symptoms and disability in an uncontrolled series of 14 patients with migrainous vertigo [",
"      <a class=\"abstract\" href=\"UTD.htm?15/8/15496/abstract/57\">",
"       57",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5752?source=see_link\">",
"       Acetazolamide",
"      </a>",
"      is effective in preventing attacks in episodic ataxia type 2. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/35/37433?source=see_link&amp;anchor=H19#H19\">",
"       \"Overview of the hereditary ataxias\", section on 'Episodic ataxias'",
"      </a>",
"      .) While not widely used in the treatment of either migraine or vertigo, some authors report that it is effective in treating their patients with migrainous vertigo [",
"      <a class=\"abstract\" href=\"UTD.htm?15/8/15496/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the absence of definitive data, a trial of therapies used to treat acute migraine or to prevent migraine seems reasonable in patients with recurrent episodes of migrainous vertigo, especially if vestibular suppressants are not effective. Indications for prophylactic therapy should mirror those for migraine headache, which consider the frequency, duration, and disabling nature of the attacks. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/44/21194?source=see_link\">",
"     \"Acute treatment of migraine in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/56/42889?source=see_link\">",
"     \"Preventive treatment of migraine in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?40/31/41460?source=see_link\">",
"       \"Patient information: Dizziness and vertigo (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Migrainous vertigo is a term used to describe episodic vertigo in patients with a history of migraines or with other clinical features of migraine (photophobia, phonophobia, visual aura, etc). Clinical criteria are proposed but are not universally accepted (",
"      <a class=\"graphic graphic_table graphicRef75023 \" href=\"UTD.htm?38/60/39883\">",
"       table 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      There is diverse evidence that the vestibular system is affected in patients with migraine. The varied clinical and epidemiologic findings and proposed pathophysiologic mechanisms suggest that migrainous vertigo is a heterogeneous condition. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Pathophysiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are no confirmatory tests for migrainous vertigo, which is a diagnosis of exclusion. Other disorders, specifically Meniere disease and structural and vascular brainstem disease, must be excluded in most patients. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Differential diagnosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9\">",
"       'Diagnostic considerations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest treatment trials with either symptomatic or prophylactic therapies used in migraine for patients with symptoms characteristic of migrainous vertigo in whom other diagnoses have been excluded (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Liveing, E. On Megrim, Sick-Headache, and Some Allied Disorders, Churchill, London 1873.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15496/abstract/2\">",
"      Sturzenegger MH, Meienberg O. Basilar artery migraine: a follow-up study of 82 cases. Headache 1985; 25:408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15496/abstract/3\">",
"      Olsson JE. Neurotologic findings in basilar migraine. Laryngoscope 1991; 101:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15496/abstract/4\">",
"      Kayan A, Hood JD. Neuro-otological manifestations of migraine. Brain 1984; 107 ( Pt 4):1123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15496/abstract/5\">",
"      Neuhauser H, Lempert T. Vertigo and dizziness related to migraine: a diagnostic challenge. Cephalalgia 2004; 24:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15496/abstract/6\">",
"      Johnson GD. Medical management of migraine-related dizziness and vertigo. Laryngoscope 1998; 108:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15496/abstract/7\">",
"      SELBY G, LANCE JW. Observations on 500 cases of migraine and allied vascular headache. J Neurol Neurosurg Psychiatry 1960; 23:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15496/abstract/8\">",
"      Kuritzky A, Ziegler DK, Hassanein R. Vertigo, motion sickness and migraine. Headache 1981; 21:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15496/abstract/9\">",
"      Bayazit Y, Yilmaz M, Mumbu&ccedil; S, Kanlikama M. Assessment of migraine-related cochleovestibular symptoms. Rev Laryngol Otol Rhinol (Bord) 2001; 122:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15496/abstract/10\">",
"      Neuhauser HK, von Brevern M, Radtke A, et al. Epidemiology of vestibular vertigo: a neurotologic survey of the general population. Neurology 2005; 65:898.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15496/abstract/11\">",
"      Baloh RW. Neurotology of migraine. Headache 1997; 37:615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15496/abstract/12\">",
"      Golding JF. Motion sickness susceptibility questionnaire revised and its relationship to other forms of sickness. Brain Res Bull 1998; 47:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15496/abstract/13\">",
"      Aromaa M, Sillanp&auml;&auml; ML, Rautava P, Helenius H. Childhood headache at school entry: a controlled clinical study. Neurology 1998; 50:1729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15496/abstract/14\">",
"      Furman JM, Marcus DA, Balaban CD. Migrainous vertigo: development of a pathogenetic model and structured diagnostic interview. Curr Opin Neurol 2003; 16:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15496/abstract/15\">",
"      Toglia JU, Thomas D, Kuritzky A. Common migraine and vestibular function. Electronystagmographic study and pathogenesis. Ann Otol Rhinol Laryngol 1981; 90:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15496/abstract/16\">",
"      Harno H, Hirvonen T, Kaunisto MA, et al. Subclinical vestibulocerebellar dysfunction in migraine with and without aura. Neurology 2003; 61:1748.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15496/abstract/17\">",
"      Ishizaki K, Mori N, Takeshima T, et al. Static stabilometry in patients with migraine and tension-type headache during a headache-free period. Psychiatry Clin Neurosci 2002; 56:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15496/abstract/18\">",
"      Dieterich M, Brandt T. Episodic vertigo related to migraine (90 cases): vestibular migraine? J Neurol 1999; 246:883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15496/abstract/19\">",
"      Cutrer FM, Baloh RW. Migraine-associated dizziness. Headache 1992; 32:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15496/abstract/20\">",
"      Thakar A, Anjaneyulu C, Deka RC. Vertigo syndromes and mechanisms in migraine. J Laryngol Otol 2001; 115:782.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15496/abstract/21\">",
"      Celebisoy N, G&ouml;k&ccedil;ay F, Sirin H, Bi&ccedil;ak N. Migrainous vertigo: clinical, oculographic and posturographic findings. Cephalalgia 2008; 28:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15496/abstract/22\">",
"      von Brevern M, Zeise D, Neuhauser H, et al. Acute migrainous vertigo: clinical and oculographic findings. Brain 2005; 128:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15496/abstract/23\">",
"      Slater R. Benign recurrent vertigo. J Neurol Neurosurg Psychiatry 1979; 42:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15496/abstract/24\">",
"      Moretti G, Manzoni GC, Caffarra P, Parma M. \"Benign recurrent vertigo\" and its connection with migraine. Headache 1980; 20:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15496/abstract/25\">",
"      Lanzi G, Balottin U, Fazzi E, et al. Benign paroxysmal vertigo of childhood: a long-term follow-up. Cephalalgia 1994; 14:458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15496/abstract/26\">",
"      Lipkin AF, Jenkins HA, Coker NJ. Migraine and sudden sensorineural hearing loss. Arch Otolaryngol Head Neck Surg 1987; 113:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15496/abstract/27\">",
"      Viirre ES, Baloh RW. Migraine as a cause of sudden hearing loss. Headache 1996; 36:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15496/abstract/28\">",
"      Neuhauser H, Leopold M, von Brevern M, et al. The interrelations of migraine, vertigo, and migrainous vertigo. Neurology 2001; 56:436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15496/abstract/29\">",
"      Oh AK, Lee H, Jen JC, et al. Familial benign recurrent vertigo. Am J Med Genet 2001; 100:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15496/abstract/30\">",
"      Neuhauser HK, Radtke A, von Brevern M, et al. Migrainous vertigo: prevalence and impact on quality of life. Neurology 2006; 67:1028.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15496/abstract/31\">",
"      Drummond PD. Motion sickness and migraine: optokinetic stimulation increases scalp tenderness, pain sensitivity in the fingers and photophobia. Cephalalgia 2002; 22:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15496/abstract/32\">",
"      Kuritzky A, Toglia UJ, Thomas D. Vestibular function in migraine. Headache 1981; 21:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15496/abstract/33\">",
"      Baloh RW, Yue Q, Furman JM, Nelson SF. Familial episodic ataxia: clinical heterogeneity in four families linked to chromosome 19p. Ann Neurol 1997; 41:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15496/abstract/34\">",
"      Jen J, Kim GW, Baloh RW. Clinical spectrum of episodic ataxia type 2. Neurology 2004; 62:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15496/abstract/35\">",
"      Ophoff RA, Terwindt GM, Vergouwe MN, et al. Familial hemiplegic migraine and episodic ataxia type-2 are caused by mutations in the Ca2+ channel gene CACNL1A4. Cell 1996; 87:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15496/abstract/36\">",
"      Baloh RW, Foster CA, Yue Q, Nelson SF. Familial migraine with vertigo and essential tremor. Neurology 1996; 46:458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15496/abstract/37\">",
"      Baloh RW, Jacobson K, Fife T. Familial vestibulopathy: a new dominantly inherited syndrome. Neurology 1994; 44:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15496/abstract/38\">",
"      Radtke A, Lempert T, Gresty MA, et al. Migraine and M&eacute;ni&egrave;re's disease: is there a link? Neurology 2002; 59:1700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15496/abstract/39\">",
"      Lee H, Lopez I, Ishiyama A, Baloh RW. Can migraine damage the inner ear? Arch Neurol 2000; 57:1631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15496/abstract/40\">",
"      von Brevern M, Radtke A, Clarke AH, Lempert T. Migrainous vertigo presenting as episodic positional vertigo. Neurology 2004; 62:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15496/abstract/41\">",
"      Ishiyama A, Jacobson KM, Baloh RW. Migraine and benign positional vertigo. Ann Otol Rhinol Laryngol 2000; 109:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15496/abstract/42\">",
"      Lempert T, Leopold M, von Brevern M, Neuhauser H. Migraine and benign positional vertigo. Ann Otol Rhinol Laryngol 2000; 109:1176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15496/abstract/43\">",
"      Seemungal B, Rudge P, Davies R, et al. Three patients with migraine following caloric-induced vestibular stimulation. J Neurol 2006; 253:1000.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15496/abstract/44\">",
"      Murdin L, Davies RA, Bronstein AM. Vertigo as a migraine trigger. Neurology 2009; 73:638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15496/abstract/45\">",
"      Reploeg MD, Goebel JA. Migraine-associated dizziness: patient characteristics and management options. Otol Neurotol 2002; 23:364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15496/abstract/46\">",
"      Lempert T, Neuhauser H. Epidemiology of vertigo, migraine and vestibular migraine. J Neurol 2009; 256:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15496/abstract/47\">",
"      Cohen JM, Bigal ME, Newman LC. Migraine and vestibular symptoms--identifying clinical features that predict \"vestibular migraine\". Headache 2011; 51:1393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15496/abstract/48\">",
"      Boismier TE, Disher MJ. Spontaneous vertigo and headache: endolymphatic hydrops or migraine? Ear Nose Throat J 2001; 80:881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15496/abstract/49\">",
"      Kim JS. Vertigo and gait ataxia without usual signs of lateral medullary infarction: a clinical variant related to rostral-dorsolateral lesions. Cerebrovasc Dis 2000; 10:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15496/abstract/50\">",
"      Baloh RW. Vertebrobasilar insufficiency and stroke. Otolaryngol Head Neck Surg 1995; 112:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15496/abstract/51\">",
"      Evans RW, Baloh RW. Episodic vertigo and migraine. Headache 2001; 41:604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15496/abstract/52\">",
"      Neuhauser H, Radtke A, von Brevern M, Lempert T. Zolmitriptan for treatment of migrainous vertigo: a pilot randomized placebo-controlled trial. Neurology 2003; 60:882.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15496/abstract/53\">",
"      Bikhazi P, Jackson C, Ruckenstein MJ. Efficacy of antimigrainous therapy in the treatment of migraine-associated dizziness. Am J Otol 1997; 18:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15496/abstract/54\">",
"      Carmona S, Settecase N. Use of topiramate (topamax) in a subgroup of migraine-vertigo patients with auditory symptoms. Ann N Y Acad Sci 2005; 1039:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15496/abstract/55\">",
"      Bisdorff AR. Treatment of migraine related vertigo with lamotrigine an observational study. Bull Soc Sci Med Grand Duche Luxemb 2004; :103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15496/abstract/56\">",
"      Marcus DA, Furman JM. Prevention of motion sickness with rizatriptan: a double-blind, placebo-controlled pilot study. Med Sci Monit 2006; 12:PI1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15496/abstract/57\">",
"      Whitney SL, Wrisley DM, Brown KE, Furman JM. Physical therapy for migraine-related vestibulopathy and vestibular dysfunction with history of migraine. Laryngoscope 2000; 110:1528.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3356 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-210.101.131.232-F6895ED81D-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_8_15496=[""].join("\n");
var outline_f15_8_15496=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H11\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PROPOSED CRITERIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Evidence of vestibular dysfunction in migraine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Migraine in patients with vertigo",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Proposed mechanisms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      CLINICAL AND EPIDEMIOLOGIC FEATURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      DIAGNOSTIC CONSIDERATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/3356\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/3356|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?38/60/39883\" title=\"table 1\">",
"      Migrainous vertigo criteria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?24/29/25051\" title=\"table 2\">",
"      Causes of vertigo",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/14/9453\" title=\"table 3\">",
"      Causes vertigo Clin Features",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/44/21194?source=related_link\">",
"      Acute treatment of migraine in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/19/32057?source=related_link\">",
"      Approach to the patient with vertigo",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/44/44743?source=related_link\">",
"      Basilar-type migraine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/13/19673?source=related_link\">",
"      Benign paroxysmal positional vertigo",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/21/42327?source=related_link\">",
"      Classification of migraine in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/11/32953?source=related_link\">",
"      Headache, migraine, and stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/61/32729?source=related_link\">",
"      Meniere disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/24/18824?source=related_link\">",
"      Motion sickness",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/35/37433?source=related_link\">",
"      Overview of the hereditary ataxias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/4/26698?source=related_link\">",
"      Pathophysiology, clinical manifestations, and diagnosis of migraine in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/38/17001?source=related_link\">",
"      Pathophysiology, etiology, and differential diagnosis of vertigo",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?40/31/41460?source=related_link\">",
"      Patient information: Dizziness and vertigo (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/56/42889?source=related_link\">",
"      Preventive treatment of migraine in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/15/13559?source=related_link\">",
"      Treatment of vertigo",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_8_15497="Epidemiology and causes of heart failure";
var content_f15_8_15497=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Epidemiology and causes of heart failure",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/8/15497/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/8/15497/contributors\">",
"     Ramachandran S Vasan, MD, DM, FACC",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/8/15497/contributors\">",
"     Peter WF Wilson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/8/15497/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/8/15497/contributors\">",
"     Wilson S Colucci, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/8/15497/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/8/15497/contributors\">",
"     Susan B Yeon, MD, JD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?15/8/15497/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 7, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aging of the population and prolongation of the lives of cardiac patients by modern therapeutic innovations has led to an increasing prevalence of heart failure (HF). Despite improvements in therapy, the mortality rate in patients with HF has remained unacceptably high [",
"    <a class=\"abstract\" href=\"UTD.htm?15/8/15497/abstract/1\">",
"     1",
"    </a>",
"    ], making early detection of susceptible persons who would benefit from preventive measures imperative.",
"   </p>",
"   <p>",
"    The epidemiology and causes of HF will be reviewed here. Diastolic dysfunction, asymptomatic left ventricular dysfunction, and causes of HF decompensation are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/22/43368?source=see_link\">",
"     \"Clinical manifestations and diagnosis of diastolic heart failure\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/59/28601?source=see_link\">",
"     \"Evaluation and management of asymptomatic left ventricular systolic dysfunction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/23/7544?source=see_link\">",
"     \"Evaluation of acute decompensated heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MAGNITUDE OF THE PROBLEM",
"    </span>",
"    &nbsp;&mdash;&nbsp;The magnitude of the problem of HF cannot be assessed with precision since reliable, population-based estimates of its prevalence, incidence, and prognosis are lacking [",
"    <a class=\"abstract\" href=\"UTD.htm?15/8/15497/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Part of the problem is that large differences exist among studies in their definition of the condition and the methods used to establish its presence. In addition, presymptomatic left ventricular dysfunction is now used increasingly as an indicator of impending, if not existing, HF [",
"    <a class=\"abstract\" href=\"UTD.htm?15/8/15497/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Prevalence",
"    </span>",
"    &nbsp;&mdash;&nbsp;At least six HF scoring methodologies based upon symptoms and signs have been developed to assess the presence of heart failure. Clinical diagnostic criteria for heart failure have generally included history, physical examination, and chest radiographs [",
"    <a class=\"abstract\" href=\"UTD.htm?15/8/15497/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. A 2010 update from the American Heart Association (AHA) estimated that there were 5.8 million people with HF in the United States in 2006 [",
"    <a class=\"abstract\" href=\"UTD.htm?15/8/15497/abstract/7\">",
"     7",
"    </a>",
"    ]. There are an estimated 23 million people with HF worldwide [",
"    <a class=\"abstract\" href=\"UTD.htm?15/8/15497/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Regardless of the definition used, the prevalence of HF and left ventricular dysfunction increases steeply with age [",
"    <a class=\"abstract\" href=\"UTD.htm?15/8/15497/abstract/1,9-14\">",
"     1,9-14",
"    </a>",
"    ]. As an example, the Framingham Heart Study found a prevalence of HF in men of 8 per 1000 at age 50 to 59 years, increasing to 66 per 1000 at ages 80 to 89 years; similar values (8 and 79 per 1000) were noted in women [",
"    <a class=\"abstract\" href=\"UTD.htm?15/8/15497/abstract/1\">",
"     1",
"    </a>",
"    ]. The prevalence in African-Americans is reported to be 25 percent higher than in whites.",
"   </p>",
"   <p>",
"    The Framingham Study estimates are primarily based upon symptomatic HF (",
"    <a class=\"graphic graphic_table graphicRef55866 \" href=\"UTD.htm?37/44/38603\">",
"     table 1",
"    </a>",
"    ). These figures do not include asymptomatic patients with a reduced LVEF. Investigations using echocardiography have found that only 50 percent of participants with left ventricular dysfunction are symptomatic [",
"    <a class=\"abstract\" href=\"UTD.htm?15/8/15497/abstract/11\">",
"     11",
"    </a>",
"    ]. In a community survey from the Mayo Clinic, of 123 patients with an LVEF &le;50 percent, 30 (24 percent) had a diagnosis of HF; of 40 patients with an LVEF &le;40 percent, 21 (53 percent) had a diagnosis of HF [",
"    <a class=\"abstract\" href=\"UTD.htm?15/8/15497/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/21/11610?source=see_link\">",
"     \"Noninvasive methods for measurement of left ventricular systolic function\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There has been an increase in the prevalence of HF in the population over time. In one study, the average increase from 1989 to 1999 was",
"    <span class=\"nowrap\">",
"     1/1000",
"    </span>",
"    and",
"    <span class=\"nowrap\">",
"     0.9/1000",
"    </span>",
"    for women and men, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?15/8/15497/abstract/15\">",
"     15",
"    </a>",
"    ]. This has been associated with a three- to fourfold rise in the rate of hospitalization for HF from 1971 to 1999 [",
"    <a class=\"abstract\" href=\"UTD.htm?15/8/15497/abstract/7,15\">",
"     7,15",
"    </a>",
"    ]. Several elements are contributing to this rise, particularly aging of the population. In addition, improved treatment of hypertension and valvular and coronary disease is allowing patients to survive an early death only to later develop HF. The prevalence of HF in the United States is projected to rise over the next four decades with an estimated 772,000 new HF cases projected in the year 2040 [",
"    <a class=\"abstract\" href=\"UTD.htm?15/8/15497/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, these trends must be interpreted with caution because of the introduction of new diagnostic methodology, changes in hospital admission and reimbursement practices, increased awareness of the problem, and changes in the prevalence of comorbidity. Coexistent disease is often the chief reason for hospitalization of HF patients [",
"    <a class=\"abstract\" href=\"UTD.htm?15/8/15497/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In 2004, there were over one million hospitalizations in the United States with a first listed discharge diagnosis of HF [",
"    <a class=\"abstract\" href=\"UTD.htm?15/8/15497/abstract/7\">",
"     7",
"    </a>",
"    ]. In addition, at least 20 percent of hospital admissions among persons older than 65 are due to HF [",
"    <a class=\"abstract\" href=\"UTD.htm?15/8/15497/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Preserved systolic function",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is now appreciated that HF often occurs with normal left ventricular systolic function, ie, presumably on the basis of diastolic dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?15/8/15497/abstract/19-21\">",
"     19-21",
"    </a>",
"    ]. Various studies estimate that as many as 40 to 60 percent of patients with HF have diastolic dysfunction as defined by a normal LVEF [",
"    <a class=\"abstract\" href=\"UTD.htm?15/8/15497/abstract/9,10,21-24\">",
"     9,10,21-24",
"    </a>",
"    ]. However, there has been a marked variability in the reported prevalence of HF with a preserved EF (ranging from 13 to 74 percent) due to the use of heterogeneous criteria and hospital-based data [",
"    <a class=\"abstract\" href=\"UTD.htm?15/8/15497/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/22/43368?source=see_link\">",
"     \"Clinical manifestations and diagnosis of diastolic heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The prevalence of HF with a preserved EF increases with age [",
"    <a class=\"abstract\" href=\"UTD.htm?15/8/15497/abstract/25-27\">",
"     25-27",
"    </a>",
"    ]. In one review, the estimated prevalence of diastolic dysfunction among patients with HF was 15, 33, and 50 percent at ages less than 50, 50 to 70, and more than 70 years, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?15/8/15497/abstract/25\">",
"     25",
"    </a>",
"    ]. In addition, another 15 percent of elderly patients with HF have mildly abnormal systolic function (LVEF 45 to 54 percent), which should not produce symptoms on its own and is therefore probably associated with an important component of diastolic dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?15/8/15497/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    HF with preserved systolic function is more often a condition of women than men [",
"    <a class=\"abstract\" href=\"UTD.htm?15/8/15497/abstract/24\">",
"     24",
"    </a>",
"    ]. In a study of 19,710 Medicare beneficiaries over age 65 hospitalized with a principal discharge diagnosis of HF, 34 percent had preserved LV function [",
"    <a class=\"abstract\" href=\"UTD.htm?15/8/15497/abstract/27\">",
"     27",
"    </a>",
"    ]. Women accounted for 71 percent of patients with preserved LV function, compared with 49 percent of those with impaired LV function. In a multivariate analysis of predictors of preserved LV function in HF, female gender was significant (odds ratio 2.07, 95% CI 1.93-2.34).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Incidence",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of HF, like the prevalence, increases with age [",
"    <a class=\"abstract\" href=\"UTD.htm?15/8/15497/abstract/14,28\">",
"     14,28",
"    </a>",
"    ]. In the Framingham Study, the incidence approximately doubled over each successive decade of life, rising more steeply with age in women than in men (",
"    <a class=\"graphic graphic_table graphicRef79137 \" href=\"UTD.htm?12/52/13131\">",
"     table 2",
"    </a>",
"    ). The annual incidence in men rose from 2 per 1000 at age 35 to 64 years to 12 per 1000 at age 65 to 94 years. Because the increase in risk with age is balanced by the decreased life expectancy with older age, the lifetime likelihood of developing HF is approximately 20 percent at all ages above 40 [",
"    <a class=\"abstract\" href=\"UTD.htm?15/8/15497/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Incidence in older adults",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the prevalence of HF is increasing due to aging of the population, the trend with regard to age-adjusted heart failure incidence is less clear. Four studies reached somewhat different conclusions.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An analysis from the Framingham study of 10,311 subjects (1075 with incident HF) found no change in age-adjusted incidence of HF in men between the time period 1950 to 1969 and the time period 1990 to 1999 [",
"      <a class=\"abstract\" href=\"UTD.htm?15/8/15497/abstract/29\">",
"       29",
"      </a>",
"      ]. Among women there was a decline in age-adjusted incidence of HF in women between the time periods 1950 to 1969 and 1970 to 1979 and no subsequent change in the period 1990 to 1999. The mean age at the diagnosis of HF rose from 63 years in the 1950 to 1969 period to 80 years in the 1990 to 1999 period.",
"     </li>",
"     <li>",
"      Similarly, a report from the Mayo Clinic based on 4537 individuals with incident HF (mean age 74 years) found no evidence of any significant change in age-adjusted HF incidence for either men or women between 1979 and 2000 [",
"      <a class=\"abstract\" href=\"UTD.htm?15/8/15497/abstract/30\">",
"       30",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In contrast, a retrospective Kaiser Permanente Center study of individuals &ge;65 years old (1942 with incident HF) found a 14 percent increase in age-adjusted incidence of HF in the time period between 1970 to 1974 and 1990 to 1994 [",
"      <a class=\"abstract\" href=\"UTD.htm?15/8/15497/abstract/31\">",
"       31",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A larger study of heart failure incidence found a decline in rate over time in individuals &ge;65 years old [",
"      <a class=\"abstract\" href=\"UTD.htm?15/8/15497/abstract/32\">",
"       32",
"      </a>",
"      ]. In a retrospective study of 622,789 Medicare beneficiaries &ge; 65 years old diagnosed with HF between 1994 and 2003, the incidence of HF declined from 32 per 1000 person-years in 1994 to 29 per 1000 person-years in 2003. Incidence declined most sharply among beneficiaries aged 80 to 84 years old (from 57.5 to 48.4 per 1000 person-years) and increased slightly among beneficiaries aged 65 to 69 years (from 17.5 to 19.3 per 1000 person-years).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Incidence in younger adults",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fewer data are available on the incidence of HF in younger adults. In the Framingham study, the five-year risk of HF among 40 year old whites was 0.1 to 0.2 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?15/8/15497/abstract/28\">",
"     28",
"    </a>",
"    ]. A report from the CARDIA study of 5115 subjects (52 percent black; 48 percent white) aged 18 to 30 years who were prospectively followed for 20 years found that incident heart failure before 50 years of age is substantially more common among blacks than whites (1.1, 0.9, 0.08,and 0 percent in black women, black men, white women, and white men, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/8/15497/abstract/33\">",
"     33",
"    </a>",
"    ]. Among blacks, independent predictors of HF before age 30 years (HF occurring on average 15 years later) included higher diastolic blood pressure, high body-mass index, lower HDL cholesterol, and kidney disease. Left ventricular systolic dysfunction on echocardiogram at age &le;35 years was also independently associated with later development of HF.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Lifetime risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the Framingham Heart Study, at age 40, the lifetime risk of developing HF for both men and women was one in five [",
"    <a class=\"abstract\" href=\"UTD.htm?15/8/15497/abstract/28\">",
"     28",
"    </a>",
"    ]. At age 40, the lifetime risk of HF occurring without antecedent MI was one in nine for men and one in six for women. Lower lifetime risk (one in seven at age 40) was observed in the Physicians Health Study, which may be due to healthy lifestyle factors [",
"    <a class=\"abstract\" href=\"UTD.htm?15/8/15497/abstract/34\">",
"     34",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Risk factor reduction'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Mortality",
"    </span>",
"    &nbsp;&mdash;&nbsp;National statistics in the United States showed a rise in the death rate attributable to HF from 5.8 per 1000 in 1970 to 16.4 per 1000 in 1993 [",
"    <a class=\"abstract\" href=\"UTD.htm?15/8/15497/abstract/35\">",
"     35",
"    </a>",
"    ]. This upward trend contrasts with reported declines in overall and coronary mortality and at least in part reflects avoidance of premature mortality from these predisposing conditions, which are only palliated, not cured, by advances in therapy.",
"   </p>",
"   <p>",
"    Among individuals with HF, analyses from Scotland, the Framingham Heart Study, the Mayo Clinic, and the cohort of older patients noted above, all found a progressive improvement in patient survival after 1980 [",
"    <a class=\"abstract\" href=\"UTD.htm?15/8/15497/abstract/29-31,36\">",
"     29-31,36",
"    </a>",
"    ]. However, average survival remained poor after hospitalization for a first episode of HF (eg, in Scotland in 2002 the median survival was 2.3 years in men and 1.7 years in women) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/8/15497/abstract/36\">",
"     36",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/61/4058?source=see_link&amp;anchor=H10#H10\">",
"     \"Prognosis of heart failure\", section on 'Survival in HF'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    HF with a preserved EF appears to be associated with a better prognosis than HF due to systolic dysfunction (annual mortality 8 to 9 versus 19 percent) in some reports [",
"    <a class=\"abstract\" href=\"UTD.htm?15/8/15497/abstract/37\">",
"     37",
"    </a>",
"    ] although some investigators have reported similar mortality rates for HF due to systolic dysfunction and HF with a preserved EF [",
"    <a class=\"abstract\" href=\"UTD.htm?15/8/15497/abstract/24\">",
"     24",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/61/4058?source=see_link&amp;anchor=H26#H26\">",
"     \"Prognosis of heart failure\", section on 'Diastolic dysfunction'",
"    </a>",
"    .) A meta-analysis of nearly 25,000 patients with HF in 17 studies suggested that mortality of HF with a preserved EF is about half that of HF with a reduced EF [",
"    <a class=\"abstract\" href=\"UTD.htm?15/8/15497/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     PREDISPOSING CONDITIONS FOR HF",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Frequency of various causes",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the 1970s, hypertension and coronary disease, particularly myocardial infarction, were the primary causes of HF in the United States and Europe [",
"    <a class=\"abstract\" href=\"UTD.htm?15/8/15497/abstract/1,39\">",
"     1,39",
"    </a>",
"    ]. However, coronary disease and diabetes mellitus have become increasingly responsible for HF while hypertension and valve disease have become less common because of improvements in detection and therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?15/8/15497/abstract/40-42\">",
"     40-42",
"    </a>",
"    ]. Over four decades of observation in the Framingham Study, the prevalence of coronary disease as a cause of HF increased 41 percent per calendar decade in men and 25 percent in women; the prevalence of diabetes as a contributing cause increased by more than 20 percent per decade [",
"    <a class=\"abstract\" href=\"UTD.htm?15/8/15497/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Treatment trials suggest a higher prevalence (60 to 65 percent) of coronary disease. However, patients in these trials represent a selected group, since those with hypertension, diabetes, and diastolic dysfunction were often excluded [",
"    <a class=\"abstract\" href=\"UTD.htm?15/8/15497/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Epidemiologically, the impact of the various predisposing conditions for HF is best determined by the population attributable risk (PAR) that takes into account both the hazard ratio and the prevalence of the predisposing condition in the population. As an example, the First National Health and Nutrition Examination Survey (NHANES I) of 13,643 men and women who were followed for 19 years found that the risk factors for HF and their population attributable risk (PAR) were as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?15/8/15497/abstract/41\">",
"     41",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Coronary heart disease &mdash; relative risk 8.1; overall PAR 62 percent, 68 percent in men and 56 percent in women",
"     </li>",
"     <li>",
"      Cigarette smoking &mdash; relative risk 1.6, PAR 17 percent",
"     </li>",
"     <li>",
"      Hypertension &mdash; relative risk 1.4, PAR 10 percent",
"     </li>",
"     <li>",
"      Overweight &mdash; relative risk 1.3, PAR 8 percent; the importance of obesity was also demonstrated in a long-term follow-up from the Framingham Heart Study which estimated that approximately 11 percent of cases of HF in men and 14 percent in women are attributable to obesity alone [",
"      <a class=\"abstract\" href=\"UTD.htm?15/8/15497/abstract/44\">",
"       44",
"      </a>",
"      ]&nbsp;(see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/35/30266?source=see_link\">",
"       \"Health hazards associated with obesity in adults\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Diabetes &mdash; relative risk 1.9, PAR 3 percent",
"     </li>",
"     <li>",
"      Valvular heart disease &mdash; relative risk 1.5, PAR 2 percent; however, valve disease is an increasingly common cause of HF at older ages, with calcific aortic stenosis being the most common disorder requiring surgery [",
"      <a class=\"abstract\" href=\"UTD.htm?15/8/15497/abstract/45\">",
"       45",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Racial differences in risk factors for HF were observed in a US cohort of 2934 adults aged 70 to 79 years followed for seven years [",
"    <a class=\"abstract\" href=\"UTD.htm?15/8/15497/abstract/46\">",
"     46",
"    </a>",
"    ]. Among blacks, a greater proportion of HF risk (68 versus 49 percent among whites) was attributable to modifiable risk factors including elevated systolic blood pressure, elevated fasting glucose level, coronary heart disease, left ventricular hypertrophy and smoking. Left ventricular hypertrophy was three-fold more prevalent in blacks compared to whites and the risk associated with left ventricular hypertrophy was additive to and independent of that associated with uncontrolled blood pressure.",
"   </p>",
"   <p>",
"    A predominance of coronary disease and a lower incidence of hypertensive heart disease were also noted in an Italian registry of over 6200 unselected outpatients with HF [",
"    <a class=\"abstract\" href=\"UTD.htm?15/8/15497/abstract/47\">",
"     47",
"    </a>",
"    ]. The underlying cardiac diagnoses were:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Ischemic heart disease &mdash; 40 percent",
"     </li>",
"     <li>",
"      Dilated cardiomyopathy &mdash; 32 percent",
"     </li>",
"     <li>",
"      Primary valvular heart disease &mdash; 12 percent",
"     </li>",
"     <li>",
"      Hypertensive heart disease &mdash; 11 percent",
"     </li>",
"     <li>",
"      Other &mdash; 5 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A separate issue is the distribution of causes in patients in whom the diagnosis is not apparent. In an evaluation of 1230 patients with an initially unexplained cardiomyopathy, the following etiologies were noted [",
"    <a class=\"abstract\" href=\"UTD.htm?15/8/15497/abstract/48\">",
"     48",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Idiopathic &mdash; 50 percent",
"     </li>",
"     <li>",
"      Myocarditis &mdash; 9 percent",
"     </li>",
"     <li>",
"      Ischemic heart disease &mdash; 7 percent",
"     </li>",
"     <li>",
"      Infiltrative disease &mdash; 5 percent",
"     </li>",
"     <li>",
"      Peripartum cardiomyopathy &mdash; 4 percent",
"     </li>",
"     <li>",
"      Hypertension &mdash; 4 percent",
"     </li>",
"     <li>",
"      HIV infection &mdash; 4 percent",
"     </li>",
"     <li>",
"      Connective tissue disease &mdash; 3 percent",
"     </li>",
"     <li>",
"      Substance abuse &mdash; 3 percent",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"       Doxorubicin",
"      </a>",
"      &mdash; 1 percent",
"     </li>",
"     <li>",
"      Other &mdash; 10 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The definition and specific causes of dilated cardiomyopathy are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/0/19465?source=see_link\">",
"     \"Causes of dilated cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An association between obstructive sleep apnea and incident heart failure is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/47/18169?source=see_link&amp;anchor=H27159755#H27159755\">",
"     \"Cardiovascular effects of obstructive sleep apnea\", section on 'Heart failure'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     In developing countries",
"    </span>",
"    &nbsp;&mdash;&nbsp;Few data are available on the causes of HF in low to middle income countries. HF in Africa has been conventionally thought to be caused predominantly by untreated rheumatic valvular disease, peripartum and idiopathic cardiomyopathy, and hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?15/8/15497/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A different distribution of causes suggestive of an epidemiological transition was found in a later study of 844 de novo presentations of HF at an urban African hospital [",
"    <a class=\"abstract\" href=\"UTD.htm?15/8/15497/abstract/50\">",
"     50",
"    </a>",
"    ]. The mean age was 55 years and women (57 percent) and black Africans (88 percent) predominated. The most common diagnoses were hypertensive HF (33 percent), idiopathic dilated cardiomyopathy (28 percent), right-sided HF (27 percent, nearly half with isolated right heart involvement),ischemic cardiomyopathy (9 percent), and valvular HF (8 percent). Black Africans had less ischemic cardiomyopathy but more idiopathic and other causes of cardiomyopathy than white Africans.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Ischemic cardiomyopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;As demonstrated by the above observations, ischemic cardiomyopathy is the most common cause of HF due to systolic dysfunction in Western countries. Ischemic cardiomyopathy is diagnosed in patients with HF who have had a myocardial infarction or have evidence of hibernating myocardium or, on angiography, severe coronary disease. In contrast, patients with single vessel disease who have no evidence of myocardial infarction or revascularization have a similar prognosis as those with nonischemic cardiomyopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?15/8/15497/abstract/51\">",
"     51",
"    </a>",
"    ]. It was suggested that such patients should be classified as nonischemic cardiomyopathy, at least for prognostic purposes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/3/24633?source=see_link\">",
"     \"Diagnosis and management of ischemic cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Hypertension",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypertension increases the risk of HF at all ages. Data from the Framingham Heart Study found that, after age 40, the lifetime risk of developing HF was twice as high in subjects with a blood pressure",
"    <span class=\"nowrap\">",
"     &ge;160/100",
"    </span>",
"    mmHg compared to",
"    <span class=\"nowrap\">",
"     &lt;140/90",
"    </span>",
"    mmHg [",
"    <a class=\"abstract\" href=\"UTD.htm?15/8/15497/abstract/28\">",
"     28",
"    </a>",
"    ]. The risk of developing HF increases with the degree of blood pressure elevation. However, even moderate elevations contribute to risk in the long term [",
"    <a class=\"abstract\" href=\"UTD.htm?15/8/15497/abstract/39\">",
"     39",
"    </a>",
"    ]. The average blood pressure of hypertensive candidates for HF in the Framingham Study was only",
"    <span class=\"nowrap\">",
"     150/90",
"    </span>",
"    mmHg.",
"   </p>",
"   <p>",
"    Another analysis from the Framingham study suggests that baseline systolic pressure and pulse pressure have a greater impact on the risk of subsequent HF than the diastolic pressure. In this analysis, 2040 participants ages 50 to 79 who were initially free of HF were followed for 17.4 years after baseline blood pressure measurements [",
"    <a class=\"abstract\" href=\"UTD.htm?15/8/15497/abstract/52\">",
"     52",
"    </a>",
"    ]. Clinical evidence of HF developed in 234 subjects (11.8 percent). Increments of one standard deviation in systolic pressure, pulse pressure, and diastolic pressure were associated with hazard ratios for HF of 1.56, 1.55, and 1.24, respectively, after adjustment for other risk factors. The investigators hypothesize that increased arterial stiffness may be important in the influence of hypertension on the development of HF. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/12/26823?source=see_link\">",
"     \"Increased pulse pressure\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/27/25018?source=see_link\">",
"     \"Treatment of hypertension in the elderly patient, particularly isolated systolic hypertension\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Among hypertensive subjects, concurrent coronary disease, diabetes, left ventricular hypertrophy, and valve disease increased the risk of HF [",
"    <a class=\"abstract\" href=\"UTD.htm?15/8/15497/abstract/39\">",
"     39",
"    </a>",
"    ]. As an example, 34 to 52 percent of hypertensive persons who progressed to HF in the Framingham Study had interim myocardial infarctions, which increased the HF risk five to six fold. Angina also increased the risk, but only half as much as an infarction. Diabetes, left ventricular hypertrophy, and valve diseases escalate the hypertensive risk two- to threefold [",
"    <a class=\"abstract\" href=\"UTD.htm?15/8/15497/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Post MI",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antecedent hypertension has an impact on left ventricular remodeling after a myocardial infarction (MI) and increases the risk of HF in these patients. This was illustrated by a series of 1093 patients, 40 percent of whom had antecedent hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?15/8/15497/abstract/53\">",
"     53",
"    </a>",
"    ]. The following results were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hypertensive patients were more likely than normotensives to have early left ventricular remodeling after the MI.",
"     </li>",
"     <li>",
"      Hypertensive patients had a significantly greater incidence of HF during hospitalization (33 versus 24 percent for normotensives).",
"     </li>",
"     <li>",
"      During a mean follow-up of two years, hypertensive patients had a significantly greater incidence of HF requiring hospitalization (12.4 versus 5.5 percent); this difference was especially evident in patients &ge;65 years of age (20 versus 8 percent).",
"     </li>",
"     <li>",
"      Limited data suggest that the incidence of post-MI HF in the community may be declining [",
"      <a class=\"abstract\" href=\"UTD.htm?15/8/15497/abstract/54\">",
"       54",
"      </a>",
"      ]. However, a recent analysis of Framingham data suggests that the increased survival of post-MI patients in recent decades may be resulting in an increase in the incidence of HF post-MI [",
"      <a class=\"abstract\" href=\"UTD.htm?15/8/15497/abstract/55\">",
"       55",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Left ventricular hypertrophy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Whether due to hypertension, coronary disease, valve disease, or diabetes, left ventricular hypertrophy (LVH) is a prominent feature of evolving HF. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/34/17959?source=see_link\">",
"     \"Clinical implications and treatment of left ventricular hypertrophy in hypertension\"",
"    </a>",
"    .) Among patients with HF in the general population, antecedent evidence of LVH is present in approximately 20 percent by ECG and 60 to 70 by echocardiogram. The risk of HF of any cause increases progressively in relation to the left ventricular mass with no discernible separation of compensatory from pathologic hypertrophy.",
"   </p>",
"   <p>",
"    Each method of demonstrating left ventricular hypertrophy (ECG, chest film, or echocardiogram) independently predicts HF. As a result, persons having any combination of them have a greater risk than those with any one alone. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/13/3285?source=see_link\">",
"     \"Electrocardiographic diagnosis of left ventricular hypertrophy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Diastolic dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common conditions associated with diastolic dysfunction are aging, hypertension, diabetes mellitus, left ventricular hypertrophy, coronary disease, and infiltrative cardiomyopathies [",
"    <a class=\"abstract\" href=\"UTD.htm?15/8/15497/abstract/25,56\">",
"     25,56",
"    </a>",
"    ]. Patients with HF and preserved systolic function tend to be older and overweight, more often women, and have renal dysfunction, concentric left ventricular hypertrophy, and higher systolic blood pressure compared to patients with HF due to systolic dysfunction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/22/43368?source=see_link\">",
"     \"Clinical manifestations and diagnosis of diastolic heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a study conducted in Olmsted County, Minnesota, 21 percent of the population had mild diastolic dysfunction, 7 percent had moderate diastolic dysfunction, 0.7 percent had severe diastolic dysfunction, and 5.6 percent had moderate or severe diastolic dysfunction with a normal LVEF [",
"    <a class=\"abstract\" href=\"UTD.htm?15/8/15497/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Data from the Olmsted County also indicate that the proportion of patients with HF with preserved systolic function may have increased in the community over time [",
"    <a class=\"abstract\" href=\"UTD.htm?15/8/15497/abstract/56\">",
"     56",
"    </a>",
"    ]. Two later reports confirmed that diastolic dysfunction prospectively predicts HF [",
"    <a class=\"abstract\" href=\"UTD.htm?15/8/15497/abstract/57,58\">",
"     57,58",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     PREVENTION OF HEART FAILURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prevention of HF requires early detection and treatment of predisposing conditions and of high-risk candidates by internists and general practitioners. Recommendations for the management of patients at high risk for HF and patients with asymptomatic left ventricular dysfunction were published in 2005 by an",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    task force (",
"    <a class=\"graphic graphic_table graphicRef75241 graphicRef67792 \" href=\"UTD.htm?2/46/2798\">",
"     table 3A-B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/8/15497/abstract/59\">",
"     59",
"    </a>",
"    ]. In this document, HF is divided into the following stages: A, Any patient with risk factors for HF but no structural abnormalities; B, Patients with asymptomatic structural and functional abnormalities predisposing to HF; C, Patients with current or prior HF symptoms; D, Patients with end-stage HF. Prevention measures are aimed at patients in Stages A and B.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Risk factor reduction",
"    </span>",
"    &nbsp;&mdash;&nbsp;The high risk for HF associated with hypertension, diabetes, coronary disease, and obesity identify these as priority areas for preventive efforts. As an example, major hypertension trials clearly indicate that treating hypertension reduces the risk of HF. One meta-analysis found that controlling hypertension in elderly adults can reduce HF incidence by 39 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?15/8/15497/abstract/60\">",
"     60",
"    </a>",
"    ], a value close to the estimated population attributable risk for hypertension by the Framingham Study [",
"    <a class=\"abstract\" href=\"UTD.htm?15/8/15497/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The impact of healthy lifestyle habits (normal body weight, not smoking, regular exercise [five or more times per week], moderate alcohol intake [5 or more",
"    <span class=\"nowrap\">",
"     drinks/week],",
"    </span>",
"    consumption of breakfast cereals, and consumption of fruits and vegetables) on heart failure risk was examined in a study of 20,900 men from the Physicians' Health Study [",
"    <a class=\"abstract\" href=\"UTD.htm?15/8/15497/abstract/34\">",
"     34",
"    </a>",
"    ]. The analysis revealed that healthy lifestyle habits were associated with lower lifetime risk, with highest risk (21 percent) in men adhering to none of the six lifestyle factors (21 percent) and the lowest risk (10 percent) in men adhering to four or more of these factors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Asymptomatic left ventricular dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early detection of asymptomatic patients with an LVEF &le;40 percent is important because effective therapy delays the onset of HF and prolongs life [",
"    <a class=\"abstract\" href=\"UTD.htm?15/8/15497/abstract/61,62\">",
"     61,62",
"    </a>",
"    ]. In the SOLVD prevention trial of patients with asymptomatic left ventricular dysfunction, the incidence of death or symptomatic HF in such patients was reduced from 39 to 30 percent at just over three years by the administration of the ACE inhibitor",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/19/8505?source=see_link\">",
"     enalapril",
"    </a>",
"    &nbsp;(",
"    <a class=\"graphic graphic_figure graphicRef60648 \" href=\"UTD.htm?28/60/29645\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/8/15497/abstract/61\">",
"     61",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/59/28601?source=see_link\">",
"     \"Evaluation and management of asymptomatic left ventricular systolic dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Echocardiography is often performed to assess left ventricular function in patients at high risk for developing HF or performed for an unrelated reason such as evaluation of a heart murmur. A reduced LVEF, if present, establishes systolic dysfunction but is not diagnostic of HF, which requires clinical signs",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    symptoms. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/21/11610?source=see_link\">",
"     \"Noninvasive methods for measurement of left ventricular systolic function\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The prevalence of asymptomatic LV systolic dysfunction was illustrated in a cross-sectional survey of 2000 men and women aged 25 to 74, who were randomly sampled from one geographical area in Scotland, the prevalence of asymptomatic left ventricular systolic dysfunction was 1.4 percent, similar to that of overt HF [",
"    <a class=\"abstract\" href=\"UTD.htm?15/8/15497/abstract/11\">",
"     11",
"    </a>",
"    ]. Over 80 percent of the subjects with left ventricular dysfunction had evidence of ischemic heart disease by history or ECG.",
"   </p>",
"   <p>",
"    A higher prevalence was noted in a study conducted in Olmsted County, Minnesota [",
"    <a class=\"abstract\" href=\"UTD.htm?15/8/15497/abstract/10\">",
"     10",
"    </a>",
"    ]. Any systolic dysfunction was present in 6 percent and moderate or severe systolic dysfunction in 2 percent.",
"   </p>",
"   <p>",
"    Issues related to screening for asymptomatic left ventricular dysfunction are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/12/20679?source=see_link\">",
"     \"Screening for asymptomatic left ventricular dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?33/5/33877?source=see_link\">",
"       \"Patient information: Heart failure (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7177090\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The worldwide magnitude of the HF problem cannot be assessed with precision since reliable, population-based estimates of its prevalence, incidence, and prognosis are lacking for many regions of the globe, and a variety of methods that include history, physical examination, and heart function have been used to diagnose the condition. There were an estimated 5.8 million people with HF in the United States in 2006. There are an estimated 23 million people with HF worldwide. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Prevalence'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The prevalence and incidence of HF increases with age and trend data suggest that the incidence in the United States has increased in persons aged &gt;65 years. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Prevalence'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5\">",
"       'Incidence'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Risk factors for HF include coronary heart disease, cigarette smoking, hypertension, overweight, diabetes, and valvular heart disease. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Predisposing conditions for HF'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Prevention of HF requires early detection and treatment of predisposing conditions and of high-risk candidates by internists and general practitioners. The high risk for HF associated with hypertension, diabetes, coronary disease, and obesity identify these as priority areas for preventive efforts. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Risk factor reduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Early detection of asymptomatic patients with an LVEF &le;40 percent is important because effective therapy delays the onset of HF and prolongs life. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Asymptomatic left ventricular dysfunction'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15497/abstract/1\">",
"      Ho KK, Pinsky JL, Kannel WB, Levy D. The epidemiology of heart failure: the Framingham Study. J Am Coll Cardiol 1993; 22:6A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15497/abstract/2\">",
"      Cowie MR, Mosterd A, Wood DA, et al. The epidemiology of heart failure. Eur Heart J 1997; 18:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15497/abstract/3\">",
"      Hoes AW, Mosterd A, Grobbee DE. An epidemic of heart failure? Recent evidence from Europe. Eur Heart J 1998; 19 Suppl L:L2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15497/abstract/4\">",
"      Bonneux L, Barendregt JJ, Meeter K, et al. Estimating clinical morbidity due to ischemic heart disease and congestive heart failure: the future rise of heart failure. Am J Public Health 1994; 84:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15497/abstract/5\">",
"      Mosterd A, Deckers JW, Hoes AW, et al. Classification of heart failure in population based research: an assessment of six heart failure scores. Eur J Epidemiol 1997; 13:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15497/abstract/6\">",
"      Roger VL. The heart failure epidemic. Int J Environ Res Public Health 2010; 7:1807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15497/abstract/7\">",
"      WRITING GROUP MEMBERS, Lloyd-Jones D, Adams RJ, et al. Heart disease and stroke statistics--2010 update: a report from the American Heart Association. Circulation 2010; 121:e46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15497/abstract/8\">",
"      McMurray JJ, Petrie MC, Murdoch DR, Davie AP. Clinical epidemiology of heart failure: public and private health burden. Eur Heart J 1998; 19 Suppl P:P9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15497/abstract/9\">",
"      Vasan RS, Benjamin EJ, Levy D. Prevalence, clinical features and prognosis of diastolic heart failure: an epidemiologic perspective. J Am Coll Cardiol 1995; 26:1565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15497/abstract/10\">",
"      Redfield MM, Jacobsen SJ, Burnett JC Jr, et al. Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA 2003; 289:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15497/abstract/11\">",
"      McDonagh TA, Morrison CE, Lawrence A, et al. Symptomatic and asymptomatic left-ventricular systolic dysfunction in an urban population. Lancet 1997; 350:829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15497/abstract/12\">",
"      Gardin JM, Siscovick D, Anton-Culver H, et al. Sex, age, and disease affect echocardiographic left ventricular mass and systolic function in the free-living elderly. The Cardiovascular Health Study. Circulation 1995; 91:1739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15497/abstract/13\">",
"      Lauer MS, Evans JC, Levy D. Prognostic implications of subclinical left ventricular dilatation and systolic dysfunction in men free of overt cardiovascular disease (the Framingham Heart Study). Am J Cardiol 1992; 70:1180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15497/abstract/14\">",
"      Bleumink GS, Knetsch AM, Sturkenboom MC, et al. Quantifying the heart failure epidemic: prevalence, incidence rate, lifetime risk and prognosis of heart failure The Rotterdam Study. Eur Heart J 2004; 25:1614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15497/abstract/15\">",
"      McCullough PA, Philbin EF, Spertus JA, et al. Confirmation of a heart failure epidemic: findings from the Resource Utilization Among Congestive Heart Failure (REACH) study. J Am Coll Cardiol 2002; 39:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15497/abstract/16\">",
"      Owan TE, Redfield MM. Epidemiology of diastolic heart failure. Prog Cardiovasc Dis 2005; 47:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15497/abstract/17\">",
"      Brown AM, Cleland JG. Influence of concomitant disease on patterns of hospitalization in patients with heart failure discharged from Scottish hospitals in 1995. Eur Heart J 1998; 19:1063.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15497/abstract/18\">",
"      Jessup M, Brozena S. Heart failure. N Engl J Med 2003; 348:2007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15497/abstract/19\">",
"      Topol EJ, Traill TA, Fortuin NJ. Hypertensive hypertrophic cardiomyopathy of the elderly. N Engl J Med 1985; 312:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15497/abstract/20\">",
"      Gaasch WH. Diagnosis and treatment of heart failure based on left ventricular systolic or diastolic dysfunction. JAMA 1994; 271:1276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15497/abstract/21\">",
"      Elesber AA, Redfield MM. Approach to patients with heart failure and normal ejection fraction. Mayo Clin Proc 2001; 76:1047.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15497/abstract/22\">",
"      Vasan RS, Larson MG, Benjamin EJ, et al. Congestive heart failure in subjects with normal versus reduced left ventricular ejection fraction: prevalence and mortality in a population-based cohort. J Am Coll Cardiol 1999; 33:1948.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15497/abstract/23\">",
"      Gottdiener JS, McClelland RL, Marshall R, et al. Outcome of congestive heart failure in elderly persons: influence of left ventricular systolic function. The Cardiovascular Health Study. Ann Intern Med 2002; 137:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15497/abstract/24\">",
"      Bursi F, Weston SA, Redfield MM, et al. Systolic and diastolic heart failure in the community. JAMA 2006; 296:2209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15497/abstract/25\">",
"      Zile MR, Brutsaert DL. New concepts in diastolic dysfunction and diastolic heart failure: Part I: diagnosis, prognosis, and measurements of diastolic function. Circulation 2002; 105:1387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15497/abstract/26\">",
"      Havranek EP, Masoudi FA, Westfall KA, et al. Spectrum of heart failure in older patients: results from the National Heart Failure project. Am Heart J 2002; 143:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15497/abstract/27\">",
"      Masoudi FA, Havranek EP, Smith G, et al. Gender, age, and heart failure with preserved left ventricular systolic function. J Am Coll Cardiol 2003; 41:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15497/abstract/28\">",
"      Lloyd-Jones DM, Larson MG, Leip EP, et al. Lifetime risk for developing congestive heart failure: the Framingham Heart Study. Circulation 2002; 106:3068.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15497/abstract/29\">",
"      Levy D, Kenchaiah S, Larson MG, et al. Long-term trends in the incidence of and survival with heart failure. N Engl J Med 2002; 347:1397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15497/abstract/30\">",
"      Roger VL, Weston SA, Redfield MM, et al. Trends in heart failure incidence and survival in a community-based population. JAMA 2004; 292:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15497/abstract/31\">",
"      Barker WH, Mullooly JP, Getchell W. Changing incidence and survival for heart failure in a well-defined older population, 1970-1974 and 1990-1994. Circulation 2006; 113:799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15497/abstract/32\">",
"      Curtis LH, Whellan DJ, Hammill BG, et al. Incidence and prevalence of heart failure in elderly persons, 1994-2003. Arch Intern Med 2008; 168:418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15497/abstract/33\">",
"      Bibbins-Domingo K, Pletcher MJ, Lin F, et al. Racial differences in incident heart failure among young adults. N Engl J Med 2009; 360:1179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15497/abstract/34\">",
"      Djouss&eacute; L, Driver JA, Gaziano JM. Relation between modifiable lifestyle factors and lifetime risk of heart failure. JAMA 2009; 302:394.",
"     </a>",
"    </li>",
"    <li>",
"     National Heart Lung and Blood Institute. Morbidity and Mortality Chartbook on Cardiovascular, Lung and blood Diseases. 1996. NIH Bethesda MD.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15497/abstract/36\">",
"      Jhund PS, Macintyre K, Simpson CR, et al. Long-term trends in first hospitalization for heart failure and subsequent survival between 1986 and 2003: a population study of 5.1 million people. Circulation 2009; 119:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15497/abstract/37\">",
"      Lam CS, Donal E, Kraigher-Krainer E, Vasan RS. Epidemiology and clinical course of heart failure with preserved ejection fraction. Eur J Heart Fail 2011; 13:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15497/abstract/38\">",
"      Somaratne JB, Berry C, McMurray JJ, et al. The prognostic significance of heart failure with preserved left ventricular ejection fraction: a literature-based meta-analysis. Eur J Heart Fail 2009; 11:855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15497/abstract/39\">",
"      Levy D, Larson MG, Vasan RS, et al. The progression from hypertension to congestive heart failure. JAMA 1996; 275:1557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15497/abstract/40\">",
"      Kannel WB, Ho K, Thom T. Changing epidemiological features of cardiac failure. Br Heart J 1994; 72:S3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15497/abstract/41\">",
"      He J, Ogden LG, Bazzano LA, et al. Risk factors for congestive heart failure in US men and women: NHANES I epidemiologic follow-up study. Arch Intern Med 2001; 161:996.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15497/abstract/42\">",
"      Gheorghiade M, Bonow RO. Chronic heart failure in the United States: a manifestation of coronary artery disease. Circulation 1998; 97:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15497/abstract/43\">",
"      Massie BM, Shah NB. Evolving trends in the epidemiologic factors of heart failure: rationale for preventive strategies and comprehensive disease management. Am Heart J 1997; 133:703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15497/abstract/44\">",
"      Kenchaiah S, Evans JC, Levy D, et al. Obesity and the risk of heart failure. N Engl J Med 2002; 347:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15497/abstract/45\">",
"      Rahimtoola SH, Cheitlin MD, Hutter AM Jr. Cardiovascular disease in the elderly. Valvular and congenital heart disease. J Am Coll Cardiol 1987; 10:60A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15497/abstract/46\">",
"      Kalogeropoulos A, Georgiopoulou V, Kritchevsky SB, et al. Epidemiology of incident heart failure in a contemporary elderly cohort: the health, aging, and body composition study. Arch Intern Med 2009; 169:708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15497/abstract/47\">",
"      Baldasseroni S, Opasich C, Gorini M, et al. Left bundle-branch block is associated with increased 1-year sudden and total mortality rate in 5517 outpatients with congestive heart failure: a report from the Italian network on congestive heart failure. Am Heart J 2002; 143:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15497/abstract/48\">",
"      Felker GM, Thompson RE, Hare JM, et al. Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med 2000; 342:1077.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15497/abstract/49\">",
"      Sliwa K, Damasceno A, Mayosi BM. Epidemiology and etiology of cardiomyopathy in Africa. Circulation 2005; 112:3577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15497/abstract/50\">",
"      Stewart S, Wilkinson D, Hansen C, et al. Predominance of heart failure in the Heart of Soweto Study cohort: emerging challenges for urban African communities. Circulation 2008; 118:2360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15497/abstract/51\">",
"      Felker GM, Shaw LK, O'Connor CM. A standardized definition of ischemic cardiomyopathy for use in clinical research. J Am Coll Cardiol 2002; 39:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15497/abstract/52\">",
"      Haider AW, Larson MG, Franklin SS, et al. Systolic blood pressure, diastolic blood pressure, and pulse pressure as predictors of risk for congestive heart failure in the Framingham Heart Study. Ann Intern Med 2003; 138:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15497/abstract/53\">",
"      Richards AM, Nicholls MG, Troughton RW, et al. Antecedent hypertension and heart failure after myocardial infarction. J Am Coll Cardiol 2002; 39:1182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15497/abstract/54\">",
"      Hellermann JP, Goraya TY, Jacobsen SJ, et al. Incidence of heart failure after myocardial infarction: is it changing over time? Am J Epidemiol 2003; 157:1101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15497/abstract/55\">",
"      Velagaleti RS, Pencina MJ, Murabito JM, et al. Long-term trends in the incidence of heart failure after myocardial infarction. Circulation 2008; 118:2057.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15497/abstract/56\">",
"      Owan TE, Hodge DO, Herges RM, et al. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 2006; 355:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15497/abstract/57\">",
"      Lam CS, Lyass A, Kraigher-Krainer E, et al. Cardiac dysfunction and noncardiac dysfunction as precursors of heart failure with reduced and preserved ejection fraction in the community. Circulation 2011; 124:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15497/abstract/58\">",
"      Kane GC, Karon BL, Mahoney DW, et al. Progression of left ventricular diastolic dysfunction and risk of heart failure. JAMA 2011; 306:856.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15497/abstract/59\">",
"      Hunt SA, Abraham WT, Chin MH, et al. 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009; 119:e391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15497/abstract/60\">",
"      Gueyffier F, Bulpitt C, Boissel JP, et al. Antihypertensive drugs in very old people: a subgroup meta-analysis of randomised controlled trials. INDANA Group. Lancet 1999; 353:793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15497/abstract/61\">",
"      Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigattors. N Engl J Med 1992; 327:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15497/abstract/62\">",
"      Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. JAMA 1995; 273:1450.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3479 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.55.141.10-11D65C23BF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_8_15497=[""].join("\n");
var outline_f15_8_15497=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H7177090\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MAGNITUDE OF THE PROBLEM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Prevalence",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Preserved systolic function",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Incidence",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Incidence in older adults",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Incidence in younger adults",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Lifetime risk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Mortality",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      PREDISPOSING CONDITIONS FOR HF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Frequency of various causes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - In developing countries",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Ischemic cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Hypertension",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Post MI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Left ventricular hypertrophy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Diastolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      PREVENTION OF HEART FAILURE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Risk factor reduction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Asymptomatic left ventricular dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7177090\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/3479\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/3479|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/60/29645\" title=\"figure 1\">",
"      Survival in asymptomatic LVD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/3479|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?37/44/38603\" title=\"table 1\">",
"      Framingham criteria Dx HF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?12/52/13131\" title=\"table 2\">",
"      Incidence of heart failure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?35/11/36028\" title=\"table 3A\">",
"      ACC AHA manage high risk for HF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?40/15/41212\" title=\"table 3B\">",
"      ACC AHA Rx asym LV dysfunction",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/47/18169?source=related_link\">",
"      Cardiovascular effects of obstructive sleep apnea",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/0/19465?source=related_link\">",
"      Causes of dilated cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/34/17959?source=related_link\">",
"      Clinical implications and treatment of left ventricular hypertrophy in hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/22/43368?source=related_link\">",
"      Clinical manifestations and diagnosis of diastolic heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/3/24633?source=related_link\">",
"      Diagnosis and management of ischemic cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/13/3285?source=related_link\">",
"      Electrocardiographic diagnosis of left ventricular hypertrophy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/59/28601?source=related_link\">",
"      Evaluation and management of asymptomatic left ventricular systolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/23/7544?source=related_link\">",
"      Evaluation of acute decompensated heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/35/30266?source=related_link\">",
"      Health hazards associated with obesity in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/12/26823?source=related_link\">",
"      Increased pulse pressure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/21/11610?source=related_link\">",
"      Noninvasive methods for measurement of left ventricular systolic function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?33/5/33877?source=related_link\">",
"      Patient information: Heart failure (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/61/4058?source=related_link\">",
"      Prognosis of heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/12/20679?source=related_link\">",
"      Screening for asymptomatic left ventricular dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/27/25018?source=related_link\">",
"      Treatment of hypertension in the elderly patient, particularly isolated systolic hypertension",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_8_15498="Extrahepatic manifestations of hepatitis C virus infection";
var content_f15_8_15498=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Extrahepatic manifestations of hepatitis C virus infection",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/8/15498/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/8/15498/contributors\">",
"     Sanjiv Chopra, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/8/15498/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/8/15498/contributors\">",
"     Adrian M Di Bisceglie, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/8/15498/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/8/15498/contributors\">",
"     Allyson Bloom, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?15/8/15498/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 2, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infection with hepatitis C virus (HCV) can lead to both acute and chronic hepatitis. In addition, there are several extrahepatic manifestations of chronic HCV infection, including [",
"    <a class=\"abstract\" href=\"UTD.htm?15/8/15498/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Hematologic diseases such as cryoglobulinemia and lymphoma",
"     </li>",
"     <li>",
"      Autoimmune disorders such as thyroiditis",
"     </li>",
"     <li>",
"      Renal disease",
"     </li>",
"     <li>",
"      Dermatologic conditions such as lichen planus and porphyria cutanea tarda",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Extrahepatic manifestations of HCV virus are common. In one series, 122 of 321 patients (38 percent) had at least one extrahepatic manifestation (",
"    <a class=\"graphic graphic_table graphicRef66842 \" href=\"UTD.htm?28/9/28828\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?15/8/15498/abstract/3\">",
"     3",
"    </a>",
"    ]. In most cases, these manifestations appear to be directly related to the presence of the virus.",
"   </p>",
"   <p>",
"    The extrahepatic manifestations of HCV infection will be reviewed here. The clinical manifestations of acute and chronic hepatitis due to HCV as well as the treatment of HCV are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/50/31530?source=see_link\">",
"     \"Clinical manifestations and natural history of chronic hepatitis C virus infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/45/43735?source=see_link\">",
"     \"Overview of the management of chronic hepatitis C virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     HEMATOLOGIC DISORDERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hematologic disorders that have been associated with chronic hepatitis C virus (HCV) include essential mixed cryoglobulinemia, monoclonal gammopathies (which may be associated with multiple myeloma), and lymphoma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Essential mixed cryoglobulinemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Essential mixed cryoglobulinemia, also called type II cryoglobulinemia, is a lymphoproliferative disorder that can lead to the deposition of circulating immune complexes in small- to medium-sized blood vessels. The most common clinical manifestations include palpable purpura, arthralgias, renal disease (usually a membranoproliferative glomerulonephritis), neurologic disease, and hypocomplementemia. The purpura often involves the lower legs, may come in \"crops\", and can leave brown spots on the skin after it resolves. The vasculitis can result in ischemic necrosis and skin ulceration, rarely leading to necrosis of a digit. Lymphoma is an uncommon manifestation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/15/34040?source=see_link\">",
"     \"Clinical manifestations and diagnosis of the mixed cryoglobulinemia syndrome (essential mixed cryoglobulinemia)\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H5\">",
"     'Lymphoma'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    More than 90 percent of patients with essential mixed cryoglobulinemia are infected with HCV, and about half of patients with HCV have cryoglobulins (69 of 127 in one study) (",
"    <a class=\"graphic graphic_figure graphicRef80075 \" href=\"UTD.htm?29/19/30013\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/8/15498/abstract/5\">",
"     5",
"    </a>",
"    ]. As a result, all patients with chronic HCV should be evaluated for cryoglobulinemia. If either the history or the physical examination is suggestive of possible cryoglobulinemia, then the patient should undergo appropriate testing. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/15/34040?source=see_link&amp;anchor=H2#H2\">",
"     \"Clinical manifestations and diagnosis of the mixed cryoglobulinemia syndrome (essential mixed cryoglobulinemia)\", section on 'HCV infection'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/15/34040?source=see_link&amp;anchor=H9#H9\">",
"     \"Clinical manifestations and diagnosis of the mixed cryoglobulinemia syndrome (essential mixed cryoglobulinemia)\", section on 'Diagnosis'",
"    </a>",
"    .).",
"   </p>",
"   <p>",
"    Treatment of HCV can result in decreased cryoglobulin levels and improvements in skin lesions and symptoms. As a result, antiviral treatment should be considered in patients with symptoms related to cryoglobulinemia, even in the absence of other indications for HCV therapy. Some patients with severe complications of cryoglobulinemia require additional therapy, such as plasmapheresis.",
"   </p>",
"   <p>",
"    However, not all patients with HCV infection and cryoglobulinemia respond to anti-HCV therapy, and a reduction in cryoglobulin titers may not be directly associated with a decrease in serum alanine aminotransferase or HCV RNA levels. These issues are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/52/36682?source=see_link\">",
"     \"Treatment of the mixed cryoglobulinemia syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Monoclonal gammopathies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hepatitis C may be a risk factor for the development of monoclonal gammopathies. However, the association is unclear, and monoclonal gammopathy is not rare in the general population over the age of 50 years. Prior to the development of tests for the hepatitis C virus (HCV), the prevalence of monoclonal gammopathies was noted to be increased in patients with chronic liver disease [",
"    <a class=\"abstract\" href=\"UTD.htm?15/8/15498/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/59/15290?source=see_link\">",
"     \"Diagnosis of monoclonal gammopathy of undetermined significance\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The results of studies looking at the association of HCV with monoclonal gammopathies have been variable:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One study of patients with chronic liver disease compared 239 HCV-positive patients to 98 HCV-negative controls (76 with chronic hepatitis B, 9 with alcoholic liver disease, and 13 with primary biliary cirrhosis) [",
"      <a class=\"abstract\" href=\"UTD.htm?15/8/15498/abstract/7\">",
"       7",
"      </a>",
"      ]. Monoclonal bands were more common in patients with HCV compared with age-matched controls (11versus 1 percent). Of the 26 patients with monoclonal bands, 9 (35 percent) had either smoldering myeloma or multiple myeloma. The incidence of monoclonal gammopathies peaked in patients between the ages of 60 and 69 years (21 percent). Of the patients with monoclonal gammopathies, 50 percent had HCV genotype",
"      <span class=\"nowrap\">",
"       2a/c,",
"      </span>",
"      which was significantly higher than the prevalence in the matched controls (18 percent).",
"     </li>",
"     <li>",
"      A second study of 824 patients with chronic liver disease (530 with HCV and 294 with other liver diseases) found that 12 percent of the HCV-positive patients had a monoclonal band, compared with 3 percent of the control patients [",
"      <a class=\"abstract\" href=\"UTD.htm?15/8/15498/abstract/8\">",
"       8",
"      </a>",
"      ]. Like the earlier study, this study also showed an increase in the prevalence of HCV genotype 2a among patients with monoclonal gammopathies.",
"     </li>",
"     <li>",
"      Other studies have failed to show an association of monoclonal gammopathies with HCV infection [",
"      <a class=\"abstract\" href=\"UTD.htm?15/8/15498/abstract/9,10\">",
"       9,10",
"      </a>",
"      ]. For example, one study of 100 patients with HCV found no cases of monoclonal gammopathy [",
"      <a class=\"abstract\" href=\"UTD.htm?15/8/15498/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Routine screening of patients with HCV for monoclonal gammopathies is not recommended. In addition, the presence of a monoclonal gammopathy alone is not an indication for antiviral therapy.",
"   </p>",
"   <p>",
"    In addition to monoclonal gammopathies, HCV has also been associated with polyclonal or oligoclonal hyperglobulinemia (most often IgG) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/8/15498/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. In these patients, gammaglobulin levels correlate with the disease severity seen on liver biopsy. In addition, serum gammaglobulin levels have been noted to decrease following successful treatment for HCV.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Lymphoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hepatitis C virus (HCV) infection has been associated with the development of B-cell non-Hodgkin lymphoma (including diffuse large B-cell lymphoma, marginal zone lymphoma, lymphoplasmacytic lymphoma, splenic lymphoma with villous lymphocytes, and extranodal marginal zone B cell lymphoma of mucosa-associated lymphoid tissue) as well as primary hepatic lymphoma [",
"    <a class=\"abstract\" href=\"UTD.htm?15/8/15498/abstract/13-23\">",
"     13-23",
"    </a>",
"    ]. In addition, HCV infection may increase the risk of hepatotoxicity related to treatment for lymphoma. In a study of 553 patients, the presence of HCV predicted severe hepatoxicity in patients with diffuse large B-cell lymphoma who were treated with rituximab-containing chemotherapy regimens (hazard ratio 15) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/8/15498/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Findings that support an association of HCV with lymphoma include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A meta-analysis that included 48 studies concluded that the prevalence of HCV in patients with B-cell non-Hodgkin lymphoma (NHL) was 15 percent, much higher than the prevalence in the general population (around 1.5 percent) or in patients with other hematologic malignancies (3 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?15/8/15498/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A large cohort study of United States Veterans published after the meta-analysis estimated the risk of NHL was increased by about 28 percent in patients with HCV (hazard ratio 1.28) compared with non-HCV infected individuals [",
"      <a class=\"abstract\" href=\"UTD.htm?15/8/15498/abstract/14\">",
"       14",
"      </a>",
"      ]. The risk was also increased for Waldenstrom macroglobulinemia and cryoglobulinemia, but not other hematologic malignancies.",
"     </li>",
"     <li>",
"      Some HCV-associated lymphomas produce soluble immunoglobulins directed against the E2 protein (an HCV envelope glycoprotein) [",
"      <a class=\"abstract\" href=\"UTD.htm?15/8/15498/abstract/25\">",
"       25",
"      </a>",
"      ]. This observation supports the hypothesis that some HCV-associated lymphomas originate from B cells that were initially activated by the HCV-E2 protein.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Lymphoma may develop due to the progression of cryoglobulinemia [",
"    <a class=\"abstract\" href=\"UTD.htm?15/8/15498/abstract/22,26\">",
"     22,26",
"    </a>",
"    ]. One hypothesis is that cryoglobulinemia arises from chronic stimulation of the immune system by HCV, predisposing to a lymphoproliferative disorder. While the steps leading to the development of a lymphoproliferative disorder are uncertain, an increased prevalence of the t(14;18) translocation in the B cells of patients with HCV may play a role [",
"    <a class=\"abstract\" href=\"UTD.htm?15/8/15498/abstract/27-30\">",
"     27-30",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/46/25322?source=see_link&amp;anchor=H16#H16\">",
"     \"Clinical manifestations, pathologic features, diagnosis, and prognosis of follicular lymphoma\", section on 'Cytogenetics'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The development of unexplained anemia or lymphadenopathy in a patient with HCV and clinically active cryoglobulinemia should raise concern about an underlying lymphoproliferative disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?15/8/15498/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While not well studied, some data suggest that successful treatment of HCV may reduce the risk of lymphoma in patients who achieve a sustained virologic response. One of the largest studies included 3209 patients with HCV, of whom 2708 (84 percent) had received treatment with interferon-based therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?15/8/15498/abstract/31\">",
"     31",
"    </a>",
"    ]. The overall annual incidence of lymphoma in patients with HCV was estimated to be 0.2 percent. The risk was reduced significantly in the 1048 patients who had achieved a sustained virologic response compared with those who had persistent infection (hazard ratio 0.13). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/45/43735?source=see_link\">",
"     \"Overview of the management of chronic hepatitis C virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Whether treatment of the underlying HCV infection could be effective in patients who have developed lymphoma is uncertain [",
"    <a class=\"abstract\" href=\"UTD.htm?15/8/15498/abstract/30\">",
"     30",
"    </a>",
"    ]. Regression of splenic lymphoma has been described in association with HCV treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?15/8/15498/abstract/23\">",
"     23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/41/22169?source=see_link&amp;anchor=H16#H16\">",
"     \"Treatment of marginal zone (MALT) lymphoma\", section on 'Antiviral therapy for hepatitis C'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     AUTOIMMUNE DISORDERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of autoimmune disorders have been associated with HCV infection, including subclinical autoantibody formation, thyroid disease, sialadenitis, and autoimmune thrombocytopenic purpura.",
"   </p>",
"   <p>",
"    In an analysis of 1020 patients with hepatitis C in an international registry, autoimmune disorders that were present included Sj&ouml;gren's syndrome (48 percent), rheumatoid arthritis (15 percent), systemic lupus erythematosus (13 percent), polyarteritis nodosa (8 percent), and antiphospholipid syndrome (6 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/8/15498/abstract/32\">",
"     32",
"    </a>",
"    ]. Many of the patients had antinuclear antibodies (61 percent), rheumatoid factor (57 percent), hypocomplementemia (52 percent),",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    cryoglobulins (52 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Autoantibodies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Autoantibodies are common in patients with chronic hepatitis C virus (HCV) infection. Antinuclear antibodies, antibodies directed against the Fc portion of IgG (rheumatoid factor), anticardiolipin antibodies, smooth muscle antibodies, or antithyroid antibodies are detected in 40 to 65 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?15/8/15498/abstract/3,32-34\">",
"     3,32-34",
"    </a>",
"    ]. While antibodies are often present in low titers, do not appear to influence the presentation or course of the infection, and are not associated with extrahepatic disease, autoimmune hepatitis and thyroid disease (primarily hypothyroidism) have been associated with chronic HCV infections.",
"   </p>",
"   <p>",
"    The presence of autoantibodies may result in diagnostic difficulties. For example, an HCV-infected patient with arthralgias, arthritis, and rheumatoid factor positivity may be misdiagnosed initially as having rheumatoid arthritis (RA). In this setting, testing for other RA-associated autoantibodies that are observed infrequently in patients with HCV infection, such as anti-citrullinated peptide (eg, anti-cyclic citrullinated peptide or CCP) antibodies, may be helpful diagnostically [",
"    <a class=\"abstract\" href=\"UTD.htm?15/8/15498/abstract/35\">",
"     35",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/41/42648?source=see_link\">",
"     \"Origin and utility of measurement of rheumatoid factors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Autoantibodies may first become detectable or increase in titer during interferon treatment. However, since their presence does not affect the disease course or the response to treatment, autoantibody formation is not a reason to stop therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/41/36505?source=see_link\">",
"     \"Principles of interferon therapy in liver disease and the induction of autoimmunity\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5757261\">",
"    <span class=\"h3\">",
"     Autoimmune hepatitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unlike some of the other autoantibodies seen in HCV that do not have clinical significance, antibodies to actin and to",
"    <span class=\"nowrap\">",
"     liver/kidney",
"    </span>",
"    microsomes (anti-LKM-1) may be clinically significant. These antibodies are characteristic of types 1 and 2 autoimmune hepatitis, respectively, and have been detected in some patients with chronic HCV infection, particularly in Europe [",
"    <a class=\"abstract\" href=\"UTD.htm?15/8/15498/abstract/36-38\">",
"     36-38",
"    </a>",
"    ], though it is not recommended that patients be routinely screened for these antibodies. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/44/35528?source=see_link\">",
"     \"Clinical manifestations and diagnosis of autoimmune hepatitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/44/35528?source=see_link&amp;anchor=H8#H8\">",
"     \"Clinical manifestations and diagnosis of autoimmune hepatitis\", section on 'Autoantibodies'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most patients with hepatitis C and anti-LKM-1 antibodies appear to benefit from interferon-based therapy to the same extent as patients with chronic hepatitis C without such antibodies. However, the presence of the antibodies alone is not an indication for antiviral therapy. However, close monitoring during interferon treatment is required since flares of aminotransferases without subsequent clearance of HCV RNA have been observed [",
"    <a class=\"abstract\" href=\"UTD.htm?15/8/15498/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. This observation suggests that these patients may behave clinically as if they have autoimmune hepatitis, which can flare in the setting of interferon therapy. In addition, some of these patients will respond to treatment for autoimmune hepatitis with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?15/8/15498/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/41/36505?source=see_link&amp;anchor=H6#H6\">",
"     \"Principles of interferon therapy in liver disease and the induction of autoimmunity\", section on 'Liver disease'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Determining the primary cause of the patient&rsquo;s hepatitis can be difficult in patients with both HCV and anti-LKM-1 antibodies. The anti-LKM-1 antibodies in patients with HCV are directed at different epitopes of cytochrome P450 2D6 (CYP2D6, the target antigen) than the antibodies in patients with autoimmune hepatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/8/15498/abstract/43,44\">",
"     43,44",
"    </a>",
"    ], which may help differentiate between patients whose hepatitis is due primarily to HCV and patients whose hepatitis is due to autoimmune hepatitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Thyroid disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thyroid disorders are common in patients with chronic hepatitis C virus (HCV) infection, particularly women [",
"    <a class=\"abstract\" href=\"UTD.htm?15/8/15498/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]. Overall, antithyroid antibodies are present in 5 to 17 percent of patients infected with HCV, and thyroid disease (primarily hypothyroidism) occurs in 2 to 13 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?15/8/15498/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]. The highest prevalence of both thyroid antibodies and thyroid disease is found in older women. However, whether or not the prevalence is higher than in age- and sex-matched controls is controversial [",
"    <a class=\"abstract\" href=\"UTD.htm?15/8/15498/abstract/47,48\">",
"     47,48",
"    </a>",
"    ]. Thyroid function tests should be checked when a patient is first diagnosed with HCV. Patients found to be hypothyroid should receive thyroid hormone replacement. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/7/26744?source=see_link\">",
"     \"Diagnosis of and screening for hypothyroidism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/53/43865?source=see_link\">",
"     \"Treatment of hypothyroidism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    One of the largest studies of thyroid disease in patients with HCV included 630 consecutive patients with HCV (without cirrhosis) who were compared with 389 subjects from an iodine-deficient area, 286 subjects from an area of iodine sufficiency, and 86 patients with chronic hepatitis B [",
"    <a class=\"abstract\" href=\"UTD.htm?15/8/15498/abstract/46\">",
"     46",
"    </a>",
"    ]. Mean thyroid stimulating hormone levels were significantly higher and free T3 and T4 levels significantly lower in patients with HCV compared with the other groups. Patients with HCV were more likely than controls to have hypothyroidism (13 versus 3 to 5 percent), anti-thyroglobulin antibodies (17 versus 9 to 10 percent), and anti-thyroperoxidase antibodies (21 versus 10 to 13 percent). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/33/3608?source=see_link\">",
"     \"Laboratory assessment of thyroid function\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/11/27833?source=see_link\">",
"     \"Pathogenesis of Hashimoto's thyroiditis (chronic autoimmune thyroiditis)\"",
"    </a>",
"    .) As with other autoimmune phenomena, thyroid disease can also develop in patients with HCV infection who are treated with interferon alfa. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/41/36505?source=see_link&amp;anchor=H5#H5\">",
"     \"Principles of interferon therapy in liver disease and the induction of autoimmunity\", section on 'Thyroid disease'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/9/16538?source=see_link&amp;anchor=H19#H19\">",
"     \"Management of the side effects of peginterferon and ribavirin being used for treatment of chronic hepatitis C virus infection\", section on 'Thyroid dysfunction'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Sialadenitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;A lymphocytic sialadenitis suggestive of Sj&ouml;gren's syndrome has been described in patients with chronic hepatitis C virus (HCV) infection [",
"    <a class=\"abstract\" href=\"UTD.htm?15/8/15498/abstract/49,50\">",
"     49,50",
"    </a>",
"    ]. A study of 137 patients with Sj&ouml;gren's syndrome and HCV suggested that the clinical and immunologic features were indistinguishable from Sj&ouml;gren's syndrome in patients without HCV [",
"    <a class=\"abstract\" href=\"UTD.htm?15/8/15498/abstract/50\">",
"     50",
"    </a>",
"    ]. However, patients with sialadenitis in the setting of HCV often have minimal to no symptoms in contrast to patients with Sj&ouml;gren's syndrome, who often have symptoms of dry eyes and dry mouth (sicca syndrome) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/8/15498/abstract/51\">",
"     51",
"    </a>",
"    ]. Histologically, patients with HCV often have mild sialadenitis with pericapillary lymphocytic infiltration (rather than periductal) with no destruction of the salivary gland ducts. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/1/11287?source=see_link\">",
"     \"Clinical manifestations of Sj&ouml;gren's syndrome: Exocrine gland disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Autoimmune thrombocytopenic purpura and hemolytic anemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of studies have suggested an association between hepatitis C virus (HCV) infection and autoimmune thrombocytopenic purpura and autoimmune hemolytic anemia, either as a consequence of interferon therapy or in the setting of chronic infection without therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?15/8/15498/abstract/52,53\">",
"     52,53",
"    </a>",
"    ]. One of the largest studies included 120,691 United States veterans with chronic HCV who were matched with 454,905 controls [",
"    <a class=\"abstract\" href=\"UTD.htm?15/8/15498/abstract/53\">",
"     53",
"    </a>",
"    ]. HCV was associated with autoimmune thrombocytopenic purpura in both treated and untreated patients (hazard ratio [HR] 1.8). An increased risk of autoimmune hemolytic anemia was also detected (HR 2.8), but only in patients who were treated with interferon-based therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/13/30938?source=see_link\">",
"     \"Clinical manifestations and diagnosis of immune thrombocytopenia (ITP) in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/3/18489?source=see_link\">",
"     \"Approach to the diagnosis of hemolytic anemia in the adult\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Myasthenia gravis",
"    </span>",
"    &nbsp;&mdash;&nbsp;An association between myasthenia gravis (MG) and hepatitis C virus infection has been suggested in case reports [",
"    <a class=\"abstract\" href=\"UTD.htm?15/8/15498/abstract/54,55\">",
"     54,55",
"    </a>",
"    ], although a causal association has not been clearly established [",
"    <a class=\"abstract\" href=\"UTD.htm?15/8/15498/abstract/56\">",
"     56",
"    </a>",
"    ]. MG has also been described in association with the administration of interferon, possibly because of exacerbation of preexisting subclinical disease [",
"    <a class=\"abstract\" href=\"UTD.htm?15/8/15498/abstract/57,58\">",
"     57,58",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/41/36505?source=see_link&amp;anchor=H10#H10\">",
"     \"Principles of interferon therapy in liver disease and the induction of autoimmunity\", section on 'Others'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Sarcoidosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sarcoidosis has been described in association with interferon treatment for HCV. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/9/16538?source=see_link&amp;anchor=H16#H16\">",
"     \"Management of the side effects of peginterferon and ribavirin being used for treatment of chronic hepatitis C virus infection\", section on 'Sarcoidosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5758040\">",
"    <span class=\"h1\">",
"     DERMATOLOGIC DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of dermatologic diseases may be associated with hepatitis C virus (HCV) infection [",
"    <a class=\"abstract\" href=\"UTD.htm?15/8/15498/abstract/59\">",
"     59",
"    </a>",
"    ]. The dermatologic response to treatment of the underlying HCV is variable [",
"    <a class=\"abstract\" href=\"UTD.htm?15/8/15498/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5758201\">",
"    <span class=\"h2\">",
"     Porphyria cutanea tarda",
"    </span>",
"    &nbsp;&mdash;&nbsp;Porphyria cutanea tarda (PCT) is a skin disease caused by a reduction of hepatic uroporphyrinogen decarboxylase activity. It is characterized by photosensitivity, skin fragility, bruising, facial hirsutism, and vesicles or bullae that can become hemorrhagic (",
"    <a class=\"graphic graphic_picture graphicRef74528 \" href=\"UTD.htm?13/30/13794\">",
"     picture 1",
"    </a>",
"    ). There is a strong association between the sporadic form of PCT and HCV infection [",
"    <a class=\"abstract\" href=\"UTD.htm?15/8/15498/abstract/61\">",
"     61",
"    </a>",
"    ]. The precise mechanism by which HCV infection might cause or act as a trigger for PCT in predisposed subjects is not known.",
"   </p>",
"   <p>",
"    All patients with PCT should be screened for HCV infection, as well as other potential precipitating factors. Treatment with interferon alfa should be considered in HCV-infected patients. Phlebotomy to deplete patients of excess iron is an important step prior to considering antiviral therapy since many of the symptoms of PCT improve with phlebotomy.",
"   </p>",
"   <p>",
"    PCT in the setting of HCV infection is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/45/30421?source=see_link\">",
"     \"Porphyria cutanea tarda and hepatitis C virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5758208\">",
"    <span class=\"h2\">",
"     Leukocytoclastic vasculitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;A leukocytoclastic vasculitis may occur in conjunction with essential mixed cryoglobulinemia, presenting clinically with palpable purpura and petechiae that usually involve the lower extremities (",
"    <a class=\"graphic graphic_picture graphicRef78697 \" href=\"UTD.htm?9/36/9794\">",
"     picture 2",
"    </a>",
"    ). Skin biopsy demonstrates cutaneous vasculitis with dermal blood vessel destruction associated with a neutrophilic infiltration in and around the vessel wall (",
"    <a class=\"graphic graphic_picture graphicRef52548 graphicRef66296 \" href=\"UTD.htm?7/58/8106\">",
"     picture 3A-B",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/15/34040?source=see_link\">",
"     \"Clinical manifestations and diagnosis of the mixed cryoglobulinemia syndrome (essential mixed cryoglobulinemia)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/15/4345?source=see_link&amp;anchor=H16171991#H16171991\">",
"     \"Evaluation of adults with cutaneous lesions of vasculitis\", section on 'Biopsy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other tissues, particularly the lower extremity peripheral nerves, may show similar vasculitic changes involving the vasa nervorum [",
"    <a class=\"abstract\" href=\"UTD.htm?15/8/15498/abstract/62\">",
"     62",
"    </a>",
"    ]. This may manifest clinically as a peripheral neuropathy that, as in other forms of vasculitis, is typically asymmetric (also called a mononeuritis multiplex). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/57/22423?source=see_link&amp;anchor=H7#H7\">",
"     \"Clinical manifestations of vasculitic neuropathy\", section on 'Mononeuritis multiplex'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As with other manifestations of essential mixed cryoglobulinemia, treatment may include antiviral therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/52/36682?source=see_link&amp;anchor=H5#H5\">",
"     \"Treatment of the mixed cryoglobulinemia syndrome\", section on 'Therapy for HCV infection'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5758215\">",
"    <span class=\"h2\">",
"     Lichen planus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lichen planus (LP) is characterized by flat-topped, violaceous, pruritic papules with a generalized distribution (",
"    <a class=\"graphic graphic_picture graphicRef50632 \" href=\"UTD.htm?0/50/805\">",
"     picture 4",
"    </a>",
"    ). It can also involve mucus membranes, hair, and nails. LP may be mediated through the cellular immune response, although the actual precipitating mechanism is not known [",
"    <a class=\"abstract\" href=\"UTD.htm?15/8/15498/abstract/63\">",
"     63",
"    </a>",
"    ]. Skin biopsy demonstrates a dense lymphocytic infiltration in the upper dermis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/27/9656?source=see_link\">",
"     \"Lichen planus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    LP can be seen in patients with a variety of liver diseases, particularly advanced liver disease. Anti-hepatitis C virus (HCV) antibodies are present in 10 to 40 percent of these patients, although whether there is a causal association is uncertain [",
"    <a class=\"abstract\" href=\"UTD.htm?15/8/15498/abstract/1\">",
"     1",
"    </a>",
"    ]. There are also reports of the development or exacerbation of lichen planus during interferon treatment for chronic HCV. In one report, the lesions improved when interferon was stopped [",
"    <a class=\"abstract\" href=\"UTD.htm?15/8/15498/abstract/64\">",
"     64",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/9/16538?source=see_link&amp;anchor=H17#H17\">",
"     \"Management of the side effects of peginterferon and ribavirin being used for treatment of chronic hepatitis C virus infection\", section on 'Dermatologic complications'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5758222\">",
"    <span class=\"h2\">",
"     Necrolytic acral erythema",
"    </span>",
"    &nbsp;&mdash;&nbsp;Necrolytic acral erythema is a pruritic, psoriasis-like skin disease characterized by a sharply marginated, erythematous to hyperpigmented plaques with variable scale and erosion on the lower extremities. In a series of 30 patients who presented with the disorder, all were found to have antibodies to hepatitis C virus (HCV) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/8/15498/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Biopsy specimens showed psoriasiform changes, keratinocyte necrosis, and papillomatosis. Improvement was observed in a patient who had been treated for HCV with interferon alfa, who subsequently relapsed nine months after therapy was discontinued. Topical and systemic corticosteroids have a variable benefits. Other reports have confirmed improvement with interferon alfa and also suggest a benefit from oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/57/17300?source=see_link\">",
"     zinc sulfate",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?15/8/15498/abstract/66-69\">",
"     66-69",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5757471\">",
"    <span class=\"h1\">",
"     DIABETES MELLITUS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hepatitis C virus (HCV) infection has been linked to diabetes mellitus in several studies [",
"    <a class=\"abstract\" href=\"UTD.htm?15/8/15498/abstract/70-79\">",
"     70-79",
"    </a>",
"    ]. A meta-analysis of 34 studies estimated that the risk was increased by almost 70 percent in HCV-infected patients compared with non-infected controls (OR 1.7) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/8/15498/abstract/80\">",
"     80",
"    </a>",
"    ]. The risk was also increased compared with patients who had chronic HBV infection. However, routine screening for diabetes mellitus is not recommended based upon the presence of HCV alone. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/16/2312?source=see_link\">",
"     \"Screening for diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some studies have identified risk factors for the development of diabetes mellitus in HCV infected patients, such as older age, obesity, severe liver fibrosis, and a family history of diabetes mellitus [",
"    <a class=\"abstract\" href=\"UTD.htm?15/8/15498/abstract/81\">",
"     81",
"    </a>",
"    ]. Patients undergoing liver transplantation for HCV also appear to be at increased risk of developing diabetes mellitus following transplantation compared with patients undergoing transplantation for other indications [",
"    <a class=\"abstract\" href=\"UTD.htm?15/8/15498/abstract/82\">",
"     82",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The cause of the association of HCV with diabetes is unknown. In addition, the magnitude of the association may be overestimated because [",
"    <a class=\"abstract\" href=\"UTD.htm?15/8/15498/abstract/83\">",
"     83",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with diabetes have more parenteral exposures than the general population, placing them at increased risk for transmission of viruses",
"     </li>",
"     <li>",
"      Not all studies controlled for the presence of cirrhosis, which may be associated with impaired glucose tolerance",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    HCV has also been linked to insulin resistance without overt diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?15/8/15498/abstract/84,85\">",
"     84,85",
"    </a>",
"    ]. Insulin resistance may contribute to hepatic fibrosis progression, particularly with HCV genotypes 1 and 4 and with high serum RNA levels [",
"    <a class=\"abstract\" href=\"UTD.htm?15/8/15498/abstract/84,86\">",
"     84,86",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Successful HCV treatment may decrease the risk of diabetes mellitus. In at least two reports, achievement of a sustained virologic response with interferon-based therapy was associated with a reduced incidence of diabetes mellitus [",
"    <a class=\"abstract\" href=\"UTD.htm?15/8/15498/abstract/87,88\">",
"     87,88",
"    </a>",
"    ]. In another report, insulin resistance decreased in patients who achieved an SVR but not in patients who failed to respond to treatment or relapsed [",
"    <a class=\"abstract\" href=\"UTD.htm?15/8/15498/abstract/89\">",
"     89",
"    </a>",
"    ]. However, insulin resistance may impair the response to antiviral therapy with interferon and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     OCULAR DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;HCV infection has been associated with a variety of ophthalmologic disorders including dry eyes, corneal ulcers (Mooren's ulcer), uveitis, scleritis, and, in patients with HCV-related Sj&ouml;gren&rsquo;s syndrome, sicca syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?15/8/15498/abstract/50,90-93\">",
"     50,90-93",
"    </a>",
"    ]. In addition, ophthalmologic disorders (retinal hemorrhages, cotton wool spots, and rarely retinal artery or vein obstruction) can occur during interferon therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/9/16538?source=see_link&amp;anchor=H12#H12\">",
"     \"Management of the side effects of peginterferon and ribavirin being used for treatment of chronic hepatitis C virus infection\", section on 'Ophthalmologic disorders'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     RENAL DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glomerular disease may occur in patients with chronic HCV infection. The pathogenesis appears to be related to the deposition of immune complexes containing anti-HCV and HCV RNA in the glomeruli. The most common patterns are membranoproliferative glomerulonephritis (usually associated with essential mixed cryoglobulinemia) and, less frequently, membranous nephropathy [",
"    <a class=\"abstract\" href=\"UTD.htm?15/8/15498/abstract/94,95\">",
"     94,95",
"    </a>",
"    ]. Several series have reported that anti-HCV antibodies are nearly universal in patients with both membranoproliferative glomerulonephritis and cryoglobulinemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/30/37353?source=see_link\">",
"     \"Renal disease associated with hepatitis C virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The Kidney Disease Improving Global Outcomes (KDIGO) clinical practice guidelines recommend screening for kidney disease at the time of HCV diagnosis and then annually thereafter with urinalysis and serum creatinine [",
"    <a class=\"abstract\" href=\"UTD.htm?15/8/15498/abstract/96\">",
"     96",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Interferon alfa is indicated in patients with membranoproliferative glomerulonephritis. A number of studies have reported a beneficial response to antiviral therapy in this setting, and the reduction in proteinuria correlates with a fall in HCV RNA [",
"    <a class=\"abstract\" href=\"UTD.htm?15/8/15498/abstract/94,97,98\">",
"     94,97,98",
"    </a>",
"    ]. However, long-term responses to interferon are unusual. Some patients will require maintenance therapy, and renal function is often not improved by treatment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/30/37353?source=see_link\">",
"     \"Renal disease associated with hepatitis C virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     MUSCULOSKELETAL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cross-sectional studies have found an association of hepatitis C virus (HCV) with decreased bone mineral density and fractures (hepatic osteodystrophy) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/8/15498/abstract/99-104\">",
"     99-104",
"    </a>",
"    ]. The mechanism may be related to chronic inflammation and liver dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?15/8/15498/abstract/100,105,106\">",
"     100,105,106",
"    </a>",
"    ]. In a study of Medicaid recipients, the risk of hip fracture was higher among those with HCV than those who were uninfected (2.7 versus 1.9",
"    <span class=\"nowrap\">",
"     events/1000",
"    </span>",
"    person-years) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/8/15498/abstract/104\">",
"     104",
"    </a>",
"    ]. The risk was highest among those coinfected with HCV and HIV (3.1",
"    <span class=\"nowrap\">",
"     events/1000",
"    </span>",
"    person-years).",
"   </p>",
"   <p>",
"    Hepatitis C-associated osteosclerosis is a rare disorder characterized by a marked increase in bone mass during adult life. While most cases have been reported in patients with a history of intravenous drug abuse, it has also been seen with HCV infection from blood transfusion [",
"    <a class=\"abstract\" href=\"UTD.htm?15/8/15498/abstract/107\">",
"     107",
"    </a>",
"    ]. Periosteal, endosteal, and trabecular bone thickening occur throughout the skeleton, with the exception of the cranium. During active disease, forearm and leg pain are common, bone remodeling (turnover) is high, and bone mineral density is two- to threefold higher than age-matched norms. The increased remodeling may respond to bisphosphonates or calcitonin, but spontaneous remission has also been described. Abnormalities in insulin-like growth factors (IGF-1 and IGF-II) or their binding proteins may contribute to the increase in bone formation in this disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?15/8/15498/abstract/108\">",
"     108",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Arthritis is noted in 2 to 20 percent of patients with HCV. It is a rheumatoid-like arthritis in two-thirds of the cases and an oligoarthritis in the rest. Arthritis alone is not an indication for antiviral therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/51/23354?source=see_link&amp;anchor=H4#H4\">",
"     \"Specific viruses that cause arthritis\", section on 'Hepatitis C virus'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/46/13033?source=see_link&amp;anchor=H3#H3\">",
"     \"Clinical features of rheumatoid arthritis\", section on 'Typical \"classic\" RA'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     MYOCARDITIS AND CARDIOMYOPATHY",
"    </span>",
"    &nbsp;&mdash;&nbsp;HCV has been associated with myocarditis and cardiomyopathy in reports from Japan. The pathogenesis is unclear. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/28/22986?source=see_link&amp;anchor=H3#H3\">",
"     \"Etiology and pathogenesis of myocarditis\", section on 'Viral or \"idiopathic\" myocarditis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/28/22986?source=see_link&amp;anchor=H20#H20\">",
"     \"Etiology and pathogenesis of myocarditis\", section on 'Hepatitis C'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?31/39/32370?source=see_link\">",
"       \"Patient information: Hepatitis C (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?17/4/17478?source=see_link\">",
"       \"Patient information: Hepatitis C (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19109716\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hepatitis C virus (HCV) infection is associated with several extrahepatic manifestations. In most cases, these manifestations appear to be directly related to the presence of the virus. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hematologic disorders that have been associated with chronic hepatitis C virus (HCV) include essential mixed cryoglobulinemia, monoclonal gammopathies, and lymphoma. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Hematologic disorders'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Essential mixed cryoglobulinemia is a lymphoproliferative disorder that can lead to the deposition of circulating immune complexes in small- to medium-sized blood vessels. The most common clinical manifestations include palpable purpura, arthralgias, renal disease (usually a membranoproliferative glomerulonephritis), neurologic disease, and hypocomplementemia. It may also be related to the increased incidence of lymphoma seen in patients with HCV. All patients with HCV should be asked about symptoms of essential mixed cryoglobulinemia, and symptomatic patients should be considered for antiviral therapy. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Essential mixed cryoglobulinemia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      HCV infection has been associated with the development of B-cell non-Hodgkin lymphomas and primary hepatic lymphoma. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Lymphoma'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A number of autoimmune disorders have been associated with HCV infection, including autoantibody formation, thyroid disease, sialadenitis, and autoimmune thrombocytopenic purpura. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Autoimmune disorders'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      HCV infection is associated with multiple dermatologic diseases, including porphyria cutanea tarda (PCT) and leukocytoclastic vasculitis. There is a strong association of the sporadic form of PCT and HCV. We recommend that patients with the sporadic form of PCT be screened for HCV infection (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5758040\">",
"       'Dermatologic disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      HCV infection has been linked to the development of diabetes mellitus, with studies showing an increase in risk of almost 70 percent. (See",
"      <a class=\"local\" href=\"#H5757471\">",
"       'Diabetes mellitus'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A variety of other extrahepatic manifestations of HCV have been described, including ocular diseases, renal diseases, musculoskeletal disorders, myocarditis, cardiomyopathies, and neurocognitive dysfunction. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Ocular disease'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H15\">",
"       'Renal disease'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5758040\">",
"       'Dermatologic disease'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H21\">",
"       'Musculoskeletal'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H22\">",
"       'Myocarditis and cardiomyopathy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with HCV should be screened for thyroid and renal disease. Testing for other extrahepatic manifestations of HCV should be based upon the development of symptoms. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Thyroid disease'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H15\">",
"       'Renal disease'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15498/abstract/1\">",
"      Gumber SC, Chopra S. Hepatitis C: a multifaceted disease. Review of extrahepatic manifestations. Ann Intern Med 1995; 123:615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15498/abstract/2\">",
"      Pawlotsky JM, Ben Yahia M, Andre C, et al. Immunological disorders in C virus chronic active hepatitis: a prospective case-control study. Hepatology 1994; 19:841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15498/abstract/3\">",
"      Cacoub P, Renou C, Rosenthal E, et al. Extrahepatic manifestations associated with hepatitis C virus infection. A prospective multicenter study of 321 patients. The GERMIVIC. Groupe d'Etude et de Recherche en Medecine Interne et Maladies Infectieuses sur le Virus de l'Hepatite C. Medicine (Baltimore) 2000; 79:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15498/abstract/4\">",
"      El-Serag HB, Hampel H, Yeh C, Rabeneck L. Extrahepatic manifestations of hepatitis C among United States male veterans. Hepatology 2002; 36:1439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15498/abstract/5\">",
"      Lunel F, Musset L, Cacoub P, et al. Cryoglobulinemia in chronic liver diseases: role of hepatitis C virus and liver damage. Gastroenterology 1994; 106:1291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15498/abstract/6\">",
"      Heer M, Joller-Jemelka H, Fontana A, et al. Monoclonal gammopathy in chronic active hepatitis. Liver 1984; 4:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15498/abstract/7\">",
"      Andreone P, Zignego AL, Cursaro C, et al. Prevalence of monoclonal gammopathies in patients with hepatitis C virus infection. Ann Intern Med 1998; 129:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15498/abstract/8\">",
"      Perrone A, Deramo MT, Spaccavento F, et al. Hepatitis C virus (HCV) genotypes, human leucocyte antigen expression and monoclonal gammopathy prevalence during chronic HCV infection. Cytobios 2001; 106 Suppl 1:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15498/abstract/9\">",
"      Al-Shemmari SH, Siddique I, Hassan F, et al. Monoclonal gammopathy among patients with chronic hepatitis C infection. Med Princ Pract 2004; 13:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15498/abstract/10\">",
"      Mangia A, Clemente R, Musto P, et al. Hepatitis C virus infection and monoclonal gammopathies not associated with cryoglobulinemia. Leukemia 1996; 10:1209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15498/abstract/11\">",
"      Tsianos EV, Di Bisceglie AM, Papadopoulos NM, et al. Oligoclonal immunoglobulin bands in serum in association with chronic viral hepatitis. Am J Gastroenterol 1990; 85:1005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15498/abstract/12\">",
"      Maruyama S, Hirayama C, Horie Y, et al. Serum immunoglobulins in patients with chronic hepatitis C: a surrogate marker of disease severity and treatment outcome. Hepatogastroenterology 2007; 54:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15498/abstract/13\">",
"      Gisbert JP, Garc&iacute;a-Buey L, Pajares JM, Moreno-Otero R. Prevalence of hepatitis C virus infection in B-cell non-Hodgkin's lymphoma: systematic review and meta-analysis. Gastroenterology 2003; 125:1723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15498/abstract/14\">",
"      Giordano TP, Henderson L, Landgren O, et al. Risk of non-Hodgkin lymphoma and lymphoproliferative precursor diseases in US veterans with hepatitis C virus. JAMA 2007; 297:2010.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15498/abstract/15\">",
"      de Sanjose S, Benavente Y, Vajdic CM, et al. Hepatitis C and non-Hodgkin lymphoma among 4784 cases and 6269 controls from the International Lymphoma Epidemiology Consortium. Clin Gastroenterol Hepatol 2008; 6:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15498/abstract/16\">",
"      Silvestri F, Pipan C, Barillari G, et al. Prevalence of hepatitis C virus infection in patients with lymphoproliferative disorders. Blood 1996; 87:4296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15498/abstract/17\">",
"      Monti G, Pioltelli P, Saccardo F, et al. Incidence and characteristics of non-Hodgkin lymphomas in a multicenter case file of patients with hepatitis C virus-related symptomatic mixed cryoglobulinemias. Arch Intern Med 2005; 165:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15498/abstract/18\">",
"      Bronowicki JP, Bineau C, Feugier P, et al. Primary lymphoma of the liver: clinical-pathological features and relationship with HCV infection in French patients. Hepatology 2003; 37:781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15498/abstract/19\">",
"      Luppi M, Longo G, Ferrari MG, et al. Additional neoplasms and HCV infection in low-grade lymphoma of MALT type. Br J Haematol 1996; 94:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15498/abstract/20\">",
"      De Vita S, De Re V, Sansonno D, et al. Gastric mucosa as an additional extrahepatic localization of hepatitis C virus: viral detection in gastric low-grade lymphoma associated with autoimmune disease and in chronic gastritis. Hepatology 2000; 31:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15498/abstract/21\">",
"      Tursi A, Brandimante G, Chiarelli F, et al. Detection of HCV RNA in gastric mucosa-associated lymphoid tissue by in situ hybridization: evidence of a new extrahepatic localization of HCV with increased risk of gastric malt lymphoma. Am J Gastroenterol 2002; 97:1802.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15498/abstract/22\">",
"      Rasul I, Shepherd FA, Kamel-Reid S, et al. Detection of occult low-grade b-cell non-Hodgkin's lymphoma in patients with chronic hepatitis C infection and mixed cryoglobulinemia. Hepatology 1999; 29:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15498/abstract/23\">",
"      Hermine O, Lefr&egrave;re F, Bronowicki JP, et al. Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection. N Engl J Med 2002; 347:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15498/abstract/24\">",
"      Ennishi D, Maeda Y, Niitsu N, et al. Hepatic toxicity and prognosis in hepatitis C virus-infected patients with diffuse large B-cell lymphoma treated with rituximab-containing chemotherapy regimens: a Japanese multicenter analysis. Blood 2010; 116:5119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15498/abstract/25\">",
"      Quinn ER, Chan CH, Hadlock KG, et al. The B-cell receptor of a hepatitis C virus (HCV)-associated non-Hodgkin lymphoma binds the viral E2 envelope protein, implicating HCV in lymphomagenesis. Blood 2001; 98:3745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15498/abstract/26\">",
"      Pozzato G, Mazzaro C, Crovatto M, et al. Low-grade malignant lymphoma, hepatitis C virus infection, and mixed cryoglobulinemia. Blood 1994; 84:3047.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15498/abstract/27\">",
"      Zignego AL, Giannelli F, Marrocchi ME, et al. T(14;18) translocation in chronic hepatitis C virus infection. Hepatology 2000; 31:474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15498/abstract/28\">",
"      Kitay-Cohen Y, Amiel A, Hilzenrat N, et al. Bcl-2 rearrangement in patients with chronic hepatitis C associated with essential mixed cryoglobulinemia type II. Blood 2000; 96:2910.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15498/abstract/29\">",
"      Zuckerman E, Zuckerman T, Sahar D, et al. bcl-2 and immunoglobulin gene rearrangement in patients with hepatitis C virus infection. Br J Haematol 2001; 112:364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15498/abstract/30\">",
"      Zignego AL, Ferri C, Giannelli F, et al. Prevalence of bcl-2 rearrangement in patients with hepatitis C virus-related mixed cryoglobulinemia with or without B-cell lymphomas. Ann Intern Med 2002; 137:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15498/abstract/31\">",
"      Kawamura Y, Ikeda K, Arase Y, et al. Viral elimination reduces incidence of malignant lymphoma in patients with hepatitis C. Am J Med 2007; 120:1034.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15498/abstract/32\">",
"      Ramos-Casals M, Mu&ntilde;oz S, Medina F, et al. Systemic autoimmune diseases in patients with hepatitis C virus infection: characterization of 1020 cases (The HISPAMEC Registry). J Rheumatol 2009; 36:1442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15498/abstract/33\">",
"      Clifford BD, Donahue D, Smith L, et al. High prevalence of serological markers of autoimmunity in patients with chronic hepatitis C. Hepatology 1995; 21:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15498/abstract/34\">",
"      Cacoub P, Musset L, Amoura Z, et al. Anticardiolipin, anti-beta2-glycoprotein I, and antinucleosome antibodies in hepatitis C virus infection and mixed cryoglobulinemia. Multivirc Group. J Rheumatol 1997; 24:2139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15498/abstract/35\">",
"      Lienesch D, Morris R, Metzger A, et al. Absence of cyclic citrullinated peptide antibody in nonarthritic patients with chronic hepatitis C infection. J Rheumatol 2005; 32:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15498/abstract/36\">",
"      Zauli D, Ghetti S, Grassi A, et al. Anti-neutrophil cytoplasmic antibodies in type 1 and 2 autoimmune hepatitis. Hepatology 1997; 25:1105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15498/abstract/37\">",
"      Bianchi FB. Autoimmune hepatitis: the lesson of the discovery of hepatitis C virus. J Hepatol 1993; 18:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15498/abstract/38\">",
"      Reddy KR, Krawitt EL, Homberg JC, et al. Absence of anti-LKM-1 antibody in hepatitis C viral infection in the United States of America. J Viral Hepat 1995; 2:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15498/abstract/39\">",
"      Muratori L, Lenzi M, Cataleta M, et al. Interferon therapy in liver/kidney microsomal antibody type 1-positive patients with chronic hepatitis C. J Hepatol 1994; 21:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15498/abstract/40\">",
"      Gschwantler M, Schrutka-K&ouml;lbl C, Weiss W. Acute exacerbation of antiliver cytosol antibody-positive autoimmune chronic hepatitis by alpha-interferon. Am J Gastroenterol 1995; 90:2239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15498/abstract/41\">",
"      Bellary S, Schiano T, Hartman G, Black M. Chronic hepatitis with combined features of autoimmune chronic hepatitis and chronic hepatitis C: favorable response to prednisone and azathioprine. Ann Intern Med 1995; 123:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15498/abstract/42\">",
"      Bortolotti F, Vajro P, Balli F, et al. Non-organ specific autoantibodies in children with chronic hepatitis C. J Hepatol 1996; 25:614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15498/abstract/43\">",
"      Yamamoto AM, Cresteil D, Homberg JC, Alvarez F. Characterization of anti-liver-kidney microsome antibody (anti-LKM1) from hepatitis C virus-positive and -negative sera. Gastroenterology 1993; 104:1762.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15498/abstract/44\">",
"      Muratori L, Lenzi M, Ma Y, et al. Heterogeneity of liver/kidney microsomal antibody type 1 in autoimmune hepatitis and hepatitis C virus related liver disease. Gut 1995; 37:406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15498/abstract/45\">",
"      Tran A, Quaranta JF, Benzaken S, et al. High prevalence of thyroid autoantibodies in a prospective series of patients with chronic hepatitis C before interferon therapy. Hepatology 1993; 18:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15498/abstract/46\">",
"      Antonelli A, Ferri C, Pampana A, et al. Thyroid disorders in chronic hepatitis C. Am J Med 2004; 117:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15498/abstract/47\">",
"      Roti E, Minelli R, Giuberti T, et al. Multiple changes in thyroid function in patients with chronic active HCV hepatitis treated with recombinant interferon-alpha. Am J Med 1996; 101:482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15498/abstract/48\">",
"      Marazuela M, Garc&iacute;a-Buey L, Gonz&aacute;lez-Fern&aacute;ndez B, et al. Thyroid autoimmune disorders in patients with chronic hepatitis C before and during interferon-alpha therapy. Clin Endocrinol (Oxf) 1996; 44:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15498/abstract/49\">",
"      Haddad J, Deny P, Munz-Gotheil C, et al. Lymphocytic sialadenitis of Sj&ouml;gren's syndrome associated with chronic hepatitis C virus liver disease. Lancet 1992; 339:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15498/abstract/50\">",
"      Ramos-Casals M, Loustaud-Ratti V, De Vita S, et al. Sj&ouml;gren syndrome associated with hepatitis C virus: a multicenter analysis of 137 cases. Medicine (Baltimore) 2005; 84:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15498/abstract/51\">",
"      Carrozzo M. Oral diseases associated with hepatitis C virus infection. Part 1. sialadenitis and salivary glands lymphoma. Oral Dis 2008; 14:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15498/abstract/52\">",
"      Pawlotsky JM, Bouvier M, Fromont P, et al. Hepatitis C virus infection and autoimmune thrombocytopenic purpura. J Hepatol 1995; 23:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15498/abstract/53\">",
"      Chiao EY, Engels EA, Kramer JR, et al. Risk of immune thrombocytopenic purpura and autoimmune hemolytic anemia among 120 908 US veterans with hepatitis C virus infection. Arch Intern Med 2009; 169:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15498/abstract/54\">",
"      Eddy S, Wim R, Peter VE, et al. Myasthenia gravis: another autoimmune disease associated with hepatitis C virus infection. Dig Dis Sci 1999; 44:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15498/abstract/55\">",
"      Reading PJ, Newman PK. Untreated hepatitis C may provoke myasthenia gravis. J Neurol Neurosurg Psychiatry 1998; 64:820.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15498/abstract/56\">",
"      Halfon P, Levy M, San Marco M, et al. Myasthenia gravis and hepatitis C virus infection. J Viral Hepat 1996; 3:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15498/abstract/57\">",
"      Harada H, Tamaoka A, Kohno Y, et al. Exacerbation of myasthenia gravis in a patient after interferon-beta treatment for chronic active hepatitis C. J Neurol Sci 1999; 165:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15498/abstract/58\">",
"      Gurtubay IG, Morales G, Ar&eacute;chaga O, G&aacute;llego J. Development of myasthenia gravis after interferon alpha therapy. Electromyogr Clin Neurophysiol 1999; 39:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15498/abstract/59\">",
"      Daoud MS, Gibson LE, Daoud S, el-Azhary RA. Chronic hepatitis C and skin diseases: a review. Mayo Clin Proc 1995; 70:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15498/abstract/60\">",
"      Berk DR, Mallory SB, Keeffe EB, Ahmed A. Dermatologic disorders associated with chronic hepatitis C: effect of interferon therapy. Clin Gastroenterol Hepatol 2007; 5:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15498/abstract/61\">",
"      Gisbert JP, Garc&iacute;a-Buey L, Pajares JM, Moreno-Otero R. Prevalence of hepatitis C virus infection in porphyria cutanea tarda: systematic review and meta-analysis. J Hepatol 2003; 39:620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15498/abstract/62\">",
"      David WS, Peine C, Schlesinger P, Smith SA. Nonsystemic vasculitic mononeuropathy multiplex, cryoglobulinemia, and hepatitis C. Muscle Nerve 1996; 19:1596.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15498/abstract/63\">",
"      Pilli M, Penna A, Zerbini A, et al. Oral lichen planus pathogenesis: A role for the HCV-specific cellular immune response. Hepatology 2002; 36:1446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15498/abstract/64\">",
"      Protzer U, Ochsendorf FR, Leopolder-Ochsendorf A, Holterm&uuml;ller KH. Exacerbation of lichen planus during interferon alfa-2a therapy for chronic active hepatitis C. Gastroenterology 1993; 104:903.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15498/abstract/65\">",
"      Abdallah MA, Ghozzi MY, Monib HA, et al. Necrolytic acral erythema: a cutaneous sign of hepatitis C virus infection. J Am Acad Dermatol 2005; 53:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15498/abstract/66\">",
"      Khanna VJ, Shieh S, Benjamin J, et al. Necrolytic acral erythema associated with hepatitis C: effective treatment with interferon alfa and zinc. Arch Dermatol 2000; 136:755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15498/abstract/67\">",
"      Abdallah MA, Hull C, Horn TD. Necrolytic acral erythema: a patient from the United States successfully treated with oral zinc. Arch Dermatol 2005; 141:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15498/abstract/68\">",
"      Hivnor CM, Yan AC, Junkins-Hopkins JM, Honig PJ. Necrolytic acral erythema: response to combination therapy with interferon and ribavirin. J Am Acad Dermatol 2004; 50:S121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15498/abstract/69\">",
"      El-Ghandour TM, Sakr MA, El-Sebai H, et al. Necrolytic acral erythema in Egyptian patients with hepatitis C virus infection. J Gastroenterol Hepatol 2006; 21:1200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15498/abstract/70\">",
"      Allison ME, Wreghitt T, Palmer CR, Alexander GJ. Evidence for a link between hepatitis C virus infection and diabetes mellitus in a cirrhotic population. J Hepatol 1994; 21:1135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15498/abstract/71\">",
"      Fraser GM, Harman I, Meller N, et al. Diabetes mellitus is associated with chronic hepatitis C but not chronic hepatitis B infection. Isr J Med Sci 1996; 32:526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15498/abstract/72\">",
"      Grimbert S, Valensi P, L&eacute;vy-Marchal C, et al. High prevalence of diabetes mellitus in patients with chronic hepatitis C. A case-control study. Gastroenterol Clin Biol 1996; 20:544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15498/abstract/73\">",
"      Ozyilkan E, Arslan M. Increased prevalence of diabetes mellitus in patients with chronic hepatitis C virus infection. Am J Gastroenterol 1996; 91:1480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15498/abstract/74\">",
"      Mason AL, Lau JY, Hoang N, et al. Association of diabetes mellitus and chronic hepatitis C virus infection. Hepatology 1999; 29:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15498/abstract/75\">",
"      Caronia S, Taylor K, Pagliaro L, et al. Further evidence for an association between non-insulin-dependent diabetes mellitus and chronic hepatitis C virus infection. Hepatology 1999; 30:1059.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15498/abstract/76\">",
"      Mehta SH, Brancati FL, Sulkowski MS, et al. Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States. Ann Intern Med 2000; 133:592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15498/abstract/77\">",
"      Mehta SH, Brancati FL, Strathdee SA, et al. Hepatitis C virus infection and incident type 2 diabetes. Hepatology 2003; 38:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15498/abstract/78\">",
"      Zein CO, Levy C, Basu A, Zein NN. Chronic hepatitis C and type II diabetes mellitus: a prospective cross-sectional study. Am J Gastroenterol 2005; 100:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15498/abstract/79\">",
"      Shintani Y, Fujie H, Miyoshi H, et al. Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance. Gastroenterology 2004; 126:840.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15498/abstract/80\">",
"      White DL, Ratziu V, El-Serag HB. Hepatitis C infection and risk of diabetes: a systematic review and meta-analysis. J Hepatol 2008; 49:831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15498/abstract/81\">",
"      Petit JM, Bour JB, Galland-Jos C, et al. Risk factors for diabetes mellitus and early insulin resistance in chronic hepatitis C. J Hepatol 2001; 35:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15498/abstract/82\">",
"      Bigam DL, Pennington JJ, Carpentier A, et al. Hepatitis C-related cirrhosis: a predictor of diabetes after liver transplantation. Hepatology 2000; 32:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15498/abstract/83\">",
"      Hadziyannis S, Karamanos B. Diabetes mellitus and chronic hepatitis C virus infection. Hepatology 1999; 29:604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15498/abstract/84\">",
"      Moucari R, Asselah T, Cazals-Hatem D, et al. Insulin resistance in chronic hepatitis C: association with genotypes 1 and 4, serum HCV RNA level, and liver fibrosis. Gastroenterology 2008; 134:416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15498/abstract/85\">",
"      Milner KL, van der Poorten D, Trenell M, et al. Chronic hepatitis C is associated with peripheral rather than hepatic insulin resistance. Gastroenterology 2010; 138:932.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15498/abstract/86\">",
"      Hui JM, Sud A, Farrell GC, et al. Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression [corrected]. Gastroenterology 2003; 125:1695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15498/abstract/87\">",
"      Romero-G&oacute;mez M, Fern&aacute;ndez-Rodr&iacute;guez CM, Andrade RJ, et al. Effect of sustained virological response to treatment on the incidence of abnormal glucose values in chronic hepatitis C. J Hepatol 2008; 48:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15498/abstract/88\">",
"      Arase Y, Suzuki F, Suzuki Y, et al. Sustained virological response reduces incidence of onset of type 2 diabetes in chronic hepatitis C. Hepatology 2009; 49:739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15498/abstract/89\">",
"      Conjeevaram HS, Wahed AS, Afdhal N, et al. Changes in insulin sensitivity and body weight during and after peginterferon and ribavirin therapy for hepatitis C. Gastroenterology 2011; 140:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15498/abstract/90\">",
"      Wilson SE, Lee WM, Murakami C, et al. Mooren's corneal ulcers and hepatitis C virus infection. N Engl J Med 1993; 329:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15498/abstract/91\">",
"      Ali Y, Ghafouri M, Weitzman M, et al. Refractory scleritis in a patient with cryoglobulinemia and hepatitis C. J Clin Rheumatol 1999; 5:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15498/abstract/92\">",
"      Moder KG, Poterucha JJ, Mahr MA. Scleritis associated with viral hepatitis C: Report of a case. J Clin Rheumatol 2000; 6:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15498/abstract/93\">",
"      Jacobi C, Wenkel H, Jacobi A, et al. Hepatitis C and ocular surface disease. Am J Ophthalmol 2007; 144:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15498/abstract/94\">",
"      Johnson RJ, Gretch DR, Couser WG, et al. Hepatitis C virus-associated glomerulonephritis. Effect of alpha-interferon therapy. Kidney Int 1994; 46:1700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15498/abstract/95\">",
"      McGuire BM, Julian BA, Bynon JS Jr, et al. Brief communication: Glomerulonephritis in patients with hepatitis C cirrhosis undergoing liver transplantation. Ann Intern Med 2006; 144:735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15498/abstract/96\">",
"      Levey AS, Atkins R, Coresh J, et al. Chronic kidney disease as a global public health problem: approaches and initiatives - a position statement from Kidney Disease Improving Global Outcomes. Kidney Int 2007; 72:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15498/abstract/97\">",
"      Agnello V, Chung RT, Kaplan LM. A role for hepatitis C virus infection in type II cryoglobulinemia. N Engl J Med 1992; 327:1490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15498/abstract/98\">",
"      Johnson RJ, Gretch DR, Yamabe H, et al. Membranoproliferative glomerulonephritis associated with hepatitis C virus infection. N Engl J Med 1993; 328:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15498/abstract/99\">",
"      Gallego-Rojo FJ, Gonzalez-Calvin JL, Mu&ntilde;oz-Torres M, et al. Bone mineral density, serum insulin-like growth factor I, and bone turnover markers in viral cirrhosis. Hepatology 1998; 28:695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15498/abstract/100\">",
"      Gonzalez-Calvin JL, Gallego-Rojo F, Fernandez-Perez R, et al. Osteoporosis, mineral metabolism, and serum soluble tumor necrosis factor receptor p55 in viral cirrhosis. J Clin Endocrinol Metab 2004; 89:4325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15498/abstract/101\">",
"      Leslie WD, Bernstein CN, Leboff MS, American Gastroenterological Association Clinical Practice Commitee. AGA technical review on osteoporosis in hepatic disorders. Gastroenterology 2003; 125:941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15498/abstract/102\">",
"      Lo Re V 3rd, Guaraldi G, Leonard MB, et al. Viral hepatitis is associated with reduced bone mineral density in HIV-infected women but not men. AIDS 2009; 23:2191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15498/abstract/103\">",
"      Rouillard S, Lane NE. Hepatic osteodystrophy. Hepatology 2001; 33:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15498/abstract/104\">",
"      Lo Re V 3rd, Volk J, Newcomb CW, et al. Risk of hip fracture associated with hepatitis C virus infection and hepatitis C/human immunodeficiency virus coinfection. Hepatology 2012; 56:1688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15498/abstract/105\">",
"      Gilbert L, He X, Farmer P, et al. Expression of the osteoblast differentiation factor RUNX2 (Cbfa1/AML3/Pebp2alpha A) is inhibited by tumor necrosis factor-alpha. J Biol Chem 2002; 277:2695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15498/abstract/106\">",
"      Pignata S, Daniele B, Galati MG, et al. Oestradiol and testosterone blood levels in patients with viral cirrhosis and hepatocellular carcinoma. Eur J Gastroenterol Hepatol 1997; 9:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15498/abstract/107\">",
"      Shaker JL, Moore BP, Whyte MP. Hyperparathyroidism and increased serum IGF-binding protein-2 levels in hepatitis C-associated osteosclerosis. J Clin Endocrinol Metab 1999; 84:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/8/15498/abstract/108\">",
"      Khosla S, Hassoun AA, Baker BK, et al. Insulin-like growth factor system abnormalities in hepatitis C-associated osteosclerosis. Potential insights into increasing bone mass in adults. J Clin Invest 1998; 101:2165.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3676 Version 14.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-61.234.146.186-E0FBF310BF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_8_15498=[""].join("\n");
var outline_f15_8_15498=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19109716\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      HEMATOLOGIC DISORDERS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Essential mixed cryoglobulinemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Monoclonal gammopathies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      AUTOIMMUNE DISORDERS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Autoantibodies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5757261\">",
"      - Autoimmune hepatitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Thyroid disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Sialadenitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Autoimmune thrombocytopenic purpura and hemolytic anemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Myasthenia gravis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Sarcoidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5758040\">",
"      DERMATOLOGIC DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5758201\">",
"      Porphyria cutanea tarda",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5758208\">",
"      Leukocytoclastic vasculitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5758215\">",
"      Lichen planus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5758222\">",
"      Necrolytic acral erythema",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5757471\">",
"      DIABETES MELLITUS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      OCULAR DISEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      RENAL DISEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      MUSCULOSKELETAL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      MYOCARDITIS AND CARDIOMYOPATHY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19109716\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/3676\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/3676|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?29/19/30013\" title=\"figure 1\">",
"      Cryos in chronic liver disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/3676|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?13/30/13794\" title=\"picture 1\">",
"      Porphyria cutanea tarda",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?9/36/9794\" title=\"picture 2\">",
"      Leukocytoclastic vasculitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?42/20/43333\" title=\"picture 3A\">",
"      Leukocytoclastic vasculitis I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?22/37/23126\" title=\"picture 3B\">",
"      Leukocytoclastic vasculitis II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?0/50/805\" title=\"picture 4\">",
"      Generalized lichen planus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/3676|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?28/9/28828\" title=\"table 1\">",
"      Extrahepatic manifestations HCV",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/3/18489?source=related_link\">",
"      Approach to the diagnosis of hemolytic anemia in the adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/46/13033?source=related_link\">",
"      Clinical features of rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/44/35528?source=related_link\">",
"      Clinical manifestations and diagnosis of autoimmune hepatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/13/30938?source=related_link\">",
"      Clinical manifestations and diagnosis of immune thrombocytopenia (ITP) in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/15/34040?source=related_link\">",
"      Clinical manifestations and diagnosis of the mixed cryoglobulinemia syndrome (essential mixed cryoglobulinemia)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/50/31530?source=related_link\">",
"      Clinical manifestations and natural history of chronic hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/1/11287?source=related_link\">",
"      Clinical manifestations of Sj&ouml;gren's syndrome: Exocrine gland disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/57/22423?source=related_link\">",
"      Clinical manifestations of vasculitic neuropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/46/25322?source=related_link\">",
"      Clinical manifestations, pathologic features, diagnosis, and prognosis of follicular lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/7/26744?source=related_link\">",
"      Diagnosis of and screening for hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/59/15290?source=related_link\">",
"      Diagnosis of monoclonal gammopathy of undetermined significance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/28/22986?source=related_link\">",
"      Etiology and pathogenesis of myocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/15/4345?source=related_link\">",
"      Evaluation of adults with cutaneous lesions of vasculitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/33/3608?source=related_link\">",
"      Laboratory assessment of thyroid function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/27/9656?source=related_link\">",
"      Lichen planus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/9/16538?source=related_link\">",
"      Management of the side effects of peginterferon and ribavirin being used for treatment of chronic hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/41/42648?source=related_link\">",
"      Origin and utility of measurement of rheumatoid factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/45/43735?source=related_link\">",
"      Overview of the management of chronic hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/11/27833?source=related_link\">",
"      Pathogenesis of Hashimoto's thyroiditis (chronic autoimmune thyroiditis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?17/4/17478?source=related_link\">",
"      Patient information: Hepatitis C (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?31/39/32370?source=related_link\">",
"      Patient information: Hepatitis C (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/45/30421?source=related_link\">",
"      Porphyria cutanea tarda and hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/41/36505?source=related_link\">",
"      Principles of interferon therapy in liver disease and the induction of autoimmunity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/30/37353?source=related_link\">",
"      Renal disease associated with hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/16/2312?source=related_link\">",
"      Screening for diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/51/23354?source=related_link\">",
"      Specific viruses that cause arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/53/43865?source=related_link\">",
"      Treatment of hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/41/22169?source=related_link\">",
"      Treatment of marginal zone (MALT) lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/52/36682?source=related_link\">",
"      Treatment of the mixed cryoglobulinemia syndrome",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_8_15499="Indications for ECT";
var content_f15_8_15499=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F55438&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=11\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F55438&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=11\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Indications for electroconvulsive therapy (ECT)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Definitely effective",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Unipolar major depression",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Refractory or resistant to antidepressant therapy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Need exists for rapid treatment response, such as in pregnancy, persistent suicidal intent, or food refusal leading to dehydration or nutritional compromise",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Medical comorbidities prevent the use of antidepressant medication",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Previous response to ECT",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Psychotic features (eg, delusions or hallucinations)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Catatonia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Persistent suicidal intent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bipolar depression or mania",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     American Psychiatric Association. Am J Psychiatry 2000; 157:1.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_8_15499=[""].join("\n");
var outline_f15_8_15499=null;
var title_f15_8_15500="Antimicrobial prophylaxis for neurosurgery";
var content_f15_8_15500=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F87202&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F87202&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Antimicrobial prophylaxis for neurosurgery",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"3\" width=\"33%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Common pathogens",
"       </td>",
"       <td class=\"subtitle1\">",
"        Recommended antimicrobials",
"       </td>",
"       <td class=\"subtitle1\">",
"        Usual adult dose*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        S. aureus, S. epidermidis",
"       </td>",
"       <td>",
"        Cefazolin",
"       </td>",
"       <td>",
"        <p>",
"         &lt;80 kg: 1 g",
"        </p>",
"        &ge;80 kg: 2 g",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         OR",
"        </strong>",
"        vancomycin",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        1 g IV",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Parenteral prophylactic antimicrobials can be given as a single IV dose begun within 60 minutes before the procedure. For prolonged procedures (&gt;3 hours) or those with major blood loss, or in patients with extensive burns, additional intraoperative doses should be given at intervals one to two times the half-life of the drug (ampicillin-sulbactam every 2 hours, cefazolin every 4 hours, cefuroxime every 4 hours, cefoxitin every 2 hours, clindamycin every 6 hours, vancomycin every 12 hours) for the duration of the procedure in patients with normal renal function. If vancomycin or a fluoroquinolone is used, the infusion should be started within 60 to 120 minutes before the initial incision to have adequate tissue levels at the time of incision and to minimize the possibility of an infusion reaction close to the time of induction of anesthesia.",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     Vancomycin can be used in hospitals in which methicillin-resistant S. aureus and S. epidermidis are a frequent cause of postoperative wound infection, in patients previously colonized with MRSA, or for those who are allergic to penicillins or cephalosporins. Rapid IV administration may cause hypotension, which could be especially dangerous during induction of anesthesia. Even when the drug is given over 60 minutes, hypotension may occur; treatment with diphenhydramine and further slowing of the infusion rate may be helpful. Some experts would give 15 mg/kg of vancomycin to patients weighing more than 75 kg, up to a maximum of 1.5 g, with a slower infusion rate (90 minutes for 1.5 g). For procedures in which enteric gram-negative bacilli are common pathogens, many experts would add another drug such as an aminoglycoside (gentamicin, tobramycin, or amikacin), aztreonam, or a fluoroquinolone.",
"    </div>",
"    <div class=\"reference\">",
"     Reprinted with special permission from: Treatment Guidelines from The Medical Letter, October 2012; Vol. 10 (122):73.",
"     <a href=\"file://www.medicalletter.org\" target=\"_blank\">",
"      www.medicalletter.org",
"     </a>",
"     .",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_8_15500=[""].join("\n");
var outline_f15_8_15500=null;
var title_f15_8_15501="Reasons for Epi nonresponse";
var content_f15_8_15501=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F61580&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F61580&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Potential reasons for lack of response to epinephrine in anaphylaxis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Relevant studies",
"       </td>",
"       <td class=\"subtitle1\">",
"        Comments",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Patient/caregiver/physician",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Rapid anaphylaxis progression",
"       </td>",
"       <td>",
"        Case reports, autopsy reports",
"       </td>",
"       <td>",
"        In 10 percent of anaphylaxis episodes, epinephrine does not work, even if given promptly",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Epinephrine given too late",
"       </td>",
"       <td>",
"        Case reports, autopsy reports",
"       </td>",
"       <td>",
"        Cause-and-effect hard to prove",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Individuals do not know how to use epinephrine auto-injectors",
"       </td>",
"       <td>",
"        Cross-sectional surveys, demonstrations",
"       </td>",
"       <td>",
"        Frequently reported",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Epinephrine-related",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Dose too low",
"       </td>",
"       <td>",
"        Few dose-response studies",
"       </td>",
"       <td>",
"        Optimal dose unknown; based on tradition, 0.3 mg is used for adults in many countries, 0.5 mg in some countries",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Lack of availability of fixed doses 0.05, 0.1, 0.2, 0.25 mg in auto-injectors",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Impossible to give an appropriate dose to infants and to some young children",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"3\">",
"        Route/site not optimal",
"       </td>",
"       <td>",
"        Intramuscular vs subcutaneous*",
"       </td>",
"       <td>",
"        Intramuscular, thigh preferred to subcutaneous, arm",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ampule and syringe*",
"       </td>",
"       <td>",
"        Non-medical personnel lack speed and accuracy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pressurized meter-dose inhaler&bull;",
"       </td>",
"       <td>",
"        For systemic effects, adults need 20-30 puffs (children 10-20; possible phase-out by 2006",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Past expiration date",
"       </td>",
"       <td>",
"        Bioavailability measured in animal models; content measured in vitro&Delta;",
"       </td>",
"       <td>",
"        Epinephrine content inversely related to number of months past expiration date",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Other",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Individual not supine",
"       </td>",
"       <td>",
"        Autopsy reports",
"       </td>",
"       <td>",
"        If the individual is standing, venous return is decreased, the ventricles are empty, and death may occur despite timely epinephrine-induced reversal of vasodilation and shock",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Individual taking medications (beta-blocker or alpha-blocker, angiotensin-converting enzyme inhibitor) that  prevent optimal epinephrine effect",
"       </td>",
"       <td>",
"        Case reports",
"       </td>",
"       <td>",
"        There is more information about lack of effect in asthma than in anaphylaxis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Adverse effects of sodium metabisulfite (antioxidant in epinephrine)",
"       </td>",
"       <td>",
"        Case reports",
"       </td>",
"       <td>",
"        Additional studies needed, because sulfite-sensitive asthmatics tolerate epinephrine",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * In obese individuals, intramuscular injections of epinephrine may inadvertently end up being subcutaneous injections unless a needle at least 2.5 cm (1 in) is used to penetrate the aft pad over the vastus lateralis muscle.",
"     <br>",
"      &bull; It is difficult to inhale the large number of epinephrine puffs required because of vasoconstriction of the oropharyngeal mucosa, causing tingling and burning sensations.",
"      <br>",
"       &Delta; Compendial limits for epinephrine content of formulations are 90 percent to 115 percent of labeled strength (United States Pharmacopeia), but in some countries, the stated content of epinephrine in auto-injectors may range from 0.23 mg to 0.37 mg. Epinephrine should be stored at room temperature (15&deg;C to 30&deg;C) to prevent oxidation and inactivation. In an EpiPen auto-injector, it is supplied in light-resistant packaging, and each 0.3-mL dose contains 0.3 mg epinephrine, 1.8 mg sodium chloride, 0.5 mg sodium metabisulfite, and hydrochloric acid to adjust the pH from 2.2 to 5.0. An EpiPen Jr contains epinephrine 0.15 mg and the same nonmedicinal ingredients in the same amounts as in the EpiPen.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Simons, FER. First-aid treatment of anaphylaxis to food: Focus on epinephrine. J Allergy Clin Immunol 2004; 113:837. Copyright &copy;2004 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_8_15501=[""].join("\n");
var outline_f15_8_15501=null;
var title_f15_8_15502="Electromagnetic spectrum";
var content_f15_8_15502=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F70045&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F70045&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 546px\">",
"   <div class=\"ttl\">",
"    Electromagnetic spectrum",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 526px; height: 266px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_8_15502=[""].join("\n");
var outline_f15_8_15502=null;
var title_f15_8_15503="Hysterosc myomectomy loop";
var content_f15_8_15503=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F61871&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F61871&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Hysteroscopic myomectomy: wire loop technique",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 380px; height: 285px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    During hysteroscopic myomectomy using the wire loop technique, the wire loop is placed at the most cephalad surface of the leiomyoma. The activated electrode is then passed through the tissue.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Linda D Bradley, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_8_15503=[""].join("\n");
var outline_f15_8_15503=null;
